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Parkinson’s disease (PD) is an incurable neurodegenerative disease of the elderly. Although the 
precise molecular mechanism is unknown, accumulative evidence suggests the involvement of 
mitochondrial dysfunction. Accordingly, a previous drug screening study was carried out in our 
group with the aim of identifying compounds that rescue mitochondrial function in fibroblasts from 
PD patients with parkin mutation. Based on the findings in that study, ursodeoxycholic acid 
(UDCA) was presented as a putative novel treatment for PD. UDCA is an approved treatment for 
primary biliary cirrhosis. Therefore, its adoption should require less time and cost than de novo 
drugs.  
The main aim of this project is to investigate the rescue effect of UDCA in the context of PD. Our 
group previously described increased activity in each of the individual respiratory chain enzymes 
following treatment with Ursocholanic acid (UCA), a structurally similar compound. Therefore, we 
first hypothesised that the rescue effect of UCA/UDCA involves upregulation in mitochondrial 
biogenesis. However, upon following the treatment protocol used with parkin patient fibroblasts, 
we were unable to demonstrate an increase in the expression of mitochondrial proteins and 
mtDNA copy number.  
Subsequently, we investigated the ability of UDCA to activate the Nrf2 pathway, which is one of 
the most important antioxidant pathways in cells and has been reported to mediate the action of 
UDCA in hepatobiliary-related research. In this project we used a specifically designed reporter 
cell line to assess Nrf2 activation. As a transcriptional factor, activated Nrf2 binds to a distinct 
sequence (named antioxidant response element (ARE)) in the promotor of its targeted genes, 
and drives their transcription. The used reporter cells contain several repeats of the ARE 
sequence linked to green fluorescent protein (GFP) motif. Thus, the measurement of green 
fluorescence should correlate with the transcription of the ARE sequences. We found that UDCA 
increased green fluorescence in a dose-dependent manner. However, this increase was not 
translated into a reduction in oxidative stress in copper-stressed cells. Moreover, UDCA treatment 
did not rescue these reporter cells when they were stressed with mitochondrial toxins. 
The reporter cells are not ideal for investigating treatments for PD since they are non-human and 
non-neuronal in nature. Therefore, the human neuroblastoma-derived SH-SY5Y cell line was 
subsequently used. UDCA significantly reduced cytotoxicity and increased ATP levels in SH-
SY5Y cells stressed with the mitochondrial uncoupler, carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP). To investigate whether this rescue effect is mediated via the Nrf2 pathway, 
we quantified the expression of Nrf2 downstream genes via RT-qPCR; however, no positive 
results were obtained.  
Subsequent experiments showed that the rescue effect was associated with significant activation 
of the AKT pathway (a cell survival pathway that has been reported to mediate the action of 
UDCA). Interestingly, the inhibition of AKT abolished the beneficial effect on ATP but not the 
cytotoxicity, indicating that the mechanism of action of UDCA is not entirely dependent on AKT. 
The effect of UDCA treatment on the phosphorylation of selected AKT downstream targets was 
investigated using western blotting and immunocytochemistry; however, no positive results were 
obtained. More work is needed to identify AKT/non-AKT downstream targets that are 
activated/inhibited upon UDCA treatment. 
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BAD            Bcl-2-associated death promoter  
BAG-1         BAG family molecular chaperone regulator 1  
BAK             Bcl-2 homologous antagonist-killer protein  
BAs             Bile acids  
BAX             BCL2-associated X protein 
BBB             Blood brain barrier  
BCL-2          B-cell lymphoma 2  
BCL-Xl         B-cell lymphoma-extra large  
BDNF          Brain-derived neurotrophic factor  
BG12           Dimethyl fumarate  
BID              BH3 interacting-domain death agonist  
BIM              Bcl-2-like protein 11  
BMP2          Recombinant bone morphogenetic protein 2  
BSA             Bovine serum albumin  
CA               Cholic acid  
CaMKII        Ca2+/calmodulin-dependent protein kinase  
cAMP          Cyclic adenosine monophosphate  
CBP             CREB-binding protein  
CCCP          Carbonyl cyanide m-chlorophenyl hydrazone 
CDCA          Chenodeoxycholic acid  
CHO            Chinese hamster ovary  
Chr              Chromosome  
Cnc              Cap 'n' Collar  
Cnc-bZIP     Cnc-basic leucine zipper  
CNS            Central nervous system  
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CREB          cAMP response element binding  
CSF             Cerebrospinal fluid  
DA               Dopaminergic  
DAT             Dopamine transporter  
DAQ            DA-quinone  
dbcAMP      Dibutyryl cyclic adenosine monophosphate  
DCA            Deoxycholic acid  
DCF             6-carboxy-2',7'-dichlorodihydrofluorescein  
DMEM         Dulbecco’s Modified Eagle Medium  
DMSO         Dimethyl sulfoxide  
DOPAL        3,4-dihydroxyphenylacetaldehyde  
Drp1            Dynamin-related Protein 1  
DTT             Dithiothreitol  
DUA            Dehydro (11,12) ursolic acid lactone 
EDTA          Ethylenediaminetetraacetic acid  
Erk2             Mitogen-activated protein kinase 1 
FBS             Foetal bovine serum  
Fis1             Mitochondrial fission 1 protein  
FMN            Flavin mononucleotide  
FOXO          Forkhead box O  
FTH1           Ferritin Heavy Chain 1 
G6P             Glucose-6-phosphate  
GAPDH       Glyceraldehyde-3-Phosphate Dehydrogenase 
GBA            Glucocerebrosidase  
GCLC          Glutamate-Cysteine Ligase Catalytic Subunit 
GDF5          Growth/differentiation factor 5  
GDNF          Glial cell line-derived neurotrophic factor  
GFP             Green fluorescent protein  
GRs             Glucocorticoid receptors  
GSH            Glutathione  
GSK3β        Glycogen synthase kinase 3 beta  
GST             Glutathione S-transferase  
GTP             Guanosine Triphosphate  
GWASs        Genome wide association studies  
HEPES        4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HES             Hospital Episode Statistics  
HMOX1        Heme Oxygenase 1 
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HRP             Horseradish peroxidase  
HtrA2           High temperature requirement protein A2 
IB                 Mitochondrial isolation buffer  
ICC              Immunocytochemistry  
IL-6              Interleukin-6  
ILK               Integrin-linked kinase  
iNPCs          neuronal progenitor cells  
iNs               Induced neurosn  
INT              Iodonitrotetrazolium violet  
iPSCs          Human induced pluripotent stem cells  
JNK              C-Jun N-terminal kinase  
K/O              knockout  
Keap1          Kelch-like ECH-associated protein 1  
KID              Kinase-inducible domain  
KIX              KID-interacting domain 
LBs              Lewy bodies 
LC3             Microtubule-associated protein 1A/1B-light chain 3  
LCA             Lithocholic acid  
LDH             Lactate dehydrogenase enzyme  
L-DOPA       L-tyrosine into L-3,4-dihydroxyphenylalanine  
LRRK2         Leucine-rich repeat kinase 2  
MAP2          Microtubule-associated protein 2  
MAPK          Mitogen-activated protein kinase         
MCL-1         Induced myeloid leukaemia cell differentiation 
MDM2         Mouse double minute 2 homolog  
MEFs          Mouse embryonic fibroblasts  
Mff               Mitochondrial fission factor 
Mfn1,2         Mitofusin 1,2  
MiD49, 51    Mitochondrial dynamics proteins 49, 51           
MPP+          1-methyl-4-phenylpyridinium     
MPTP          1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MTA            Material Transfer Agreement  
mtDNA        Mitochondrial DNA  
mTORC2     Mechanistic target of rapamycin (mTOR) complex 2  
mtSSB         Mitochondrial single-stranded DNA-binding protein  
NADH/NAD+Nicotinamide adenine dinucleotide  
ND1             NADH dehydrogenase subunit 1  
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Neh              Nrf2-ECH homology  
NQO1          NAD(P)H:quinone oxidoreductase  
Nrf2             Nuclear factor erythroid 2-like 2 or [NFE2L2] 
Ns                Not Statistically Significant  
NSAIDs       Non-steroidal anti-inflammatory drugs  
OPA1           Optic Atrophy 1  
OR               Odds ratio 
OXPHOS     Oxidative phosphorylation  
PARIS         Parkin interacting substrate  
PBS             Phosphate-buffered saline  
PD               Parkinson’s disease  
PDK1             Pyruvate dehydrogenase kinase 
PFA             Paraformaldehyde  
PGC-1α       Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PH               Pleckstrin homology 
PHLPPs       PH-domain leucine-rich repeat protein phosphatases  
PKC             Protein kinase C            
PI3               Phosphoinositide 3 
Pl3K             Phosphoinositide 3-kinase 
PIP2             Phosphatidylinositol 4,5-bisphosphate  
PIP3             Phosphatidylinositol 3,4,5 trisphosphate  
POLRMT      Mitochondrial RNA polymerase  
POLG           DNA polymerase subunit gamma-1 
PP2A           Protein phosphatase 2A  
PTEN           Phosphatase and tensin homologue  
PTM             Post-translational modification  
PUMA          P53 upregulated modulator of apoptosis 
PVDF           Polyvinylidene fluoride  
RA               Retinoic acid  
RARE          Retinoic acid response element 
RHEB          Ras homolog enriched in the brain  
ROS            Reactive oxygen species 
S6K1            S6 kinase beta-1  
SD               Standard deviation 
SDS             Sodium dodecyl sulfate  
SHIP           Src homology domain 2 (SH2)-containing inositol phosphatase  
SMAC          Second mitochondria-derived activator of caspases 
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SNpc            Substantia nigra pars compacta  
SNPs           Single-nucleotide polymorphisms  
SOD2          Superoxide dismutase 2  
STH            Sheffield Teaching Hospitals  
TBST           Tris-buffered saline with Tween 20  
TFAM          Mitochondrial transcription factor A 
TFB2M        Mitochondrial transcription Factor B2 
TGR5          G-protein coupled receptor  
TH               Tyrosine hydroxylase  
TOM            Translocase of the outer membrane 
TPA             12-O-tetradecanoylphorbol-13-acetate  
TSC 1, 2      Tuberous sclerosis complexes 1, 2 
TUDCA        Tauroursodeoxycholic acid 
TuJ1            Neuron-specific class III β-tubulin  
UA               Ursolic acid 
UCA            Ursocholanic acid 
UCP1, 2      Uncoupling protein 1, 2  
UDCA          Ursodeoxycholic acid 
VDAC          Voltage-dependent anion channel  
VMAT2        Vesicular monoamine transporter 2  
















1.1 Parkinson’s disease 
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. It has an 
estimated prevalence of 0.1 to 0.2% in the entire population and affects about 1% of people older 
than 60 years (Tysnes and Storstein, 2017, Pringsheim et al., 2014).  
PD is a chronic progressive motor disease that influences patients’ lives significantly. Treatment 
of PD in the United Kingdom (UK) has an estimated cost of more than £15,000 per patient, per 
year (Bovolenta et al., 2017). According to a cross-sectional analysis of British hospitals, the total 
number of PD admissions in the UK was more than 180,000 between 2009 and 2013 (Low et al., 
2015). In this study, the Hospital Episode Statistics (HES) database was used to investigate the 
burden of hospitalisation of PD, in comparison to other admissions (Low et al., 2015). It was found 
that PD patients have a 1.5 to 2.6 greater chance of suffering serious conditions, such as 
pneumonia, urinary tract infection and hip fracture (Low et al., 2015). A meta-analysis report, 
which included more than 80 studies, found an approximate 5% annual decrease in survival rate 
and a crude mortality ratio of around 1.5 in comparison to healthy controls (Macleod et al., 2014). 
1.1.1 History, manifestations and pathology 
The history of PD extends back to 1817, when English physician James Parkinson described and 
grouped the features of the disease as one neurological syndrome. Based on observations of 
only six cases, he specified all major cardinal manifestations, including bradykinesia (slowness of 
movement), rest tremor (occurs involuntarily when the muscle is relaxed), rigidity and gait 
disturbance (walking with steps of little acceleration) (Duvoisin, 1987). 
The diagnosis of PD requires detailed patient history and full physical examination. Even when a 
patient has the primary motor signs, the physician still needs to exclude alternative diagnoses, 
and might start a trial treatment to assess the response of the patient before giving a definite 
diagnosis (Poewe et al., 2017). In addition to motor signs, there are various non-motor 
manifestations that might appear before or after the classical motor features (Pont‐Sunyer et al., 
2015). Since PD treatment only alleviates motor symptoms, non-motor symptoms can become a 
major problem for patients (Schapira et al., 2017). These include sensory malfunctions, such as 
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pain, hyposmia and visual disturbances, or neuropsychiatric features, such as sleep disorders, 
anxiety, depression, cognitive deficits and dementia (Schapira et al., 2017). PD patients might 
also have bladder and gastrointestinal dysfunctions.  
Motor manifestations of PD are predominantly attributed to the degeneration of dopaminergic 
(DA) neurons in the substantia nigra pars compacta (SNpc) in the basal ganglia. The 
degeneration re-shapes the circuitry of the basal ganglia and consequently alters their projection 
activity and overall functionality (Wichmann et al., 2011). The basal ganglia’s primary function is 
to control motor signals. Nonetheless, the basal ganglia are also connected to various specific 
areas in the brain, such as orbitofrontal, limbic and association areas, via their projection loops 
(Ikemoto et al., 2015). This explains, at least in part, the non-motor manifestations in PD  
(Shulman et al., 2011). Pathological studies have found that a significant portion of DA neurons 
are already degenerated at the early stages of PD, suggesting that the degeneration and the 
pathological process may start years before clinical recognition of the disease (Dijkstra et al., 
2014) [Figure 1.1]. 
Another characteristic pathological feature in PD is the presence of intra-cytoplasmic eosinophilic 
inclusions, called Lewy bodies (LBs) (Poewe et al., 2017). LBs are protein aggregates that are 
mainly composed of α-synuclein protein (Baba et al., 1998). They are often found in various areas 
in the central and peripheral nervous system. Non-basal LBs have been linked to the non-motor 






Figure 1.1 The relationship between the manifestations of PD and the loss of dopaminergic neurons.  
By the time clinical manifestations appear, significant DA neuronal loss has already occurred. Dopamine 
replacement therapy only alleviates motor manifestations, but does not modulate the rate of degeneration. 
Re-produced with permission from Schapira (2017). 
 
1.1.2 Genetics of Parkinson’s disease 
PD can be classified into familial and sporadic. There are currently 21 chromosomal loci (PARK 
loci) that segregate with the familial form of the disease. Yet, the causative genes and mutations 
in some of these loci still await confirmation (Kumaran and Cookson, 2015). Monogenic PD, which 
is caused by a single mutation in a dominantly or recessively inherited gene, accounts only for 5 
to 10% of all cases (Poewe et al., 2017). PD loci, as well as their inheritance pattern and 
associated form of the disease, are listed in Table 1.1.  
The first identified mutation in PD gene was the α-synuclein gene SNCA in 1987 (Polymeropoulos 
et al., 1997). The identified missense mutation, Ala53Thr, in this gene, was associated with a 
relatively high progression autosomal dominant early onset PD (Polymeropoulos et al., 1997). To 
date, only five more mutations have been discovered: Ala30Pro, Glu46Lys, Gly51Asp, His50Gln 
and Ala53Glu. The pathogenicity of His50Gln has been disputed (Blauwendraat et al., 2018). In 
addition to point mutations, α-synuclein duplication/triplication has also been linked to familial PD 
(Chartier-Harlin et al., 2004, Singleton et al., 2003). In these conditions, the amount of α-synuclein 
22 
 
has been found to positively correlate with the severity of the disease, and to negatively correlate 
with the age of onset. Despite these interesting findings, α-synuclein mutations are rare and 
account only for 1 to 2% of all cases of autosomal dominant PD (Kalinderi et al., 2016). 
Leucine-rich repeat kinase 2 (LRRK2) mutations are more common than α-synuclein mutations 
and represent 10% of all familial PD cases (Kalinderi et al., 2016). Dozens of LRRK2 mutations 
have been identified. However, only seven of these have a high degree of association with PD. 
The most common is Gly2019Ser, followed by Arg1441His, Arg1441Gly, Arg1441Cys, 
Y1699Cys, Ile2020Thr and Asn1437His (Abdullah et al., 2015). The prevalence of the 
Gly2019Ser mutation in PD patients vary across populations. The highest percentage is found in 
northern African Arab populations (37 to 41% of both familial and sporadic PD) (Lesage et al., 
2006), followed by Ashkenazi Jewish populations (10 to 20% of both familial and sporadic PD) 
(Ozelius et al., 2006). The penetrance of this mutation increases with age, as the risk increases 
from around 30% at age 60 up to 74% at age 80 (Healy et al., 2008). While clinically 
indistinguishable from sporadic PD, pathological examination showed tauopathy and 
neurofibrillary tangles, as well as LB (Kalinderi et al., 2016). 
The parkin gene was identified one year after the discovery of an α-synuclein mutation in a family 
with autosomal recessive juvenile parkinsonism (ARJP) (Kitada et al., 1998). Generally, this class 
of PD has some atypical signs, such as psychiatric manifestations and dystonia, but the major 
feature is the early age of onset (Kalinderi et al., 2016). Parkin mutations are the most common 
cause for ARJP, with a prevalence of approximately 50% in PD patients aged under 25 (Kalinderi 
et al., 2016). Dozens of parkin mutations have been identified. Notably, LB pathology was not 
found in all parkin cases (Kalinderi et al., 2016). However, a significant generalised degeneration 




Table 1.1 The loci of familial PD. 
Loci Gene Inheritance Phenotype Reference 
PARK1 SNCA AD Early onset (Polymeropoulos et al., 1997) 
PARK2 parkin AR Early onset (Kitada et al., 1998) 
PARK3 Unknown AD Classical (Gasser et al., 1998) 
PARK4 SNCA AD Early onset (Singleton et al., 2003) 
PARK5 UCHL1 AD Classical (Leroy et al., 1998) 
PARK6 PINK1 AR Early onset (Valente et al., 2004) 
PARK7 DJ-1 AR Early onset (Bonifati et al., 2003) 
PARK8 LRRK2 AD Classical (Paisán-Ruıź et al., 2004) 
PARK9 ATP13A2 AR Atypical PD (Ramirez et al., 2006) 
PARK10 Unknown Risk factor Classical (Hicks et al., 2002) 
PARK11 Unknown AD Late onset (Pankratz et al., 2003b) 
PARK12 Unknown Risk factor Classical (Pankratz et al., 2003a) 
PARK13 HTRA2 AD / Risk factor Classical (Strauss et al., 2005) 
PARK14 PLA2G6 AR Early onset (Paisan‐Ruiz et al., 2009) 
PARK15 FBX07 AR Early onset (Di Fonzo et al., 2009) 
PARK16 Unknown Risk factor Classical (Satake et al., 2009) 
PARK17 VPS35 AD Classical (Zimprich et al., 2011) 
PARK18 EIF4G1 AD Classical (Chartier-Harlin et al., 2011) 
PARK19 DNAJC6 AR Juvenile atypical PD (Edvardson et al., 2012) 
PARK20 SYNJ1 AR Juvenile atypical PD (Krebs et al., 2013) 
PARK21 DNAJC13 AD Late onset (Vilariño-Güell et al., 2013) 
A list of PD loci showing the affected genes (if identified), the mode of inheritance and the associated 
phenotype. The term PARKs is used to denote chromosomal loci that have been associated with PD and 
they are numbered in chronological order. (AD): autosomal dominant, (AR): autosomal recessive. 
 
1.1.3 Risk factors for Parkinson’s disease 
While the majority of PD cases are sporadic, with no definitive cause, epidemiological 
investigations have shown that there are environmental, behavioural and genetic factors that 
increase or, occasionally, decrease the risk of the disease. It is important to point out that in 
comparison to these factors, ageing is still the most important risk factor. However, studying these 
risk factors has significantly enhanced our understanding of PD. 
Environmental risk factors 
The discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) - induced Parkinsonism in 
drug abusers led to the assumption that environmental toxins may contribute to the aetiology of 
PD (Langston et al., 1983). There are numerous epidemiological studies investigating the link 
between environmental or industrial toxins and PD, driven by the fact that MPTP is structurally 
similar to pesticides. Additionally, researchers have investigated the effect of metals such as iron, 
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zinc, lead and copper. While many studies showed controversy with regard to metal exposure 
and the risk of PD (Goldman, 2014), the results were more consistent with regard to pesticide 
exposure. A worldwide meta-analysis of more than 40 studies showed an increased risk ratio of 
about 1.6 (95% confidence interval: 1.4 to 1.9) for those who have been exposed to pesticides 
(Mark et al., 2012). A large case control study that involved 767 patients with PD around Europe 
concluded that pesticide exposure was statistically associated with PD (attributable risk: 8.1%, 
odds ratio: 3.22, p-value: 0.002, confidence interval: 1.56 to 6.65) (Gorell et al., 2004). The same 
study found that exposure to metals (copper, iron, lead and manganese) did not increase the risk 
of PD. In a longitudinal agricultural health study that lasted for 10 years, the risk of PD was 
positively correlated with the number of days of pesticide exposure (Ascherio and Schwarzschild, 
2016). The association was higher with pesticides that compromise mitochondria, such as 
rotenone and paraquat (Ascherio and Schwarzschild, 2016). Since pesticides are widely used in 
agriculture, it is not surprising that many studies have suggested a link between PD and farming, 
rural living and well-water drinking (Das et al., 2010, Moisan et al., 2011).  
Genetic risk factors 
Gaucher disease is an autosomal recessive storage disorder caused by bi-allelic mutations in the 
glucocerebrosidase gene (GBA) (Ferreira and Massano, 2017). Clinicians have noted that 
patients and their relatives have a higher incidence rate of PD. Initial studies in the Ashkenazi 
Jewish population revealed that GBA mutations increased the risk of PD up to seven fold (Chen 
et al., 2007b). A subsequent worldwide study also found that GBA mutations are consistently 
associated with an increased risk of PD disease (odds ratio: 5.43, 95% confidence interval: 3.89 
to 7.57) (Sidransky et al., 2009). To date, GBA mutations are the most common genetic risk 
factors for PD (Ferreira and Massano, 2017). 
A leap forward in PD research has been accomplished following the advent of genome-wide 
association studies (GWAS), which allow researchers to identify novel associations in genes that 
may not have been strong priori candidates for PD. The largest GWAS was performed in 2014 
and investigated over seven million variants across 13,708 cases and 95,282 controls, identifying 
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more than 20 independent risk variants for PD (Nalls et al., 2014). The identified single-nucleotide 
polymorphisms (SNPs) are listed in Table 1.2.  
 
Table 1.2 Risk loci identified in a large-scale meta-analysis of genome-wide association data. 







rs35749011 1 GBA-SYT11 A G 1.824 1.37 × 10−29 
rs823118 1 RAB7L1-NUCKS1 T C 1.122 1.66 × 10−16 
rs10797576 1 SIPA1L2 T C 1.131 4.87 × 10−10 
rs6430538 2 ACMSD-TMEM163 T C 0.875 9.13 × 10−20 
rs1474055 2 STK39 T C 1.214 1.15 × 10−20 
rs115185635 3 KRT8P25-APOOP2 C G 1.142 0.022 
rs12637471 3 MCCC1 A G 0.842 2.14 × 10−21 
rs34016896 3 NMD3 T C 1.067 1.08 × 10−5 
rs34311866 4 TMEM175-GAK-DGKQ T C 0.786 1.02 × 10−43 
rs11724635 4 BST1 A C 1.126 9.44 × 10−18 
rs6812193 4 FAM47E-SCARB2 T C 0.907 2.95 × 10−11 
rs356182 4 SNCA A G 0.76 4.16 × 10−73 
rs9275326 6 HLA-DQB1 T C 0.826 1.19 × 10−12 
rs199347 7 GPNMB A G 1.11 1.18 × 10−12 
rs591323 8 FGF20 A G 0.916 6.68 × 10−8 
rs60298754 8 MMP16 T C 1.078 0.181 
rs117896735 10 INPP5F A G 1.624 4.34 × 10−13 
rs7077361 10 ITGA8 T C 1.092 4.16 × 10−5 
rs3793947a 11 DLG2 A G 0.929 3.96 × 10−7 
rs329648 11 MIR4697 T C 1.105 9.83 × 10−12 
rs76904798 12 LRRK2 T C 1.155 5.24 × 10−14 
rs11060180 12 CCDC62 A G 1.105 6.02 × 10−12 
rs11158026 14 GCH1 T C 0.904 5.85 × 10−11 
rs1555399 14 TMEM229B A T 0.897 6.63 × 10−14 
rs2414739 15 VPS13C A G 1.113 1.23 × 10−11 
rs14235 16 BCKDK-STX1B A G 1.103 2.43 × 10−12 
rs17649553 17 MAPT T C 0.769 2.37 × 10−48 
rs11868035 17 SREBF1-RAI1 A G 0.939 5.98 × 10−5 
rs12456492 18 RIT2 A G 0.904 7.74 × 10−12 
rs62120679 19 SPPL2B T C 1.097 5.57 × 10−7 
rs8118008 20 DDRGK1 A G 1.111 3.04 × 10−11 
rs2823357 21 USP25 A G 1.031 0.027 
A list of SNPs identified in the meta-analysis of a genome-wide association study. The joint phase 
represents the combination of the cases from the discovery phase and the replication phase. The replication 
phase was conducted to identify which of the putatively associated loci were truly relevant to the disease, 
via the addition of independent sample series. (SNP): Single-nucleotide polymorphism, (Chr.): 





Interestingly, variants of known familial PD genes are present in this list. A complex polymorphic 
microsatellite repeat named Rep1, which is located in the promotor region of the SNCA gene, is 
the best example. The 261bp variant increases the risk for PD, while the 259bp variant is 
protective, arguably via modulating the gene expression level (Maraganore et al., 2006, Mata et 
al., 2010, Kalinderi et al., 2016). In addition, variants in LRRK2, such as Gly2385Arg and 
Arg1628Pro polymorphisms, have been linked to increased PD risk in the Asian population 
(Kalinderi et al., 2016). These findings suggest that sporadic PD is mechanistically related to 
inherited disease. Thus, studying the underlying pathological pathways in familial PD may be 
relevant to the sporadic form as well. The evidence of genetic involvement in the disease has led 
researchers to propose that Mendelian and sporadic forms of PD can be considered as two 
extremes of one spectrum, where a single mutation causes the disease, whereas others 
contribute to increasing the risk to different degrees (Spataro et al., 2015).  
Other risk factors 
Identifying novel risk factors for PD has been an objective of a vast number of researchers. While 
some have found statistically significant results, others have either failed to do so, or have 
reached conclusions that are inconsistent with other studies. The investigated risk factors include 
body mass index, diabetes, cholesterol level, hypertension, antioxidant vitamins such as vitamin 
C and E, intake of vitamin D and calcium, iron intake, oral contraceptives and pregnancy (Ascherio 
and Schwarzschild, 2016). The inconsistency between results does not necessarily mean a lack 
of association, as there might be unidentified factors that modulate the association. Amongst 
confirmed associations, overconsumption of milk and dairy products have consistently been 
shown to increase the risk of PD in several papers (Chen et al., 2007b, Jiang et al., 2014). Another 
well-established association is observed between PD and melanoma, where the presence of 
either of them increases the risk of the other (Wirdefeldt et al., 2013, Constantinescu et al., 2014). 
In contrast to milk consumption and melanoma, the risk of PD is reduced amongst smokers (Li et 
al., 2015). The decrease in risk is positively correlated with the duration of smoking and negatively 
correlated with the number of years passed after quitting smoking (Thacker et al., 2007). Other 
protective factors include caffeine and non-steroidal anti-inflammatory drugs (NSAIDs) (Ascherio 
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and Schwarzschild, 2016). Alcohol intake was also associated with a small decrease in PD risk, 
unless overconsumption of alcohol took place (Ascherio and Schwarzschild, 2016).  
 
1.2 Mitochondria 
Impairment of different molecular biological pathways has been suggested as an underlying 
cause of the neuronal degeneration in PD, such as altered proteolysis, inflammatory changes and 
excitotoxicity (Celardo et al., 2014). However, numerous discoveries in genetically-based studies 
have placed mitochondrial dysfunction as a central part of the disease pathology. This is not a 
novel finding since the first link between mitochondrial dysfunction and PD was suggested 
decades before the genetic breakthrough (Lin and Beal, 2006). The MPTP-induced Parkinsonism 
in drug abusers was found to be associated with mitochondrial respiratory complex l inhibition. A 
similar finding was also reported in different brain regions of PD patients, as well as in fibroblasts, 
lymphocytes and blood platelets (Yoshino et al., 1992, Krige et al., 1992, Mytilineou et al., 1994). 
Genetic studies of PD have shown that other elements in the mitochondria can also be affected. 
Hence, understanding mitochondrial biology is important in PD research. 
1.2.1 Mitochondrial origin and history 
Mitochondria generate the energy-storing molecule adenosine triphosphate (ATP), which is the 
main source of energy in all human cells. ATP is also crucial for various cellular functions, such 
as biosynthesis, protein folding and degradation, cellular migration, neuronal cell signalling and 
muscle contraction (Kühlbrandt, 2015). In the course of evolution of eukaryotic cells, the 
emergence of the mitochondria is considered as one of the most critical stages. It is believed that 
an interaction between primogenitor oxidative bacteria and glycolytic cells led to the development 
of a syntrophic relationship, which eventually resulted in the engulfment of the live bacteria by the 
cells (endosymbiosis). The endosymbiosis occurred one and a half billion years ago. With time, 
the bacteria became what we now know as mitochondria (Ettema, 2016). This endosymbiosis 
process was remarkably beneficial to the eukaryotic cells, as it provided a superfluous amount of 
energy that facilitated the emergence of more complex cellular components and pathways. In the 
current time, Mitochondria still have their own genetic system and protein translation machinery 
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(Dennerlein et al., 2017). However, they have become heavily integrated into the biology of the 
cells (Couvillion et al., 2016). The current mitochondria rely mostly on nuclear genes for protein 
synthesis (Couvillion et al., 2016).  
1.2.2 Mitochondrial structure 
The gross structure of mitochondria was revealed by light more than 100 years ago (Ernster and 
Schatz, 1981, Kühlbrandt, 2015). However, the visualisation of their detailed structure was not 
possible until the invention of the high-resolution electron microscope in 1952 (Ernster and 
Schatz, 1981, Kühlbrandt, 2015). The advance in imaging technology allowed a more in-depth 
study of mitochondrial structure. For example, the use of electron tomography revealed the 
structure of the inner membrane in three-dimensional space, while the use of Cryo-EM revealed 
mitochondrial macromolecular components at nanometre scales (Perkins and Frey, 2000). 
The mitochondrion is composed of outer and inner membranes [Figure 1.2], which correspond to 
the cellular membrane-derived vesicle and the bacterial membrane, according to the 
endosymbiosis theory (Ettema, 2016). The outer membrane has channels that are made by 
distinct proteins (porins), such as the voltage-dependent anion channel (VDAC), which makes it 
permeable to ions and small uncharged molecules (Prasai, 2017). There are also specific 
transporters for larger proteins (Prasai, 2017). On the other hand, the inner membrane only allows 
the passage of certain molecules by highly sophisticated transporters (Prasai, 2017). The 
innermost compartment of the mitochondria [Figure 1.2], the mitochondrial matrix, has a high pH 
(7.9) and protein concentration, and it is the site for mitochondrial transcription and translation 
(Prasai, 2017). All mitochondrial genes are present in this compartment (Kühlbrandt, 2015). The 
inner membrane form cristae that extend deep into the matrix (Cogliati et al., 2016). Since the 
inner membrane is the site of oxidative phosphorylation, these invaginations significantly increase 
the surface area of the inner membrane and, consequently, increase the efficiency of ATP 
production. Most of the inner membrane contributes to the cristae, particularly in cells that require 
a high energy supply, such as myocytes (Kühlbrandt, 2015). The cristae region of the inner 
membrane contains all of the respiratory chain protein complexes. The remaining parts of the 
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inner membrane are separated from the outer membrane by the intermembrane space 
(approximately 20nm) [Figure 1.2] (Prasai, 2017). 
1.2.3 Oxidative phosphorylation and energy production 
Oxidative phosphorylation (OXPHOS) is the process through which cells produce ATP via the 
use of the five respiratory chain complexes. In this process, four of the complexes pump protons 
from the matrix into the intermembrane space, leading to an increase in the electrochemical 
gradient across the inner membrane (Lemarie and Grimm, 2011). Concentrated protons can only 
pass through the fifth respiratory chain complex, the ATP synthase complex, resulting in the 
phosphorylation of the low energy molecule adenosine diphosphate (ADP) into ATP (Lemarie and 
Grimm, 2011).  
Complex I ( Nicotinamide adenine dinucleotide (NADH) dehydrogenase) is a large complex that 
is composed of more than 40 proteins (Zhu et al., 2016). The functions of most of its subunits are 
not yet understood. Complex I oxidises a molecule of NADH into NAD+. In this process, two 
electrons are released and transported via the flavin mononucleotide (FMN) and several iron 
sulphur centres within complex I, and bind to coenzyme Q10 (also known as ubiquinone) 
(Efremov et al., 2010). In addition, two hydrogen ions (H+) from the matrix bind ubiquinone and 
reduce it to ubiquinol (Efremov et al., 2010). In contrast to the stationary respiratory complexes, 
ubiquinone/ubiquinol are electron acceptors/donors, which move freely between the complexes, 
facilitating electron transfer. Following the reduction, ubiquinol travels through the inner 
membrane and associates with respiratory complex III (Chaban et al., 2014). The NADH oxidation 
also results in pumping four hydrogen ions from the matrix to the intermembrane space (Chaban 
et al., 2014). 
Complex III (cytochrome c oxidoreductase) extracts the two electrons from the ubiquinol via 
cytochrome b and c1 subunits (Chaban et al., 2014). Consequently, the two electrons are 
transferred into two cytochrome c molecules, another mobile protein that is usually associated 
with complex III. A further four hydrogen ions are pumped into the intermembrane space as a 




Complex IV (cytochrome c oxidase) uses the two electrons to reduce oxygen into one water 
molecule. Therefore, oxygen is the final electron acceptor in the respiratory chain. This step is 
associated with pumping two hydrogen ions into the intermembrane space (Chaban et al., 2014). 
The hydrogen ions pass through the F0 part (the transmembrane part) of Complex V (ATP 
synthase) in compliance with their electrochemical gradient, and rotate the C subunits (belong to 
the F1 part which presents in the matrix) (Koopman et al., 2013). This rotation drives the 
conversion of ADP into ATP at the matrix side of the inner mitochondrial membrane (Koopman et 
al., 2013). The passage of three to four hydrogen ions is required to generate one ATP molecule 
(Hattori and Gouaux, 2012). Accordingly, oxidative phosphorylation of one NADH molecule 
results in the generation of 2.5 - 3 ATP molecules, theoretically.  
Complex II (succinate oxireductase) is an alternate electron entry point from complex I (Chaban 
et al., 2014). Complex II facilitates the conversion of succinate into fumarate within the citric acid 
(Krebs) cycle, and concomitantly reduces FAD into FADH2 (Chaban et al., 2014). FADH2 
provides the electrons that will be transported through the electron chain. Complex II transfers 
the two electrons via its iron centres into ubiquinone and reduces it to ubiquinol, which 
translocates to complex III as described above (Chaban et al., 2014). This process is not 
associated with pumping of hydrogen ions from the matrix to the intermembrane space. Notably, 
the total number of pumped hydrogen ions associated with the FADH2 molecule is six, because 
it does not pass through complex I. Therefore, oxidative phosphorylation of one FADH2 molecule 
generates 1.5 – 2 ATP molecules, theoretically.  
It is important to note that energy production is not the only function of the mitochondria. Through 
the course of evolution, the mitochondria developed multiple roles to support the survival of 
organisms. For example, in mammals, mitochondria can maintain body temperature by 
generating heat instead of ATP (Cedikova et al., 2016). This phenomenon is attributed to a 
mitochondrial inner membrane channel protein named thermogenin or uncoupling protein 1 
(UCP1), which leaks protons and causes mitochondrial uncoupling (Cedikova et al., 2016). In 
addition, mitochondria have a pivotal role in determining cell fate, as they can initiate apoptotic 
signalling. Via the production of reactive oxygen species (ROS), mitochondria are involved in 
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homeostatic pathways and contribute to adaptive stress signalling pathways (Hamanaka and 
Chandel, 2010). Moreover, mitochondria can modulate the levels of amino acids, metabolites and 
numerous regulatory enzymes, such as histone deacetylases, and play an important role in iron 
metabolism, which is a vital component in haemoglobin and respiratory chain complexes (Nunnari 
and Suomalainen, 2012). With regard to neurons, mitochondria play a role in lipid acid synthesis, 
which is particularly important for neuronal physiology (Mayr et al., 2011). Moreover, the ability of 
the mitochondria to regulate Ca+2 flux from the plasma membrane and endoplasmic reticulum is 
critical for neurogenesis, neuronal plasticity and neurotransmitter release (Nunnari and 
Suomalainen, 2012).  
 
 
Figure 1.2 An overview of mitochondrial structure and respiratory chain complexes.  
Mitochondria are double-membrane organelles that contain three separate compartments. All respiratory 
protein complexes are distributed along the inner membrane, and are organised to pump hydrogen ions 
into the intermembrane space (Adam-Vizi and Chinopoulos, 2006). 
1.2.4 Mitochondrial dynamics 
Mitochondrial morphology varies depending on a number of factors, including cell type and 
metabolic/nutrient status (Mishra and Chan, 2016). Mitochondria undergo two main dynamic 
processes that regulate their morphology: fission and fusion. The net balance between these two 
processes determines whether the mitochondria look fragmented or elongated (Mishra and Chan, 




Mitochondrial fission is mainly regulated by dynamin-related protein 1 (Drp1) (Youle and Van Der 
Bliek, 2012). The process involves the accumulation of Drp1 as a ring around the outer 
mitochondrial membrane, via binding to a group of receptors such as mitochondrial fission factor 
(Mff), mitochondrial fission 1 protein (Fis1) and mitochondrial dynamics proteins (MiD49), and 
(MiD51) (van der Bliek et al., 2013). Then, the Drp1 ring incises the mitochondria in a guanosine 
triphosphate (GTP)-dependent manner (van der Bliek et al., 2013). In humans, Drp1 mutation has 
been linked to microencephaly, refractory epilepsy and neonatal death (Vanstone et al., 2016, 
Waterham et al., 2007). 
Drp1 activity is mainly regulated via phosphorylation, but other post-translational modifications 
(PTM) such as SUMOylation and ubiquitination are also reported (Chang and Blackstone, 2010). 
Various kinases and phosphorylation sites have been identified (Dickey and Strack, 2011) 
(Kashatus et al., 2015). The response of Drp1 to either phosphorylation or dephosphorylation is 
site dependant. For example, phosphorylation at ser637 by protein kinase A supresses Drp1 
activity and increases mitochondrial length (Chang and Blackstone, 2007). Similarly, 
phosphorylation at ser637 as a result of mTOR inhibition diminishes Drp1 activity (Gomes et al., 
2011). On the other hand, mitogen-activated protein kinase 1 (Erk2) and Ca2+/calmodulin-
dependent protein kinase (CaMKII) phosphorylate Drp1 at ser616 and enhance its activity 
(Kashatus et al., 2015, Bo et al., 2018). Mitochondrial uncouplers, such as carbonyl cyanide m-
chlorophenyl hydrazone CCCP, which classically induce mitochondrial fragmentation, also 
activate Drp1. The activation is achieved via dephosphorylating ser637 through the action of 
Ca2+-dependent phosphatase calcineurin (Cereghetti et al., 2008). Moreover, CCCP stimulates 
the mitochondrial metalloprotease Oma1 to increase the amount of the short form of optic atrophy 
1 (Opa1), which indirectly promotes fission by downregulating fusion (Mishra and Chan, 2016). 
Fusion 
Mitochondrial fusion is mainly regulated by the outer membrane proteins, Mitofusin 1 (Mfn1) and 
Mitofusin 2 (Mfn2), and the inner membrane protein, Opa1 (Westermann, 2012). The deletion of 
fusion proteins results in significant mitochondrial fragmentation and eliminates the free 
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movement of mitochondrial content within the mitochondria (Mishra and Chan, 2016). 
Mitochondrial fusion has a positive correlation with OXPHOS. Mitochondria tend to elongate in 
conditions that require more energy via OXPHOS, such as culturing cells in a galactose medium 
(Ren et al., 2017). In contrast, fragmented mitochondria are less efficient in energy production 
(Liesa and Shirihai, 2013). Evidence suggests that the response to reduced fusion is cell 
dependant. Embryonic fibroblasts can tolerate deletion of a single Mfn protein, while neurons 
show a significant decrease in survival, which has been attributed to a decline in mitochondrial 
DNA (mtDNA) content and compromised respiratory chain activity (Chen et al., 2007a). Therefore, 
it is not surprising that mutations in those proteins result in neuron-related diseases, such as 
Charcot-Marie-Tooth disease type 2A (Mfn2 mutation) (Hikiami et al., 2018) and dominant optic 
atrophy (Opa1 mutation) (Millet et al., 2016).  
The long-inner membrane bound form of Opa1 can be cleaved into a short soluble form by the 
metalloproteases Yme1L and Oma1 (MacVicar and Langer, 2016). In contrast to the long Opa1, 
the cleavage of Opa1, together with the increase in its shorter form, is believed to stimulate 
mitochondrial fission (MacVicar and Langer, 2016). Evidence suggests that Yme1L and Oma1 
regulate inner membrane fusion according to the metabolic state of the cells. As an inner 
membrane protein, Opa1 also plays a role in stabilising mitochondrial cristae and respiratory chain 
supercomplex (Cogliati et al., 2013). 
 
1.3 Mechanisms of Parkinson’s disease 
1.3.1 Lessons learned from Parkinson’s genetics 
SNCA 
α-synuclein is a small protein that is believed to play a role in exocytosis and complex assembly 
of vesicles (Helley et al., 2017). α-synuclein predominantly presents in the cytoplasm. However, 
it is capable of interacting with mitochondria via its N-terminus, which has a specific mitochondrial 
targeting sequence (Helley et al., 2017). Research has revealed that some modified forms of α-
synuclein can bind Translocase of the outer membrane (Tom20) and block the import of proteins, 
leading to mitochondrial dysfunction (Di Maio et al., 2016). Additionally α-synuclein can travel 
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through VDAC, access the inner mitochondrial compartment and damage respiratory complex 
proteins and mtDNA (Rostovtseva et al., 2015). α-synuclein also inhibits mitochondrial biogenesis 
via downregulating PGC1 α, the key transcriptional factor in mitochondrial biogenesis 
(Rostovtseva et al., 2015). 
α-synuclein has a natural capability to aggregate to form oligomers and larger insoluble fibrils 
(Dehay et al., 2015). Studies have suggested that α-synuclein exists in different conformations 
that are in dynamic equilibrium (Dehay et al., 2015). When a toxic mutation presents, the balance 
shifts towards the insoluble fibril that aggregates to form LB. Artificially mutant α-synuclein that is 
unable to form insoluble fibrils has excessive toxicity in vivo (Winner et al., 2011). This observation 
indicates that LB body formation might be a protective process that prevents the mutated α-
synuclein from reaching the mitochondria. Transferring LB extract from PD patients into mice and 
monkeys induces progressive DA neuron degeneration and pathological conversion of 
endogenous α-synuclein, possibly via altering the dynamic of endogenous α-synuclein (Recasens 
et al., 2014).  
LRRK2 
LRRK2 is a protein that consists of multiple domains (Cookson, 2015). LRRK2 has a GTPase 
domain, kinase domain and several other protein interacting domains (Cookson, 2015). 
Therefore, LRRK2 is believed to have a complex role in cell biology. Research has shown that 
LRRK2 is involved in many cellular functions, such as cytoskeletal and vesicle dynamics, 
autophagy and mitochondrial functions (Helley et al., 2017). However, our understanding of 
LRRK2 is far from complete.  
In PD, most of the reported LRRK2 mutations have been associated with an increase in kinase 
activity which was associated with increased mitochondrial fragmentation (Helley et al., 2017) 
(Cookson, 2015). Researchers have found a direct interaction between LRRK2 and various 
mitochondrial dynamic proteins, such as Mfn1, Mfn2 and Opa1 (Kang and Marto, 2017). The 
expression of Gly2019Ser mutant LRRK2, as well as the overexpression of the wild type, was  
associated with Drp1-dependent mitochondrial fragmentation (Kang and Marto, 2017). These 
35 
 
findings are consistent with a previous study that reported Drp1 activation upon interaction with 
LRRK2 via phosphorylation at Thr595 (Su and Qi, 2013).  
In addition to abnormal mitochondrial morphology, functional mitochondrial impairments, such as 
decreased mitochondrial membrane potential and ATP levels, have been observed in patient 
fibroblasts (Mortiboys et al., 2010, Mortiboys et al., 2015). Increased levels of UPC2 have also 
been linked to LRRK2 mutations. In human neuroblastoma and mouse fibroblast models of 
LRRK2 Gly2019Ser mutation, mitochondrial membrane potential was increased upon using UCP 
activity inhibitors, as well as the LRRK2 kinase inhibitor (Papkovskaia et al., 2012).  
In human fibroblasts of Gly2019Ser mutant individuals, fibroblasts of both affected and carrier 
donors showed a decreased mitochondrial membrane potential (Grünewald et al., 2014b). 
However, the increase in UPC2 was seen only in cells of affected donors. In addition, not all cells 
with increased UPC2 showed an increase in oxidative stress levels (Grünewald et al., 2014b). 
Therefore, the increase in UCP2 expression could be a secondary outcome of LRRK2 pathology. 
The UCP2 level is known to be elevated in oxidative stress states to eliminate the effect of ROS 
through mild uncoupling of the respiratory chain (Hass and Barnstable, 2016).  
PINK1 and parkin 
There are several lines of defence to maintain a healthy mitochondrial pool. For example, 
mitochondrial chaperones facilitate proper folding of newly synthesised polypeptides (Harbauer 
et al., 2014). If chaperones fail, mitochondrial proteases can eliminate the misfolded proteins 
(Quirós et al., 2015). In addition, mitochondrial antioxidant enzymes help to lessen the effect of 
ROS on mitochondrial DNA and proteins (Sena and Chandel, 2012). When these mechanisms 
fail and mitochondrial damage occurs, the defective part is removed via a selective autophagy 
process (mitophagy), to be replaced by a newly synthesised component (Bingol and Sheng, 
2016). Mitophagy is vital to the cells since the presence of dysfunctional mitochondria does not 




Under normal conditions, PINK1 is continuously imported into the mitochondria, inserted into the 
inner mitochondrial membrane and cleaved by matrix-processing peptidases (Rüb et al., 2017). 
Under stressful conditions, PINK1 accumulates on the mitochondrial surface. This occurs as a 
result of decreased mitochondrial membrane potential, which interferes with PINK1 import into 
the mitochondrial inner membrane (Rüb et al., 2017). PINK1 recruits and activates Parkin via 
phosphorylation at ser65 (Rüb et al., 2017). Then, activated Parkin ubiquitinates nearby outer 
mitochondria membrane proteins, such as porin, mitofusin and Miro proteins (Sarraf et al., 2013). 
PINK1 also phosphorylates the ubiquitinated domains, which in turn activate more Parkin (Rüb et 
al., 2017). Adaptor proteins bind both ubiquitinated proteins and Microtubule-associated protein 
1A/1B-light chain 3 (LC3), allowing the mitochondria to be targeted by the autphagosomal 
membranes (Rüb et al., 2017). Ultimately, autophagosomes merge with lysosomes and 
mitochondrial contents degrade through the action of lysosomal enzymes. Via this mechanism, 
the PINK1/Parkin system ensures that autophagic membranes target only the defective part of 
the mitochondria. Interestingly, recent evidence shows that highly metabolic cells (such as 
neurons) have elevated basal mitophagy rates that occur independently of PINK1. This finding 
indicates that there might be other pathways involved in mitochondrial quality control (McWilliams 
et al., 2018).  
Other genes 
The role of mitochondria in PD pathogenesis has also been suggested through studying genes 
that increase the risk of PD. In vitro, blocking GBA significantly compromises mitochondrial 
function and increases mitochondrial fragmentation (Cleeter et al., 2013). Although the 
mechanism through which this happens is still unclear, it has been suggested that the process 
involves an impairment in the mitophagy pathway. Interestingly, α-synuclein has a direct 
reciprocal relationship with GBA. When α-synuclein is overexpressed, GBA activity tends to 
decrease (Yang et al., 2016). Conversely, in mutant GBA, α-synuclein accumulates in aggregate 
and promotes lysosomal impairment (Du et al., 2015).  
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1.3.2 Mechanisms of environmental toxins 
Toxins that interfere with mitochondria are associated with a higher risk of PD (Ascherio and 
Schwarzschild, 2016). Many of these toxins have been used to induce PD in animals for research 
purposes. Since MPTP is the first toxin known to induce PD, its mechanism of action has been 
investigated thoroughly. MPTP is capable of crossing the blood brain barrier (BBB) due to its 
lipophilic nature (Jagmag et al., 2016). When MPTP enters the brain, it is oxidised and converted 
into its active form, 1-methyl-4-phenylpyridinium (MPP+), primarily within astrocytes (Brooks et 
al., 1989). MPP+ has a high affinity to dopamine active transporter (DAT), with comparatively 
lower affinities to the norepinephrine and serotonin transporters (Javitch et al., 1985). Once 
transported into the DA neurons, MPP+ is concentrated in the mitochondria through energy-
dependant mechanisms (Ramsay and Singer, 1986). MPP+ possesses an inhibitory effect on 
complex l of the mitochondrial transport chain, which in turn leads to a decrease in overall ATP 
production. Blocking the electron transport chain increases the production of ROS and, 
consequently, oxidative stress levels (Hasegawa et al., 1990). Unlike MPTP, which is only used 
in labs for research purposes, the structurally similar compound, rotenone, has been used in 
veterinary medicine to eliminate mites, lice and/or ticks that grow on domestic animals (Rohan et 
al., 2015). It has also been used in agriculture to control beetles and aphids, and in water to 
eliminate unwanted fish (Rohan et al., 2015). Paraquat, which is another similar compound to 
MPTP, is a widely used pesticide in agriculture. Both rotenone and paraquat are widely used in 
in labs for research purposes. 
1.3.3 Role of ageing 
Ageing is not only the strongest risk factor for PD, but it is also a determinant of the progression 
rate and the response to the treatment (Rodriguez et al., 2015). Evidence shows that the 
underlying mechanisms of ageing and PD are shared at some levels. Thus, ageing acts as a 
factor that increases the baseline threshold of PD susceptibility, so that other factors, such as 
genetic mutations and environmental toxins, can initiate the pathological process. DA neuron loss 
has been observed in aged healthy individuals and non-human primates (Rodriguez et al., 2015, 
Collier et al., 2011). Studies have also shown that the loss occurs autonomously within the 
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lifespan, at a rate of approximately 7% per decade. In PD, the rate of this process accelerates 
significantly above that baseline (Stark and Pakkenberg, 2004).  
At molecular levels, PD and ageing also share common mechanisms, where mitochondria play a 
pivotal role. In fact, the mitochondrial theory of ageing proposed that the mitochondria are the 
pacemaker of ageing (Navarro and Boveris, 2010). ROS, which are produced by dysfunctional 
mitochondria, are responsible for oxidative damage of various cellular components, as well as 
DNA mutations with telomere shortening (Hindle, 2010). In the long term, the accumulated 
damage leads to tissue ageing. Neurons have higher energy demands and are more sensitive to 
the accumulated effects of ageing. Decreased activity of respiratory complex I and IV, and 
decreased overall ATP production have been reported in mammalian ageing brains (Boveris and 
Navarro, 2008). Compensatory mechanisms that alleviate the harmful effects of mitochondrial 
dysfunction, such as lysosome-mediated autophagy, also decline with ageing (Tai and Schuman, 
2008).  
1.3.4 Oxidative stress and neuronal vulnerability 
Oxidative stress 
ROS can be produced as by-products upon metabolising certain compounds and toxins, or upon 
the exposure to harmful radiation (Liochev, 2013). However, the major source of ROS in cells is 
the mitochondria (Song and Zou, 2015). The generation of ROS via the respiratory chain 
consumes about 2% of the O2 utilised by the mitochondria (Orrenius, 2007). ROS are mainly 
produced via respiratory complexes I and III, but small amounts are also produced via complex II 
(Song and Zou, 2015). In the brain, complex I is superior to complex III in ROS production (Kim 
et al., 2015). 
Under healthy conditions, low level of ROS has physiological functions and serve as cellular 
singling molecules. Oxidative stress occurs when ROS accumulate and the cellular antioxidant 
mechanisms fail to neutralise them (Dasuri et al., 2013). The generation of ROS is enhanced in 
mitochondrial dysfunction, especially when electron transfer is interrupted, such as when the 
respiratory complexes are blocked (Lushchak, 2015). As a result, electrons leak and reduce 
molecular oxygen into superoxide anions, which can be transformed into other type of ROS 
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(Lushchak, 2015). Oxidative stress damages DNA, induces cellar membrane peroxidation and 
alters the structures and functions of proteins via oxidation (Dasuri et al., 2013). Since the 
mitochondria are the main producers of ROS, they are at higher risk of ROS-mediated damage, 
which in turn leads to further increases in ROS production.  
One of the important PD-related proteins affected by oxidative stress is α-synuclein. Lipid 
peroxidation of the cell membrane by ROS produces 4-hydroxy-2-nonenal, which mediates α-
synuclein damage and renders it unable to form insoluble fibrils (Bae et al., 2013). As a result, 
the amount of toxic soluble α-synuclein increases, as well as its toxicity (Bae et al., 2013). 
Naturally, there are various mechanisms through which cells protect themselves from the 
deleterious effect of oxidative stress. The activation of phase ll detoxification enzymes via the 
Nrf2 pathway is considered to be one of the most important mechanisms. This pathway is 
discussed in detail in the fourth chapter. In addition, Adaptive stress response involve the 
activation of other pathways such as activator protein 1 (AP-1),  resulting in the expression of 
genes required for the detoxification of oxidizing molecules (Espinosa-Diez et al., 2015). AP-1 is 
a family of dimeric bZIP transcription factors. This family includes Jun, Fos, CREB and MAF, 
which usually dimerise and bind to TPA-responsive element or cAMP response elements (Glover 
and Harrison, 1995). AP-1 is involved in several cellular processes such as cell proliferation, 
apoptosis, survival, and differentiation (Karin et al., 2001). AP-1 activity is regulated both through 
the increased synthesis of its components, the Jun and Fos proteins, and through their 
phosphorylation (Shaulian and Karin, 2001). Two main signaling pathways whose activation leads 
to upregulation of jun and fos genes are the JNK and MAPK pathways (Silvers et al., 2003). JNK 
activation is particularly important, as it enhance AP-1 activity post transcriptionally via 
phosphorylation of the Jun proteins (Musti et al., 1997).  
Neuronal vulnerability 
In comparison to other types of cells, neurons are more sensitive to oxidative stress. There are 
many reasons behind this vulnerability. First, the brain has high energy demands, as it is one of 
the most active organs in the body. The brain’s use of oxygen accounts for about 20% of the total 
body needs, although it represents only 2% of body mass (Bélanger et al., 2011). Second, the 
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brain contains relatively copious amounts of iron and copper, which are important for the formation 
of ROS (Scheiber et al., 2014). Third, the brain is enriched with polyunsaturated fatty acids, which 
are preferable targets for ROS and mediate the formation of secondary reactive species, such as 
4-hdyroxy-2-nonenal (Wang and Michaelis, 2010). Finally, the capacity of the neurons to 
neutralise ROS is relatively low in comparison to other types of cells (Kim et al., 2015).  
DA neurons lack the myelin sheet around their axons (Haddad and Nakamura, 2015), which is 
important for energetically efficient impulse propagation (Almeida and Lyons, 2017). Therefore, DA 
neurons have higher energetic demand, which renders them more vulnerable when mitochondrial 
dysfunction occurs. In line with this, axons of DA neurons are the sites where pathological α-synuclein 
accumulates and where neurodegeneration initially starts (Haddad and Nakamura, 2015). The 
selective DA neuronal loss in the brain also suggests dopamine metabolism as an additional 
contributing factor in the vulnerability of this subset of neurons. In fact, hydroxylated dopamine, 
6-hydroxydopamine (6-OHDA), is a classical toxin used for modelling PD in animals. 6-OHDA 
treatment results in selective injury to nigrostriatal DA cells (Blesa et al., 2016). 
Dopamine synthesis starts with the hydroxylation of L-tyrosine into L-3,4-dihydroxyphenylalanine 
(L-DOPA), which is converted into dopamine through the action of aromatic acid decarboxylase 
(Puspita et al., 2017). Within cells, dopamine is stored in vesicles through the action of vesicular 
monoamine transporter 2 (VMAT2), to protect it from oxidation by cytoplasmic molecules (Puspita 
et al., 2017). Following dopamine release into the synaptic space, DAT mediates its reuptake into 
the cells, where it can be either re-stored in vesicles, or degraded by enzymes such as 
monoamine oxidases and aldehyde dehydrogenase (Puspita et al., 2017). This process 
generates the ROS, 3,4-dihydroxyphenylacetaldehyde (DOPAL) and H2O2 (Goldstein et al., 
2013). In addition, cytoplasmic metals, such as iron, can oxidise the reabsorbed dopamine into 
DA-quinone (DAQ) and the more stable highly reactive compound, aminochrome (Puspita et al., 
2017). DAQ interacts with mitochondrial proteins and inhibits respiratory complexes I and IV 
(Puspita et al., 2017). DAQ also modulates various important proteins, such as α-synuclein, 
Parkin, DJ-1, DAT and Tyrosine hydroxylase (TH), and exerts a negative effect on lysosomal 
interaction in autophagy (Blesa et al., 2015).  
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1.3.5 Cell death in PD 
The mitochondria play a key role in determining the fate of the cells by triggering apoptosis. The 
intrinsic pathway of apoptosis, also referred to as the mitochondrial pathway, is induced by most 
apoptotic stimuli (Lopez and Tait, 2015). A critical step in this pathway is the permeabilisation of 
the mitochondrial outer membrane and the leak of the cytochrome c from the intermembrane 
space (Lopez and Tait, 2015). In the cytoplasm, apoptosomes are formed through the binding of 
cytochrome c to the apoptotic protease activating factor 1 (APAF-1) (Zhou et al., 2015). 
Apoptosomes attract and activate pro-caspase 9, which in turn cleaves caspase 3 and caspase 
7 into their active forms (Zhou et al., 2015). The activation of the caspases drives apoptosis by 
consequently cleaving a battery of apoptosis-related proteins. However, it has been shown that 
mitochondrial outer membrane permeabilisation can initiate apoptosis independently of caspase 
activation (Tait et al., 2014).  
The integrity of the outer mitochondrial membrane is regulated by the balance between pro-
apoptotic proteins and anti-apoptotic proteins. Pro-apoptotic proteins Bcl-2-associated X (BAX) 
and Bcl-2 homologous antagonist killer (BAK) are usually activated upon interaction with pro-
apoptotic BH3-only proteins, such as BH3 interacting-domain (BID), Bcl-2-like protein 11 (BIM), 
Bcl-2-associated death promoter (BAD) and p53 upregulated modulator of apoptosis (PUMA) 
(Lopez and Tait, 2015). Some of the BH3-only proteins facilitate apoptosis by interfering with the 
anti-apoptotic proteins. On the other hand, the anti-apoptotic proteins (B-cell lymphoma 2 (BCL-
2), BCL-B,  B-cell lymphoma-extra large (Bcl-xL) and induced myeloid leukemia cell differentiation 
protein (MCL-1)) antagonise the activity of BAX and BAK (Lopez and Tait, 2015). Activated BAX 
and BAK oligomerise with the mitochondrial membrane and disturb its lipid structure to form pores 
that allow the leakage of cytochrome c (Lopez and Tait, 2015). Other leaked proteins, such as 
Second mitochondria-derived activator of caspases (SMAC) and High temperature requirement 
protein A2 (HtrA2) act synergistically and promote apoptosis by neutralising cytoplasmic caspase 
inhibitors (Lopez and Tait, 2015). Despite the supportive evidence for apoptosis, the exact 
mechanism of cell death in PD is not fully understood. Other proposed mechanisms include 
extrinsic apoptosis, autophagic cell death, necroptosis and ferroptosis (Guiney et al., 2017). 
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1.3.6 The role of mitochondrial dysfunction in Parkinson’s disease 
The first evidence that linked mitochondrial dysfunction to PD arose from studying MPTP-induced 
Parkinsonism in drug abusers (Langston et al., 1983). Research showed that MPTP mediates its 
action via selective inhabitation of mitochondrial respiratory complex I (Hasegawa et al., 1990). 
Subsequently, complex l inhibition was reported in the substantia nigra of PD patients (Mann et 
al., 1992, Schapira et al., 1990). Common environmental toxins that increased the risk of PD 
(such as rotenone and paraquat) also interfere with mitochondrial respiratory complexes 
(Ascherio and Schwarzschild, 2016) [Figure 1.3]. Mitochondrial dysfunction, and in particular, 
complex l inhibition, leads to increased production of ROS (Li et al., 2003). Oxidative stress is 
believed to be the driver of the pathological process in PD. Notably; elevated oxidative stress is 
also a feature of aging which is the strongest risk factor for PD (Hindle, 2010).  
The deleterious effect of ROS involves all organelles in the cell including the mitochondria 
themselves. In addition, ROS may damage the mitochondria indirectly via their interaction with α-
synuclein [Figure 1.3].  ROS modify α-synuclein into a misfolded toxic form (Bae et al., 2013), 
which is similar to the mutated α-synuclein in patients with autosomal dominant PD. Misfolded α-
synuclein are known to damage the mitochondria either via interfering with mitochondrial protein 
import or via inducing mutations in mitochondrial DNA. Thus, the aggregation of α-synuclein in 
Lewy Bodies is believed to be a protective process as it quarantines the toxic form of α-synuclein. 
Although the generation of ATP is the main function of the mitochondria, cell death in PD disease 
is not attributed to a failure in maintaining cellular energetic demands. Instead, it is attributed to 
the activation of apoptotic cell death programme, which is highly regulated by the mitochondria, 
and is typically activated in case of mitochondrial dysfunction (Choudhury et al., 2012) [Figure 
1.3]. In post-mortum brain tissue of PD patients, research demonstrated significant increase in 
the expression of apoptotic related proteins such as p53, CD95 and activated caspase-3 
(Hartmann et al., 2000, Sohn et al., 1998). 
Research shows that various PD related genes are required for normal mitochondrial function 
and dynamic. Mitochondrial fission allows the cells to isolate dysfunctional mitochondria and 
consequently removes them via aoutophagic degradation (mitophagy), which hinder the 
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activation the cell death program (Kim et al., 2007). Mutations of PINK1 and Parkin, the most 
studied mitophagy related proteins, are known causes of familial PD (Rüb et al., 2017). 
Additionally, in vitro study showed that Parkin knock-out mice have reduced activity of complex I 
and complex IV as well as lower respiratory capacity, indicating that the mitochondrial role of this 
proteins is not limited to mitophagy (Palacino et al., 2004). Fusion is also required for a normal 
mitochondria function as it allows the mitochondria to mix their contents, thus enabling protein 
complementation, mtDNA repair and equal distribution of metabolites (Bose and Beal, 2016). 
LRRK2, which is linked to 10% of all familial PD cases has been reported to interact with various 
mitochondrial fission and fusion factors (Kang and Marto, 2017), resulting in the appearance of 
more fragmented mitochondria. This morphological change is also associated with functional 
mitochondrial impairments, such as decreased MMP and ATP levels (Mortiboys et al., 2010, 




Figure 1.3 A summary of the proposed mechanisms for neuronal degeneration in PD.  
Defective mitochondria and oxidative stress are the major drivers of the process. They can develop as a 
consequent of genetic defects, environmental insults or a mix of both. Misfolded α-synuclein can increase 
the level of reactive oxygen species by damaging the mitochondrial proteins and/or can be a consequence 
of the action of reactive oxygen species on its normal form. PINK1 and Parkin play a role in mitochondrial 
quality control, as they remove the dysfunctional mitochondria from the system. In the end, the accumulative 
defects force the cells to commence apoptosis.   
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1.4 Cellular models of PD 
1.4.1 General advantages and limitations of cellular models 
PD modelling can be applied at the cellular level or at the level of living organisms. The models 
can be based either on toxins or genetics. The choice of a specific model depends on the 
experimental question. In drug testing experiments, complex multicellular organisms are useful in 
studying the effect of the drug on pathophysiology, such as changes in neural network properties 
or in motor and sensory responses. On the other hand, cellular models are crucial for investigating 
the molecular mechanisms of a given drug at the level of intracellular organelles. 
In comparison to animals, cellular models are more flexible in terms of handling, propagation and 
storing. Dealing with cells has fewer ethical concerns and require less time and effort. In addition, 
cells are more practical in high throughput drug screening experiments. In PD, human cells that 
have been used in research or drug screening can be grouped into three major categories. First, 
non-patient immortalized human cell lines such as SH-SY5Y and immortalized human embryonic 
mesencephalic cells, LUHMES. Second, primary patient-derived cells, such as primary skin 
fibroblasts. Third, stem cell models, such as human embryonic and adult neural stem cells and 
human induced pluripotent stem cells (iPSCs), which can be transformed into more relevant types 
of cells (Schüle et al., 2009). Interestingly, patient primary cells, such as skin fibroblasts, can be 
programmed to produce iPSCs, which can be differentiated into neuronal progenitor cells (iNPCs) 
and then into neurons (Mertens et al., 2016). Direct conversion of patient fibroblasts into neurons 
(iNs) is also possible. In this approach, the cells retain the transcriptomic feature of aging (Mertens 
et al., 2015). 
One apparent limitation of the cellular model is the lack of in vivo natural factors and substances 
that surround the cells, which are replaced by the culture medium. Another limitation is that the 
development of the connections between the cells occurs in a two-dimensional plane and does 
not involve other types of cells that might be important in shaping and determining the final 
biological response in vivo. To tackle this issue, researchers occasionally use co-culture and 3D 
culture techniques. In the following section, skin-derived fibroblasts will be discussed in detail, 
due to their relevance to this project.  
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1.4.2 Fibroblasts of PD patients 
Skin fibroblasts carry all of the genetic information of the patient, including the age-related 
changes that are extremely important, given the fact that aging is the strongest risk factor for PD. 
The process of obtaining and generating the cell line is relatively simple and straightforward 
(Burbulla and Krüger, 2012). Crude samples are usually extracted from a 2mm punch skin biopsy, 
taken from the inner side of the upper arm. Although this procedure is safe, it should be performed 
by a physician or a nurse under sterile conditions and local anaesthesia. The specimen, which is 
typically 4×4 mm or 6×6 mm, can be split and seeded into a T25 flask coated with foetal bovine 
serum (FBS). Then, the flask is placed gently in the incubator after the addition of a mixture of 
culture medium and FBS (50/50). Over the following few days, the samples are regularly fed by 
replacing 50% volume of the mixture. Initially, only circular epithelial cells appear. In four to five 
days, fibroblasts become apparent and are usually fed by the careful addition of drops of the 
mixture on alternative days. Once an adequate number of fibroblasts are present in the flask (30 
to 50 cells around each skin sample), a culture medium with the standard 10% FBS and 
supplements can be used for feeding. Fibroblasts are cultured in a regular incubator at standard 
settings (37°C, 5% CO2). Once confluent, primary fibroblasts can be split into three T75 flasks. 
Generally, the handling of these cells is not significantly different from other cell lines. The culture 
specimen initially contains other types of cells, such as keratinocytes (Auburger et al., 2012). 
However, by the time the third passage is reached, only fibroblasts remain. The sample might 
also be contaminated with mycoplasma, which can result in an inflammatory process and 
oxidative stress, and can slow the growth of the cells (Auburger et al., 2012). Therefore, a routine 
mycoplasma test is necessary. If the test is positive, the cells should be treated with ciprofloxacin.  
Skin fibroblasts have many advantages in comparison to other in vitro models. Probably the most 
important one is that they encompass all the accumulative chronological and biological changes 
of the patient, as well as the primary genetic abnormality, which make them superior to artificially 
induced genetic models. Accordingly, skin fibroblasts are probably the best method to model 
sporadic PD. The fact that they are derived from humans is also an advantage. Although 
fibroblasts do not extend neurites like neurons, they are capable of making dynamic contacts, a 
feature that is not evident with other types of patient cells often used in research, such as blood 
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cells (Auburger et al., 2012). In addition, fibroblasts can be programmed and differentiated into 
DA neurons (Jang and Jung, 2017). The downside of this path is the practical difficulty, and 
required time and resources. Yet, it holds significant promise in the field of PD research.  
On the other hand, one of the disadvantages of fibroblasts as a model for PD is that they are skin 
cells and their transcriptional profile is different from that of neurons. For example, the expression 
of the α-synuclein is extremely low in fibroblasts (Auburger et al., 2012). Fibroblasts are also more 
resistant to stressors in comparison to neurons (Auburger et al., 2012). When compared to 
primary fibroblasts, immortalised fibroblasts have a higher growth rate. Yet, it is still behind the 
average growth rate of other commonly used immortalised cells, such as SHSY5Y and HEK cells 
(1 to 2 weeks vs. 3 to 5 days). The change in genetics is inevitable with increasing passages. The 
protein expression profile of passaged fibroblasts has been compared to the primary fibroblasts 
(Sprenger et al., 2010). Sprenger’s study showed that the difference between the two lines is 
generally minor. However, changes in the expression of proteins involved in the tyrosine kinase 
pathway and cellular cytoskeleton have been reported (Auburger et al., 2012). Therefore, 
accurate monitoring of passaging history is important and matched conditions should be at equal 
passages as possible. 
To be able to use fibroblasts as a model for PD, it is crucial to demonstrate that these cells carry 
molecular defects that are exclusive to the patients. Fibroblasts from sporadic patients have 
shown an increased sensitivity towards rotenone (Ambrosi et al., 2014) and also have been 
reported to a have a decreased microtubule mass, which was also noticed in LRRK2 and parkin 
mutant fibroblasts (Cartelli et al., 2012). However, more interesting findings have come from 
patients with a familial form of PD. Parkin mutant fibroblasts have shown a significant 
mitochondrial defect in terms of function and morphology (Mortiboys et al., 2008). The decrease 
in ATP levels (around 60%) was mostly attributed to reduced complex I activity in these cells. 
Increased mitochondrial branching has also been observed in parkin-mutant fibroblasts 
(Mortiboys et al., 2008). Knocking down parkin in control fibroblasts produced a similar result, 
which confirmed that the observed defects were a result of Parkin dysfunction (Mortiboys et al., 
2008). In another study, it was reported that the activity of complexes IV was reduced as well 
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(Pacelli et al., 2011). In contrast to these findings, Haylett and colleagues assessed mitochondrial 
function via measuring the oxygen consumption rate using the Seahorse XF Cell Mito Stress Test, 
and found an increase in mitochondrial readings in parkin patient fibroblasts (Haylett et al., 2016). 
Specifically, there was an increase in basal respiration, ATP-coupled respiration and maximal 
respiratory rate, suggesting elevated oxidative phosphorylation. These conflicting findings were 
believed to be a result of a compensatory mechanism in the fibroblasts used in the study. Zanellati 
and colleagues used the same method to assess mitochondrial function in parkin fibroblasts and 
found reduced ATP-coupled respiration and low total ATP levels in patient cells (Zanellati et al., 
2015). Other findings include high basal respiration, high maximal respiration and an impairment 
of mitochondrial membrane potential, which suggests mitochondrial uncoupling (Zanellati et al., 
2015). The fact that the fibroblasts in these two studies were obtained from different patients with 
different parkin mutations, and that the cell culture was performed in different types of medium, 
might contribute to the discrepancy between the findings. 
Similarly, investigating fibroblasts from LRRK2 G2019S patients revealed a decreased ATP level, 
decreased mitochondrial membrane potential and a specific reduction in the activity of respiratory 
chain complex IV (Mortiboys et al., 2010, Mortiboys et al., 2015, Papkovskaia et al., 2012). 
Mitochondrial morphology was changed in the direction of increasing interconnectivity in those 
fibroblasts (Mortiboys et al., 2010). Grünewald and colleagues reported similar mitochondrial 
defects, although the mitochondria were more fragmented in patient fibroblasts (Grünewald et al., 
2014a). Interestingly, the defect was present in non-manifesting LRRK2 carriers as well. The 
study of the autophagy pathway revealed an increase in the LC3-II to LC3-I ratio in the LRRK2 
G2019 patient fibroblasts, as well as an increase in the p62 levels (Grünewald et al., 2014a). 
Collectively, these findings suggest an increase in the mitophagy process. However, quantifying 
the mitochondrial protein, glucose-regulated protein 75, to assess the mitochondrial mass did not 
show a significant change (Grünewald et al., 2014a). Overall, the cumulative evidence confirms 
the presence of mitochondrial defects in the fibroblasts of familial PD patients. These results have 




1.5 Drug discovery in Parkinson’s disease 
Regardless of all the discoveries in the field, PD is still an incurable disease. Dopamine 
replacement therapy with administration of its precursors, such as levodopa, can provide 
symptomatic relief of the motor deficit. As the disease progresses, the effect of the treatment 
usually declines. All available treatment options (whether drugs or surgeries) target only 
symptomatic relief and improving the quality of life of the patient, rather than slowing disease 
progression. The growing understanding of PD has been accompanied by increasing efforts to 
find a disease-modifying treatment. Research carried out in our own group demonstrated a 
systematic stepwise approach in searching the Microsource compound library for compounds that 
rescue mitochondrial function (Mortiboys et al, 2013). Importantly, the study was performed on 
PD patients’ fibroblasts (with parkin mutations). This was the first compound screen performed in 
patient derived cells in PD. Relying on the accumulative evidence that links mitochondrial 
impairment to PD, the screening process aimed to identify compounds that improve mitochondrial 
membrane potential and increase ATP levels. After excluding compounds that showed toxicity 
and compounds that failed to generate a sigmoidal dose response curve, 29 positive hits 
remained. The screening was performed on fibroblasts obtained from two PD patients with parkin 
mutation. However, the mitochondrial rescue effect of the remaining 29 compounds was further 
verified in fibroblasts from two other parkin patients. 14 compounds failed to pass this step. 
Compounds known for their harmful side-effects in humans and others that have shown no 
neuroprotective effects in previous research were excluded. Two compounds were finally 
identified, which were pursued further: ursocholanic acid (UCA) and dehydro (11,12) ursolic acid 
lactone (DUA).  
Despite the substantial advances in the literature and screening technologies, the process of drug 
validation and approval is still long and arduous (Ciociola et al., 2014). Besides time and effort, 
financial impacts cannot be omitted. Establishing a novel treatment can cost up to 800 million 
pounds (Ciociola et al., 2014). Indeed, these expenses will have an effect on the price of the 
treatment, which will then be a burden on patients or health care systems. Therefore, identifying 
a new use for an already approved drug can significantly decrease the cost and facilitate the 
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availability of the treatment to the patient. With regard to the results in our group screening project 
(Mortiboys et al, 2013); the identified two compounds have never been used in clinical trials. 
However, two relatively commonly used compounds were found to be structurally very close to 
DUA and UCA: ursolic acid (UA) and ursodeoxycholic acid (UDCA) [Figure 1.4]. As expected, 
both reproduced the rescue effect observed in their corresponding compounds (Mortiboys et al, 
2013). UA and UDCA also restored the ATP level in fibroblasts obtained from PD patients with 
manifesting and non-manifesting LRRK2 G2019S mutation and Parkin-deficient cortical mouse 
neurons (Mortiboys et al., 2013, Mortiboys et al., 2015). This indicates that the response is not 
limited to one form of PD and that the drugs can rescue different relevant types of cells (Mortiboys 
et al., 2013). UA is a pentacyclic triterpenoid carboxylic acid, which is naturally present in apple 
peel and other fruits (Zhang et al., 2014b). UDCA, on the other hand, is a bile acid and a drug 
that has been approved for decades as a treatment for primary biliary cirrhosis (Zhang et al., 
2013b). Therefore, the adoption of UDCA as a treatment for PD should require less time and cost 
in comparison to de novo drugs. 
 
Figure 1.4 Some of the identified drugs in the Bandmann group screening project.  
The figure shows the drugs (highlighted in blue) in comparison to similar compounds at structural and 
conformational levels (Mortiboys et al., 2013). 
Abbreviations: UDCA:  Ursodeoxycholic acid, UCA: Ursocholanic acid, UA: Ursolic acid, DUA: Dehydro (11,12) ursolic 
acid lactone  
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1.6 Bile acids and UDCA 
Bile acids (BAs) are steroid-based molecules that facilitate the digestion and the absorption of 
lipids in the gastrointestinal tract. BAs are primarily synthesised in the liver and are stored in the 
gallbladder in a concentrated form. They are secreted into the duodenum after fatty meal 
ingestion. The majority of BAs follow the enterohepatic circulation, through which they are 
absorbed and recycled (Martinot et al., 2017). There are various types of naturally occurring BAs 
that differ in their chemical structure and characteristics. Nevertheless, all BAs are composed of 
24 carbon atoms with a steroid core. 
In humans, there are two primary BAs synthesised directly by liver cells: chenodeoxycholic acid 
(CDCA) and cholic acid (CA) (McMillin and DeMorrow, 2016b). The synthesis starts with 
cholesterol molecules, which are converted into 7α-hydroxycholesterol through the action of 
microsomal cytochrome P-450, CYP7A1 (also called cholesterol 7 α-hydroxylase) (McMillin and 
DeMorrow, 2016a) [Figure 1.5]. This compound is subsequently hydroxylated by sterol 12α-
hydroxylase or 7 α,12α-hydroxylase and modified by other enzymes, resulting in the formation of 
CDCA and CA. There is an alternative pathway for bile acid synthesis, which is facilitated by 
CYP27A1 (cholesterol 27-hydroxylase), and leads to the conversion of cholesterol into 27-
hydroxycholesterol [Figure 1.5]. Further hydroxylation by CYP7B1 (25-hydroxycholesterol 7-α-
hydroxylase), and modification by other enzymes results in the production of primary BAs, mainly 
CDCA (McMillin and DeMorrow, 2016a). Within the hepatocyte, taurine/glycine conjugated BAs 
are produced through the action of the peroxisomal enzyme bile acid coenzyme-A: amino acid N-
acyltransferase (BAAT) (Martinot et al., 2017). Most of the BAs excreted from the liver are 
conjugated (98%); two-thirds of them are taurine conjugates, because BAAT has a higher affinity 
towards taurine (Martinot et al., 2017). Bile acid conjugation is important for their function. It 
makes the BAs more hydrophilic, which is crucial for the emulsification of lipids. In this process, 
the hydrophobic side of BAs is inserted into the lipid, while the hydrophilic side stays at the 
surface. This results in large lipid aggregates being broken down into smaller droplets that have 
a greater surface area. Thus, this increases the contact with the hydrophilic lipase molecules 
(Sarkar et al., 2016). Conjugation also ameliorates bile acid toxicity, which will be discussed in 
52 
 
more detail in the next section. Intestinal microbial flora play an important role in modifying BAs 
through de-conjugation and decarboxylation, resulting in the formation of secondary BAs, such 
as UDCA,  deoxycholic acid (DCA) and lithocholic acid (LCA) (Camilleri and Gores, 2015). All of 
these can be re-circulated and/or re-conjugated via the enterohepatic circulation (Camilleri and 
Gores, 2015). This cycle can be repeated up to 12 times per day and, as a result, eliminates the 
need for daily total replacement of the bile acid pool (Ikegami and Matsuzaki, 2008). In fact, 95% 
of the bile acid pool is not derived from de novo biosynthesis in the liver (Ikegami and Matsuzaki, 
2008). 
Bile acid toxicity has been extensively studied in cholestatic diseases. Research shows that the 
hydrophobicity is the major determinant of the toxicity of a given bile acid. Generally, BAs are 
amphipathic molecules. Yet, their hydrophobicity varies according to the number, position and 
orientation of the hydroxyl group [Figure 1.6]. Bile acid molecules are relatively planar, with a 
convex face that is hydrophobic because of methyl radicals, and a hydrophilic face with hydroxyl 
radicals (Sarkar et al., 2016). Accordingly, tri-hydroxylated BAs are more hydrophilic than di-
hydroxylated BAs. Moreover, conjugation of BAs with taurine or glycine makes them more 
hydrophilic. Exceptionally, UDCA has a hydroxyl group in the 7β position in an equatorial 
orientation [Figure 1.6]. This unique structure makes UDCA the most hydrophilic bile acid (Perez 
and Briz, 2009). The toxicity of hydrophobic BAs is believed to be mediated via interfering with 
mitochondrial physiology. Toxic BAs decrease the activity of respiratory chain complexes and 
increase mitochondrial membrane permeability, with consequent mitochondrial uncoupling (Perez 
and Briz, 2009). These events increase ROS production, which in turn can exaggerate toxicity 
and trigger the apoptotic pathway. There are other reported mechanisms, such as direct cellular 
and organelle membrane damage due to the detergent-like properties of hydrophobic BAs (Perez 
and Briz, 2009). The toxicity is not exclusive to liver cells, as it has been observed in placental, 
foetal, renal and pulmonary cells (Perez and Briz, 2009, Perez et al., 2006). On the other hand, 
hydrophilic BAs are cytoprotective. It has been proposed that biliary diseases arise from an 
imbalance between toxic and protective BAs. In line with this, treatment with the most hydrophilic 
bile acid, UDCA, is beneficial in biliary diseases. In fact, UDCA is the main FDA-approved 
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treatment for primary biliary cholangitis and primary biliary cirrhosis (Chascsa et al., 2017, FDA, 
2009). Despite its established effectiveness, its main mechanism of action is still under debate.  
BAs from dozens of animals have been used as remedies in traditional oriental medicines for 
centuries (Wang and Carey, 2014). The bile is steroidal in nature and contains different fat-soluble 
vitamins, which might contribute to the observed beneficial effects. Concentrated bear bile has 
been used in traditional Chinese medicine as a treatment for liver diseases (Wang and Carey, 
2014). Interestingly, UDCA is the most abundant bile acid in bear bile (Wang and Carey, 2014). 
UDCA-packed tablets were commercially available in Japan in the mid-twentieth century 
(Hofmann and Hagey, 2014). However, it was offered as a 10mg tablet and the FDA-
recommended dose is approximately 1000mg/day (13 to 15mg/kg/day). Therefore, it is most likely 
that patients did not benefit from the full therapeutic action of UDCA at that time. Currently, UDCA 
is available as 250 or 500mg tablets (FDA, 2009). Following oral intake, UDCA diffuses passively 
through the intestinal epithelium. The unabsorbed UDCA is dihydroxylated into LCA and excreted 
in the faeces. Only 50% of UDCA is uptaken from the blood by hepatocytes in healthy individuals 
(FDA, 2009). Normally, UDCA constitutes 3% of the bile acid pool in humans (Ikegami and 
Matsuzaki, 2008). Upon chronic UDCA treatment, the amount increases up to 50% (FDA, 2009). 
Hepatic conjugation of UDCA into more active hydrophilic BAs is highly efficient, even in 
cholestasis liver. Therefore, it is unnecessary to prescribe conjugated UDCA for those patients 
(Poupon, 2012). 
UDCA-related clinical studies are mostly concerned with liver disease. Little is known about its 
bioavailability in the CNS. However, it has been reported that oral UDCA administration has led 
to an increase in its level in the cerebrospinal fluid (CSF) in a dose-dependent manner. Treating 
ALS patients with high doses (15mg/kg/day to 50mg/kg/day) eventually led to doubling the 
concentration in the CSF (140nM to 280nM). Notably, high-dose UDCA treatment was safe and 
tolerable in those patients (Parry et al., 2010).  
The beneficial effect of UDCA has been studied extensively in the context of hepatobiliary 
diseases. Multiple mechanisms of action have been proposed. These can be divided broadly into 
two groups: the first is concerned with bile acid homeostasis and the second is concerned with a 
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cytoprotective effect. Within the gastrointestinal tract, UDCA can decrease the levels of toxic BAs. 
Conjugated UDCA competes with other endogenous toxic BAs and prevents their absorption at 
the distal part of the small intestine (Poupon, 2012). In addition, UDCA stimulates bile acid 
secretion and serves as an anti-cholestatic reagent (Poupon, 2012). Cholestasis is a well-
recognised pathology in primary biliary cholangitis and primary sclerosing cholangitis, and is 
believed to intensify the effect of toxic BAs. UDCA acts at transcriptional and post-transcriptional 
levels to increase the expression of transporter proteins in the basolateral and canalicular 
membranes and facilitate the secretion (not synthesis) of BAs (Ikegami and Matsuzaki, 2008). 
Evidence suggests that UDCA and its conjugates facilitate the trafficking and insertion of 
transporter proteins by regulating intracellular Ca2+, protein kinase C (PKC) isoforms, and cyclic 
adenosine monophosphate (cAMP) (Ikegami and Matsuzaki, 2008). 
Within cells, evidence suggests that inhibition of apoptosis is one of the main protective effects of 
UDCA. UDCA and its conjugates inhibit apoptosis by preventing mitochondrial membrane 
perturbation, pore formation, BAX translocation, cytochrome c release, caspase activation and 
subsequent substrate cleavage (Amaral et al., 2009). It has also been reported that 
Tauroursodeoxycholic acid (TUDCA) can ameliorate ER stress by decreasing calcium efflux and 
caspase-12 activation (Xie et al., 2002). The shared chemical structure between BAs and 
steroids, as well as the shared associated anti-inflammatory responses, have led to the 
assumption that they both activate glucocorticoid receptors (GRs). Nuclear translation of the GR 
was reported after UDCA treatment. However, several studies have shown that UDCA does not 
bind to the GR, indicating that there is an indirect mechanism for the activation (Hapgood et al., 
2016). In addition, it has been demonstrated that UDCA activates important survival signalling 
pathways, such as mitogen-activated protein kinase (MAPK) and Phosphoinositide 3-kinase 
(PI3K) (Amaral et al., 2009). Besides the anti-apoptotic effect, UDCA has also been reported to 
increase cellular defence against oxidative stress. In iron-stressed HepG2 cells, UDCA treatment 
elevated Glutathione (GSH) levels and decreased ROS production via the activation of the 
nuclear factor-like 2 (Nrf2) pathway (Arisawa et al., 2009). Further validation came from 
experiments on mice liver cells, where UDCA significantly enhanced Nrf2 expression and 
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translocation into the nucleus. These results suggest that Nrf2 activation plays an important role 
in the mechanism of action of UDCA (Shin et al., 2013). Besides their ability to activate different 
signal transduction pathways, BAs bind specifically to a distinct group of receptors, such as the 
G-protein coupled receptor (TGR5), and nuclear receptors, such as the farnesoid X receptor, 
vitamin D receptor and pregnane X receptor (Martinot et al., 2017). Therefore, BAs in general are 
increasingly recognised as signalling molecules. Investigating the mechanism of action mediated 
through these receptors is currently ongoing. 
Independent groups have reported the beneficial effect of UDCA/TUDCA in PD. In a rat rotenone 
model, UDCA treatment restored striatal dopamine content and significantly improved the 
behaviour in the open field test (Abdelkader et al., 2016). Pre-treatment with TUDCA also 
increased DA neurons by 30% in a mouse MPTP model (Castro-Caldas et al., 2012). The 
increase in neuron numbers was associated with an increase in TH immunofluorescence intensity 
and a decrease in DA fibre degeneration (Castro-Caldas et al., 2012). The effect of TUDCA on 
motor disability in the mouse MPTP model was extensively investigated recently (Rosa et al., 
2018). The results showed that TUDCA treatment significantly improved gait quality and reduced 
foot dragging. Moreover, there was a reduction in PD-related manifestations, such as tremors and 
inability to initiate movement (Rosa et al., 2018). In these animal models, UDCA and TUDCA 
increased ATP levels and decreased ROS production. Proposed mechanisms of action involved 
the activation of the protein kinase B (AKT) pathway and the inhibition of intrinsic and extrinsic 
apoptotic pathways (Abdelkader et al., 2016, Castro-Caldas et al., 2012, Rosa et al., 2018). Rosa 
and colleagues have recently investigated the rescue effect of TUDCA in a primary culture of mice 
cortical neurons stressed with MPP+ and confirmed the positive effect on ATP, mitochondrial 
membrane potential, cytotoxicity and oxidative stress (Rosa et al., 2017). The results showed 
increased expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha 
(PGC1α) and Mitochondrial transcription factor A (TFAM), indicating enhanced mitochondrial 
biogenesis. In addition, the results suggest the involvement of autophagy and mitophagy in the 
mechanism of action. TUDCA induced an accumulation in mitochondrial PINK1 and Parkin, as 
well as an increase in LC3 lipidation (Rosa et al., 2017). Importantly, the positive effect on ATP 
56 
 
levels was lessened when the experiment was repeated using parkin knock down SH-SY5Y cells, 
which indicates that Parkin plays a role in the protective action of TUDCA in MPP stressed cells 
(Rosa et al., 2017). Parkin was also found to play a role in the TUDCA-mediated protective effect 
observed in CCCP stressed SY-SY5Y cells (Fonseca et al., 2017).   
 
Figure 1.5 An overview of the bile acid pathway in humans. 
 The figure summarises bile acid synthesis pathway and shows the different forms of endogenous BAs. 
Abbreviations: CYP27A1: sterol 27-hydroxylase, CYP7A1: cholesterol 7-alpha-monooxygenase, CYP8B1: sterol 12-




Figure 1.6 A comparison between bile acids in term of hydrophilicity. 
 The figure shows the chemical structure of LCA and illustrates how the addition of hydroxyl groups can 
change LCA into a different bile acid. Generally, the greater the number of hydroxyl groups, the greater the 
hydrophilicity. The only exception is for UDCA. Blue arrows indicate the site for hydroxylation. The red 
arrow indicates the site for conjugation with taurine/glycine, which will further increase the hydrophilicity. 
Abbreviations: LCA: lithocholic acid, DCA: deoxycholic acid, CDCA: chenodeoxycholic acid, CA: cholic acid, UDCA: 
Ursodeoxycholic acid  
1.7 Aims and objectives 
In the light of the accumulative evidence of mitochondrial dysfunction in PD, the identified 
compounds in the screen undertaken in our group might be of significant promise as novel 
treatments. Although considerable work has been done to unveil the mechanism of action of 
UDCA in liver disease, little is known about the precise mechanisms in relation to PD. The main 
aim of this project is to assess and to investigate the rescue effect of UDCA in the context of PD.  
Objectives: 
1) To determine if the UDCA-mediated rescue effect is due to an increase in mitochondrial 
biogenesis; 
2) To determine if treatment with UDCA activates the Nrf2 pathway and alleviates oxidative 
stress; 
3) To assess the rescue effect of UDCA in human neuronal-like cell line, in which 
mitochondrial dysfunction was induced via the use of mitochondrial toxins; 
4) To determine if UDCA exerts its rescue effect via AKT activation and, if so, identify AKT 















2 Materials and methods 
2.1 List of materials and reagents used in this project 
Material Catalogue Company Source 
Tissue culture 
Multiwall plate for suspension culture, 24 well 662102 Greiner Bio One Germany 
CELL CULTURE MICROPLATE, 96 WELL, 
µCLEAR®, BLACK 
655090 Greiner Bio One Germany 
CELL CULTURE MICROPLATE, 96 WELL, 
µCLEAR®, WHITE 
655098 Greiner Bio One Germany 
Corning® 96 Well 3590 Corning USA 
CELL CULTURE MICROPLATE, 384 WELL, 
µCLEAR®, BLACK 
781091 Greiner Bio One Germany 
T75 Nunc™ Cell Culture Treated EasYFlasks™ 156499 Thermos Scientific Denmark 
T175 Nunc™ Cell Culture Treated EasYFlasks™  Thermos Scientific Denmark 




Cryovial 123263 Greiner Bio One Germany 




Haemocytometer 0640010 Marienfeld-superior Germany 












MEM Eagle with Earle’s BSS, with L-glutamine  
(EMEM) 
BE12-611F Lonza Belgium 
Dulbecco’s Modified Eagle Medium (DMEM) D5796 Sigma-Aldrich USA 




Life Technologies USA 




Foetal Bovine Serum (sigma) 12105C Sigma-Aldrich USA 
Foetal Bovine Serum (labtech)  labtech UK 
Uridine A15227 Alfa Aesar UK 
10x trypsin BE02-007E Lonza Belgium 
Penicillin/Streptomycin (P/S) DE17-603E Lonza Switzerland 
MEM Eagle Vitamin Mixture (100X) 13-607C Lonza USA 
Non-Essential Amino Acid Solution (NEAA) 
100X 
13-114E Lonza Belgium 
Uridine U-3003-5G Sigma-Aldrich USA 
Sodium Pyruvate S8636 Sigma-Aldrich USA 
D-(+)-Galactose G5388 Sigma-Aldrich China 
2-Deoxy-D-glucose D8375 Sigma-Aldrich China 
Retinoic acid R2625 Sigma-Aldrich China 










DMSO (TC) D2650 Sigma-Aldrich USA 
Industrial methylated spirit 11442874 Fisher Scientific UK 
Drugs and toxins 
Ursocholanic acid (UCA) C7628-5G Sigma-Aldrich USA 
Ursodeoxycholic acid (UDCA) U5127-25G Sigma-Aldrich USA 
Tauroursodeoxycholic acid 580549 Merck Millipore Italy 
Glycoursodeoxycholic acid 06863 Sigma-Aldrich China 
Resveratrol R1776 LKT Laboratories USA 
Trolox 56510 Fluka USA 
BG12 242926 Sigma-Aldrich USA 
G 418 disulphate salt A1720 Sigma-Aldrich China 
Triciribine hydrate T3830 Sigma-Aldrich USA 
Recombinant Human IGF-I 291-G1 R&D Systems USA 
Rotenone R8875 Sigma-Aldrich USA 
Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (CCCP) 
C2920 Sigma-Aldrich Israel 
Antimycin A A8674 Sigma-Aldrich USA 
Hydrogen peroxide solution H1009 Sigma-Aldrich Germany 
Copper(II) sulphate pentahydrate C7631 Sigma-Aldrich USA 
DMSO (anhydrous) 276855 Sigma-Aldrich USA 
Western blotting 
RIPA buffer R0278 Sigma-Aldrich USA 
10x Protease Inhibitor Cocktail (PIC) P8340 Sigma-Aldrich USA 
Phosphatase Inhibitor Cocktail 2 P5726 Sigma-Aldrich USA 
Coomassie protein reagent 1856209 ThermoScientific USA 
ProtoGel (30%) EC-890 National Diagnostics USA 
TEMED T3100 Melford UK 
Ammonium persulphate A3678 Sigma-Aldrich Japan 
Sodium dodecyl sulphate 10090490 Fisher Scientific UK 
Isopropanol P/7500/17 Fisher Scientific UK 
Methanol M/4000/17 Fisher Scientific UK 
Immobilon®-P Polyvinylidene difluoride 
membranes (PVDF) 
IPVH00010 Millipore UK 
Chromatography papers (filter papers) 3030-917 GE Healthcare China 
Precision Plus Protein™ Dual Color Standards 161-0374 Bio-Rad Laboratories USA 
Chemiluminescent reagents (EZ-ECL) 20-500-120 Biological Industries Israel 
Immunocytochemistry 
Triton™ X-100 T9284 Sigma-Aldrich USA 
Horse serum H0146 Sigma-Aldrich USA 
Paraformaldehyde P6148 Sigma-Aldrich USA 
RT-PCR 
Hard-Shell® 96-Well PCR Plates HSP9635 Bio-Rad Laboratories USA 
Microseal® ‘C’ PCR Plate-Sealing Film msc1001 Bio-Rad Laboratories USA 
Brilliant III Ultra-Fast SYBR 600882 Agilent Technologies USA 





Sucrose S0809 Melford UK 
D-Mannitol A14030 Alfa Aesar UK 
























TWEEN 20 233360010 Acros Organics USA 




Minisart® NML Syringe Filter, 0.45µm 16555 sartorius Germany 
Bovine serum albumin (BSA) EQBAH Europa Bioproducts UK 
Sodium azide S8032 Sigma-Aldrich Germany 
TRIS B2005 Melford UK 
Glycine G0709 Melford UK 





2.2 Cell lines  
The fibroblasts were either obtained from Coriell/Rudgers Cell repository (https://www.coriell.org/, 
https://nindsgenetics.org/), or from the Sheffield-based clinic. Fibroblast details are listed in Table 
2.1. Coriell/Rudgers fibroblasts are covered by the research agreement and Material Transfer 
Agreement (MTA) between the repository and Dr Heather Mortiboys at the University of Sheffield. 
Sheffield-based fibroblasts are covered by the local ethics committee under Sheffield Teaching 
Hospitals (STH) ethics number 16350. The two types of Chinese hamster ovary (CHO) cells, 
ARE-TK-GFP and TK-GFP reporter constructs, were a kind gift from Dr Richard Mead from the 
Sheffield Institute for Translational Neuroscience; the SH-SY5Y cells were a kind gift from Dr 
Adrian Higginbottom from the Sheffield Institute for Translational Neuroscience.  
Table 2.1 Information on patient and control fibroblasts  
Sample ID Case Age Gender Mutation Source 
OB064 control 67 male - Sheffield based 
ND37731 parkin 64 female 
40bp deletion in 
exon3; unspecified 




ND30171 parkin 46 male ARG42PRO 
Coriell/Rudgers 
Institute 
ND31618 parkin 63 female ARG42PRO 
Coriell/Rudgers 
Institute 
GM07924 control 63 male - 
Coriell/Rudgers 
Institute 
GM23967 control 52 male - 
Coriell/Rudgers 
Institute 







2.3 Tissue culture 
2.3.1 Growing cells 
The handling of the cells was performed under sterile conditions inside a class II biohazard 
cabinet. For optimum growth rate, the cells were fed with 10ml of cultured medium, replenished 
every two days [Table 2.2]. The cells were kept at 37°C in 5% CO2 in air (the default cell incubating 
setting in this project). Fibroblasts were grown in T75 flasks, whereas CHO cells and SH-SY5Y 
were grown in 10 cm petri dishes. The medium was replaced every two to three days and the 
cells were tested for mycoplasma infections initially upon defrost and, subsequently, every two 
weeks. The galactose medium was prepared using glucose-free Dulbecco’s Modified Eagle 
Medium (DMEM) supplement with galactose (at final concentration of 5mM) plus the other 
additives listed in Table 2.2.   
Table 2.2 Contents of the prepared cultured medium for different types of cells 
Constituent concentration Fibroblast CHO SH-SY5Y 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
1x  √ √ 
MEM Eagle with Earle’s BSS, with L-
glutamine (EMEM) 
1x √   
Foetal Bovine Serum (sigma) 10% (v/v)  √  
Foetal Bovine Serum (labtech) 10% (v/v) √   
Foetal Bovine Serum (LSP) 10% (v/v)   √ 
Penicillin/Streptomycin (P/S) 1% (v/v) √ √ √ 
Sodium Pyruvate 1% (v/v) √   
Uridine (50mg/ml solution) 0.1% (v/v) √   
Non-Essential Amino Acid Solution 
(NEAA) 100X 
1% (v/v) √   





2.3.2 Collecting and passaging the cells  
Cells were passaged when they had reached approximately 80–90% confluence, which was 
estimated through inspecting different areas of the flask/dish under a brightfield optic microscope 
at 10x objective. To passage the cells, the 10ml medium in the flask/dish was removed and they 
were washed with 5ml of phosphate buffered saline (PBS). Then the cells were trypsinised with 
5ml of 1x trypsin, for approximately five to six minutes inside the incubator. A light tap on the side 
of the flask/dish ensured that most of the cells were detached from the floor, which was confirmed 
under the microscope. Subsequently, the removed medium was transferred back to the flask/dish 
to deactivate the trypsin. The mix in the flask/dish was then transferred into a 15ml falcon tube 
and centrifuged at 400rcf (brake 9, acceleration 9) for four minutes in a benchtop centrifuge (MSE 
– Harrier 15/80). The supernatant was aspirated and discarded and the cell pellet was re-
suspended in an appropriate amount of corresponding culture medium. Fibroblasts were split into 
three new T75 flasks pre-loaded with 9ml of culture medium. CHO and SH-SY5Y cells were split 
into four new dishes pre-loaded with 9ml of culture medium. Unused cells and contaminated 
plasticware were disinfected and discarded according to the department protocol for biosafety. 
2.3.3 Cryopreservation 
A stock of live cells was made by storing early passages in liquid nitrogen. The harvested 
centrifuged cell pellet was re-suspended in 1ml of freezing-down medium (contents: culture 
medium, PBS and dimethyl sulfoxide (DMSO), in a volume ratio of 8:1:1, respectively). The re-
suspended cells were split into two cryovials and cooled gradually to -80°C using alcohol-free cell 
freezing containers. Then, the cryovials were immersed in liquid nitrogen for long-term storage.  
2.3.4 Pelleting cells 
Cells to be used for DNA, RNA or protein extractions were pelleted and stored at -80 °C until 
needed. The cells were harvested and centrifuged as described before. The supernatant was 
then discarded. Then, the cell pellet was re-suspended in 1ml PBS to dilute any remnants of 
culture medium. The PBS-cell mix was transferred into a 1.5 Eppendorf, centrifuged at 400 rcf 
and the cell pellet was stored at -80°C after removing the supernatant. 
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2.3.5  Counting cells  
A haemocytometer was used to estimate the concentration of cells suspended in the culture 
medium. 10µl of the suspension was pipetted onto one side of the haemocytometer. The chamber 
was examined by an optic microscope under 10x objective. The cells were counted in the four 
corner squares and the average was multiplied by 104 to express the density as cells/ml. The 
chamber and the coverslip were then cleaned with 70% alcohol before and after every use. The 
required amount of medium was added to the cell suspension to reach the desired concentration 
using the formula: total cell count = cell concentration (cells/ml) x total volume of the suspension 
(ml). The cells were plated in a specific volume and density according to the design of the 
experiment.  
2.3.6 Drugs and toxins 
Drugs and toxins were prepared from their solid powders and were dissolved in anhydrous 
DMSO, except for CCCP, which was prepared in ethanol. Stock concentrations were prepared 
according to the following formula: concentration in mol/L [Molar or M] = (mass of solute in grams/ 
volume of solution in litres) x (1/ molecular weight in g/mol). The prepared drugs and toxins were 
either stored in oxygen and a moisture-free MultiPod storage system, or were aliquoted and 
stored at -80°C in order to avoid the thaw freeze cycle. The final concentrations of the drugs, as 
well as the type of containing medium were determined according to the design of the experiment. 
The dilution of stock concentration was performed according to the following formula: 
concentration of the stock solution x volume to be removed from stock solution = final 
concentration of the diluted solution x final volume of the diluted solution. Vehicle backfill was 
applied when the experiments required different concentrations and volumes of the tested drug 
to ensure that all conditions contained equal volumes of the vehicle. The application of the drugs 
was performed either manually or by the use of the ECHO 550 liquid handler (Labcyte). 
2.3.7 Differentiation of SH-SY5Y cells 
SH-SY5Y cells were plated in a 96-well plate or a 24-well plate, according to the design of the 
experiment, in regular SH-SY5Y culture medium [Table 2.2]. The cells were allowed to grow to 
reach 60% - 70% confluence before starting the differentiation protocol. At the first day of 
differentiation (day 0), the culture medium in the wells was completely replaced by an equal 
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volumes of the differentiation medium. Subsequently, only half of the volume of the differentiation 
medium in each well was replaced every two days. At day 14, drugs/toxins were added according 
to the design of the experiment. The differentiation medium constitutes of 50% volume 
Neurobasal® Media, 50% volume DMEM/F-12, GlutaMAX™ supplement, retinoic acid (RA) (10 
µM), N-2 supplement (1X) and L-glutamine (1X). RA stock was aliquoted and kept in dark at -
20°C, and was added to the prepared differentiation medium at the time of medium replacement. 
 
2.4 Western blotting 
2.4.1 Cell lysis 
The stored frozen cell pellet from a T75 flask or a 10 cm dish was defrosted on ice and was lysed 
in a mixture of 44.5μl of RIPA buffer, 5μl of 10x Protease Inhibitor Cocktail and 0.5μl of 
Phosphatase Inhibitor Cocktail2. The cells were vortexed for 30 seconds to homogenise the 
suspension, kept on ice for 30 minutes and then centrifuged at 13,000 rpm for 30 minutes at 4°C. 
The protein-rich supernatant was then transferred into a new 1.5ml Eppendorf tube and the pellet 
of cellular debris was discarded. Protein extracts were kept on ice at all times. 
2.4.2 BSA assay 
To prepare the standard curve, 5μl of increasing concentrations of Bovine serum albumin (BSA) 
were pipetted into wells pre-loaded with 250μl of Coomassie protein reagent [Figure 2.1]. 5μl of 
diluted samples (1:10 in H2O) were also added to other wells pre-loaded with 250μl of Coomassie. 
All conditions were prepared in triplicate using a clear 96 well plate (Corning® 96 Well). Protein 
absorbance was measured immediately using a Pherastar plate reader at a wavelength of 620nm 
(BMG Labtech). Microsoft Excel was used to calculate the protein concentration according to the 
linear regression analysis of the standards [Figure 2.1]. Once the concentration of the sample 
was calculated, the sample was diluted in H2O to reach 2 μg/μl, and was then mixed with an equal 
volume of Laemmli buffer 2x (4% Sodium dodecyl sulphate (SDS), 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris HCl; PH6.8) to yield a final 




Figure 2.1 BSA assay for quantification of protein concentration.  
(a) An image of a plate loaded with increasing concentrations of BSA to serve as standards. (b) The 
absorbance readings were plotted at the y axis against the concentrations of the standards. The obtained 
linear equation was then used to calculate the concentration of the protein sample. 
 
2.4.3 Gel electrophoresis and transfer 
SDS-PAGE was performed using the Mini-Protean Tetra Cell apparatus (Bio-Rad). The resolving 
gel solution (12%) was swiftly pipetted in between the 1.0 mm or 1.5 mm glass plates, leaving 
enough space for the stacking gel. A layer of isopropanol was added to eliminate any bubbles 
that might have formed while filling the casting cassette, and to prevent evaporation during the 
polymerisation process. The resolving gel was left to polymerise for 15 minutes, then the 
isopropanol layer was removed. The stacking gel was then swiftly pipetted into the remaining 
space and a suitable comb was inserted. The stacking gel was then left to polymerise for 15 
minutes. The residual stacking and resolving gel solutions in the tubes were used as indicators 
to confirm gel polymerisation. The components of stacking and resolving gel are listed in Table 
2.3. The gel-containing glass plates were then transferred into a gel holder assembly to form a 
closed inner compartment. The assembly was placed inside a tank and filled with running buffer 
(tank buffer) [Table 2.4]. Then the comb was carefully removed and the lanes were cleaned of 
any gel fragments by forceful repetitive pipetting to the side of the lanes. 5µl of Precision Plus 
0 µg/µl (5ul of distilled water was added) 
 0.125 µg/µl 
 0.25 µg/µl 
 0.5 µg/µl 
 0.75 µg/µl 
 1 µg/µl 
 1.2 µg/µl 






Protein™ ladder was loaded into the first lane. The protein samples were boiled at 95°C for two 
minutes before loading them into the gel (20 μg/lane). In order to run the sample through the 
stacking gel, a required voltage of 50V was applied for approximately 30 minutes. Then, the 
voltage was increased to 120V until sufficient separation of the ladder bands was seen, depending 
on the proteins to be separated.  
Following electrophoresis, the gel was extracted and the stacking gel segment was removed. The 
gel was equilibrated in a tray filled with the transferring buffer [Table 2.4] and 10% (V/V) methanol. 
A proper size polyvinylidene fluoride (PVDF) membrane was activated in 100% methanol for 15 
seconds (to facilitate the protein transfer) before being soaked in the transferring buffer. The 
transfer assembly was arranged in the transfer buffer-containing tray in the following order: 
sponge, filter paper, PVDF membrane, gel, filter paper, sponge. The transfer assembly was 
placed in a tank filled with transfer buffer. The tank was connected to a power pack with the right 
polarity orientation and the transfer was performed under a running current of 250 mA for 60 
minutes. An ice pack was placed inside the tank to avoid overheating. Alternately, the transfer 
could be performed overnight under a running current of 40 mAmp at 4°C. Afterwards, the PVDF 
membrane was stained with Ponceau to confirm the transfer of the proteins. The Ponceau was 
washed with Tris-buffered saline with Tween 20 (TBST) [Table 2.4]. The membrane was 
subjected to 5% of Non-Fat Dry Milk (in TBST) at room temperature for 1 hour to block non-










Table 2.3 Components of stacking and resolving gel 
 Components Volume (μl) 
Stacking gel 
30% acrylamide 600 
Tris in H2O,1.5M, pH6.8 888 
H2O 2000 
TEMED 10 
10% APS 56 
(12%) Resolving gel 
30% acrylamide 4000 
Tris in H2O,1.5M, pH8.8 2500 
H2O 3300 
10% SDS 100 
TEMED 4 
10% APS 100 
 
 
Table 2.4 Buffers used in Western blotting (all made in H2O) 
Constituent Tank buffer Transfer buffer 
TBST 
(pH 7.5) 
TRIS 25mM 25mM 20mM 
glycine 190mM 192mM  
SDS 3.5mM   
NaCl   150mM 
tweeen20   0.1% (v/v) 
methanol  20% (v/v)  
 
2.4.4 Probing and imaging 
Primary and matched Horseradish peroxidase (HRP)-conjugated secondary antibodies were 
prepared in 5% of Non-Fat Dry Milk (in TBST) and were applied as shown in Table 2.5. Following 
the application of each antibody, the membrane was subjected to 3 x five-minute washes with 
TBST. For imaging purposes, equal volumes of chemiluminescent reagents A and B were mixed 
and kept in the dark for five minutes. Then, the mixture was evenly distributed over the membrane 
and kept in the dark for one minute. The G-Box chemi system (Syngene) was used to visualize 
the blot using the intellichemi mode. The size of the target proteins was estimated according to 
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the positions of the ladder bands. Following the imaging, the membrane was stored in TBST at 
4°C. If the membrane was planned to be probed with a different antibody, a mild stripping was 
performed by soaking the membrane in the stripping solution (10µl 0.1% Sodium azide (in PBS) 
+ 10ml 5% of Non-Fat Dry Milk (in TBST)) for at least six hours at 4°C. All equipment used in 
western blotting (WB), including the glass plates, were washed and cleaned before and after 
every use. 
 















































































































































170-6516 Bio-Rad 1:5000 








170-6515 Bio-Rad 1:5000 





2.4.5 Quantitative analysis 
Image analysis was performed using Geni Tool software (Syngene). The data obtained by the 
densitometric analysis were further processed by Microsoft Excel to normalise the values against 






Cells were plated either in a black 96-well plate or in a black 384-well plate. The cells were seeded 
at various densities according to the design of the experiment. 
2.5.2 Fixation 
Following drug/toxin treatment, the plated cells were washed once with PBS to remove any trace 
of medium, incubated with 4% paraformaldehyde (PFA) (in PBS) at room temperature for 30 
minutes and then washed again with PBS. For SH-SY5Y, an alternative fixation method was used 
to reduce the detachment of the cells during the washing steps. In this method, half of the volume 
of the medium in the well was replaced with 4% PFA and the plate was kept in the incubator for 
15 minutes. Then, the medium-PFA mixture was removed and the cells were covered with 4% 
PFA for 15 minutes at room temperature. The fixed cells were either stored at 4°C in PBS for a 
few days or in 0.1% sodium azide solution (in PBS) for up to four weeks. 
2.5.3 Antibody staining 
To prepare the fixed cells for immunostaining, they were first incubated in 0.1% of Triton X-100 
(in TBST) at room temperature for ten minutes. Then, the Triton X-100 was removed and was 
followed by 3 x five-minute washes with TBST. The cells were blocked with 5% horse serum (in 
TBST) at room temperature for 60 minutes. Following the application of the primary antibody 
[Table 2.6], the cells were washed with TBST (3 x five minutes). Then, an appropriate 
fluorochrome-conjugated secondary antibody was applied for one hour [Table 2.6], and the cells 
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1:1000 Overnight at 4°C Chicken - 
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Donkey 488 
Secondary Anti – mouse 
A11001 / Life 
Technologies 
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Secondary Anti – rabbit 
A21428 / Life 
Technologies 
1:1000 
1 hour at room 
temperature 
Goat 555 
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2.5.4 Nuclear staining and imaging 
The cells were stained with Hoechst (10µM final concentration) for ten minutes at room 
temperature. Then, the cells were washed once with TBST and were kept in the dark at 4°C. The 
images were captured by the Opera Phenix confocal microscope (PerkinElmer) using 40x 
Objective Magnification and three channels with different excitation/emission wavelengths (Alexa 
488: ex488/em522, Alexa 568: ex561/em599 and DAPI: ex405/em456). 20 fields per well were 
imaged. For each field, at least eight image planes were captured (to produce an image stack), 
and the maximum projection images were used in the analysis. Image analysis was performed 
using Harmony high-content analysis software. For the CHO-AKT experiments [Heading 6.2.2], 
the imaging was performed using confocal microcopy (Leica) (63x Objective Magnification, 
Leica/Alexa 555 and Leica/DAPI channels, 20 fields per well. For each field, 15 image planes 
were captured (to produce an image stack) and the maximum projection of the images was used 
in the analysis). The images were then analysed using ImageJ software. The IN Cell Analyser 
2000 (GE Healthcare) was used to count the cell number in the DCF experiments (2x Objective 
Magnification, DAPI: ex350/em455) [Heading 4.3]. The In Cell Developer Toolbox 1.9 software 
was used to analyse the images and to calculate the total number of nuclei per well.  
 
2.6 Quantitative real-time PCR  
2.6.1 DNA extraction 
DNA extraction was performed using a DNA extraction kit from Qiagen (DNeasy Blood & Tissue 
Kit # 69504, UK). The kit contains a buffer system that is optimised to allow direct cell lysis, which 
is followed by selective binding of DNA (nuclear and mitochondrial) to the DNeasy membrane. 
The DNeasy procedure efficiently recovers DNA fragments as small as 100 bp. 
DNA extraction was performed according to the manufacturer’s manual. The frozen cell pellet 
was equilibrated to room temperature before it was re-suspended in 200µl PBS, 200µl buffer AL 
(provided with the kit) and 20µl of proteinase k (provided with the kit). These volumes are 
adequate to lyse a maximum of 1x107 cells. The cell suspension was mixed thoroughly through 
vortexing and the cells were lysed for 10 minutes at 56°C. Then, the lysate was mixed with 200µl 
of 100% ethanol through vortexing. The mix was transferred into a DNeasy Mini spin column, 
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placed in a 2ml collection tube (provided with the kit) and centrifuged at 6,000 x g for one minute. 
Ethanol and salts are used in the DNA extraction to precipitate the DNA and to prevent it from 
dissolving in the water. The collection tube, which contained the flowthrough of different cell 
components, was discarded. The spin column, which had the DNA trapped within the DNeasy 
membrane, was placed into a new 2ml collection tube. Then, it was subjected to two washing 
steps to remove the remaining contaminants and enzyme inhibitors. First, 500µl of buffer AW1 
(provided with the kit) was added and the Mini spin column was centrifuged at 6,000 x g for one 
minute. Then, the Mini spin column was loaded with 500µl of buffer AW2 (provided with the kit) 
and centrifuged at 20,000 x g for 3 minutes. To elute the DNA, the spin column was placed in a 
1.5ml Eppendorf, loaded with 200µl of buffer AE (provided with the kit), incubated for one minute 
at room temperature and centrifuged at 6,000 x g for a further minute. The extracted DNA was 
then stored at -20°C. 
2.6.2 RNA extraction  
RNA extraction was performed using a RNA extraction kit from Qiagen (RNeasy Mini Kit # 74104, 
UK). As with the DNA extraction kit, the RNA extraction is also based on the selective binding 
properties of a silica-based membrane and the speed of the microspin. The lysis buffer contains 
a highly denaturing guanidine-thiocyanate, which immediately inactivates RNases to preserve the 
integrity of the RNA. The system allows the purification of RNA molecules that are longer than 
200 nucleotides and up to 100 µg. With the exception of mRNA, most RNAs are less than 200 
nucleotides. Therefore, this kit provides an enrichment for mRNA, which makes it suitable for 
gene expression studies. 
RNA extraction was performed according to the manufacturer’s manual. The frozen cell pellet 
was equilibrated to room temperature before it was re-suspended in 600µl of buffer RLT (provided 
with the kit). This volume is adequate to lyse a maximum of 1x107 cells. Following vortexing, an 
equal volume of 70% ethanol (in H2O) was added and mixed well through repetitive pipetting. 
Then 700µl of the mix was transferred into an RNeasy Mini spin column, placed in a 2ml collection 
tube (provided with the kit), and centrifuged at 8,000 x g for 15 seconds. The flowthrough was 
discarded and the remainder of the lysate was loaded into the same RNeasy Mini spin column 
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and re-centrifuged to accumulate the RNA in the membrane. Afterwards, the Mini spin column 
was placed in a new 2ml collection tube and was subjected to a series of washing steps to remove 
contaminants from the RNA. First, the Mini spin column was loaded with 700µl of buffer RW1 
(provided with the kit) and centrifuged at 8,000 x g for 15 seconds. Then, 500µl of buffer PRE 
(provided with the kit) was loaded and centrifugation was repeated. Afterwards, 500µl of PRE was 
loaded and centrifugation was performed at 8,000 x g for two minutes. The Mini spin column was 
centrifuged for one minute at full speed at the end of the washing steps in order to dry the 
membrane. In order to elute the RNA, 30µl of RNase-free water was loaded and the Mini spin 
column was centrifuged at 8,000 x g for one minute. The extracted RNA was kept on ice and 
stored at -80°C.  
2.6.1 Quality control 
Qualitative and quantitative analysis of the extracted DNA and RNA were performed using a 
spectrophotometer (#ND-1000, NanoDrop, Wilmington, DE). Prior to loading the sample, the 
machine was calibrated using the media in which the DNA/RNA was eluted (buffer AE, RNase-
free water, respectively). The ratios of A260/A230 and A260/A280 were used for qualitative 
assessment. The purity of the DNA samples was accepted when the values of A260/A280 and 
A260/A230 were at least 1.8 and 2, respectively. For RNA, the accepted value of A260/A280 was 
at least 2. The measurement of absorbance at these wavelengths is based on the fact that all 
nucleotides have absorbance maxima at 260, while proteins have absorbance maxima at 280. 
Other contaminants also absorb at 230; therefore, A260/A230 ratio was used as a secondary 
measure of nucleic acid purity. In comparison to DNA, RNAs are expected to have a higher 
260/280 ratio because they have a higher uracil/thymine ratio. 
2.6.2 cDNA synthesis 
The superscript iii kit (#11752050, Thermo Fisher Scientific, USA) was used to synthesise cDNA 
for the subsequent qPCR. The reaction mix of 20µl/tube was prepared as follows: 10µl of 2x RT 
reaction mix, 2µl of RT enzyme mix, 1 µg of RNA sample and an adequate volume of DEPCE-
treated water to reach a total of 20µl (all provided with the kit). The required volume of the RNA 
sample to reach 1 µg was calculated according to the concentration obtained by 
spectrophotometry. Reverse transcriptase negative control was prepared by adding DEPCE-
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treated water instead of the sample. The sample and the RT mix were kept on ice at all times. 
The reaction was performed in accordance with the manufacturer’s manual using G-Storm GS2 
Multi Block Thermal Cycler (G-Storm): 25°C for ten minutes, 50°C for 30 minutes, and 85°C for 
five minutes. To eliminate remnant RNA in the mix, 1µl of Halics RNase (provided with the kit) 
was added and the mix was incubated at 37°C for 20 minutes. The synthesised cDNA was stored 
at -20°C.  
2.6.3 qPCR reaction 
UCSC Genome Browser and primer-BLAST tool were used to find and to design the primers used 
in this project [Table 2.7]. Using a 5µM stock, various concentrations of the forward/reverse primer 
were tested in order to find the optimum combination. The final tested concentrations in the qPCR 
reaction were (expressed in nM): F 150/R 150, F 150/R 300, F 300/R 150, F 300/R 300, F 300/R 
600, F 600/R 300, F 600/R 600. Relative DNA quantification was performed using the CFX96 
Touch™ Real-Time PCR Detection System (Bio-Rad). The content of each well of the 96-well 
PCR plates was prepared via mixing the following: 10µl of SYBR mix, 1µl of F primer (5µM stock), 
1µl of R primer (5µM stock), 7µl of DNase/RNase-Free Distilled Water and 1µl of the DNA/cDNA 
sample. The qPCR plate was kept on ice during the loading and was sealed with plate-sealing 
film before it was loaded into the qPCR machine. The PCR programme was: 95°C for ten minutes; 
95°C for 30 seconds; 62°C for one minute; plate read. The cycle was repeated 40 times. At the 
end, a melt curve was performed by monitoring loss of fluorescence signal after ten-second 
incubation steps, rising from 65 °C to 95 °C in 0.5 °C increments. 
Five times of ten-fold serial dilution of an undiluted control sample was used to generate a 
standard curve for each primer to assess the efficiency. The loading of the samples, qPCR 
negative controls and/or reverse transcriptase negative control were done in triplicates. Since the 
amount of the loaded sample should double with every cycle, the Ct value of the prepared 
serial dilution is expected to be 3.3 cycles apart. The negative controls should have no signals 
below 35 cycles to exclude contamination. The cycle threshold was set to be within the 
straight line stretch in the log phase. A cycle threshold of 2,000 was set as standard for all 
qPCR reactions. When the standard dilutions were plotted, the efficiency was calculated 
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according to the slope of the linear regression. The efficiency indicates accurate dilution and 
pipetting but it is also affected if the primer design is not optimal. The accepted efficiency 
range was 90–110%. Following the qPCR, melt curve analysis was performed to assess the 
reaction specificity. The presence of a single peak or a single shoulder in the melting peak or the 
melting curve graphs indicates high specificity, which implies that the reaction leads to the 
amplification of only a specific sequence in the mix. The melting temperature, where most of the 
signal loss occurs, should match the expected melting point of the used primers. 
The drug-induced expression of the gene of interest was assessed relatively by calculating the 
fold change in treated samples in comparison to the untreated ones using GAPDH as a loading 
control. The relative quantification of mtDNA was based on the fact that cells have multiple copies 
of mtDNA and only two copies of nuclear DNA. The mtDNA copy number was calculated 




Table 2.7 Primers used in q-PCR 



































































2.7 ARE reporter assay 
The CHO-ARE and the CHO-TK cell lines were used to assess ARE expression under various 
treatment conditions. The TK-EGFP reporter construct consists of a 123bp thymidine kinase 
promoter inserted in the multiple cloning site of the EGFP plasmid. The ARE-TK-EGFP contains 
four repeats of a 41bp GST ARE motif (TAGCTTGGAAATGACATTGCTAATCGTGACAAAGCAA 
CTTT) 3′ to the TK promoter (Mead et al., 2013). Since the construct contains the G418 resistant 
gene, the cells were kept under selective pressure by growing them in a G418-containing medium 
(0.5 mg/ml). Following drug treatment, the expression of the EGFP was measured using the 
Pherastar plate reader (485 nm excitation, 520 nm emission detection) at 647 gain. 
 
2.8 Oxidative stress assay 
6-carboxy-2',7'-dichlorodihydrofluorescein (DCF) is a chemically reduced acetylated form of 
fluorescein that is commonly used as a sensor of ROS. When applied, DCF is trapped inside the 
cells due to its negative charges. Upon exposure to ROS, DCF is converted into a green 
fluorescence molecule.  
The cells were cultured in a black 96-well plate and were treated according to the experiment 
design. On the day of the assay, the medium was removed and the cells were washed once with 
PBS. Then the cells were covered with phenol red free medium containing 20mM DCF and kept 
in the incubator for one hour. Afterwards, the fluorescence was measured by the Pherastar plate 
reader (485 nm excitation, 520 nm emission detection) at a fixed gain of 413. A series of ten 
readings (one minute apart) were performed to calculate the kinetic slope, which was used as an 
indicator of oxidative stress levels. 
 
2.9 Cytotoxicity measurement 
2.9.1 LDH assay 
Cell death is associated with a deterioration in membrane integrity and concomitant leakage of 
various intracellular enzymes. Among them, lactate dehydrogenase enzyme (LDH) is the most 
stable one with a relatively long half-life (9 hours). The CytoTox 96® Non-Radioactive Cytotoxicity 
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Assay (G1781, Promega, Madison, USA) used in the project allows relative quantification of LDH. 
The assay measures the released LDH by supplying lactate, NAD+ and tetrazolium salt as 
substrates [Figure 2.2]. LDH drives the conversion of the tetrazolium salt into a red molecule in a 
dose-dependent manner. Therefore, the measurement of the colour should reflect the amount of 
the released LDH. 
The cells were plated in a 96-well plate at a specific density according to the experiment design 
in a total volume of 200 µl/well. Matching wells for each condition were used to obtain the total 
LDH release. The total LDH release was used to calculate the percentage cytotoxicity of that 
condition. A CytoTox 96® Non-Radioactive Cytotoxicity Assay was performed according to the 
manufacturer’s manuals. On the day of the assay, 20µl from each well assigned for total LDH 
release was replaced with an equal volume of 10x lysis buffer (provided with the kit). The cells 
were kept in the incubator for 45 minutes. Cell lysation was confirmed under optic microscopy. 
Then 50µl from each well was transferred to a transparent 96-well plate and mixed with an equal 
amount of the cytotox reagent. The plate was kept in the dark for 30 minutes at room temperature. 
Afterwards, 50µl of stopping solution was added to each well to stop the reaction, allowing a one-
hour window to read the plate. The Pherastar plate reader was used to measure the absorbance 
at a wavelength of 490nm. In each experiment, cell-free wells were used to determine the medium 
background level, which was subtracted from the readings of all other wells. In addition, other 
cell-free wells were treated with 1µl of pure LDH (supplied with the kit) to ensure that the assay 
reagent was active and to obtain the maximum reading. All conditions were made in triplicates. 
The preparation and the storage of different the substrates and reagents was performed in 




Figure 2.2 The principle of the CytoTox Cytotoxicity Assay.  
The provided substrate mix contains lactate, NAD+ and iodonitrotetrazolium violet (INT). The latter is 
converted into a red-colour molecule (Formazan) in the presence of LDH. 
 
2.9.1 Trypan blue assay 
An alternative approach to assessing cytotoxicity was performed by the use of trypan blue 
staining. The cells were cultured and treated according to the experiment design in a 24-well 
plate. To assess the cytotoxicity, the cells were detached from the well floor via repetitive pipetting 
of the medium. Then the total content of the well was aspired and transferred into a 1.5ml tube 
and was subjected to four minutes of centrifugation at 400rcf (brake 9, acceleration 9). The 
supernatant was removed and the cells were re-suspended in 40µl of culture medium. Equal 
volumes of the cell suspension and trypan blue stain were mixed thoroughly. Then 10µl of the mix 
was loaded into one side of the Countess™ Cell Counting Chamber Slide and the cytotoxicity 
was assessed by the use of the Countess® Automated Cell Counter (Invitrogen). Trypan blue is 
unable to infiltrate an intact cellular membrane and, therefore, can only stain dead cells that lack 
membrane integrity. The automated cell counter differentiates between live and dead cells 
according to their staining pattern. The cytotoxicity was calculated as 100 minus the percentage 
of the live cells to the total cell count. 
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2.10 ATP assay 
Relative quantification of total cellular ATP levels was achieved via the use of the ATPlite assay 
(6016941, PerkinElmer, Waltham, MA, USA). The ATPlite assay is an ATP monitoring system 
based on firefly (Photinus pyralis) luciferase. The assay provides substrates, which in the 
presence of ATP can emit light in a dose-dependent manner according to the reaction scheme in 
Figure 2.3. 
The cells were plated in a white 96-well plate at a specific density according to the experiment 
design in a total volume of 200µl/well. All conditions were made in triplicates. The ATPlite assay 
was performed according to the manufacturer manuals. First, the medium was removed and the 
cells were washed once with PBS. Then, 50µl of mammalian cell lysis solution (provided with the 
kit) was added and the plate was subjected to 700rpm on an orbital shaker for five minutes to 
facilitate the lysation. This step was followed by the addition of 50µl of the ATP substrate solution, 
and the plate was shaken for another five minutes to ensure that the lysate and the substrate 
were homogenously mixed. Subsequently, 100µl of PBS was added and the plate was kept in the 
dark at room temperature for ten minutes. The luminescence was measured by the Pherastar 
plate reader at 3,600 gain using the LUM plus mode. The preparation and storage of different 
substrates and reagents were performed in accordance with the manufacturer’s manual. 
Afterwards, the readings were normalised against the DNA content in each well using CyQUANT 
NF Cell Proliferation Assays (#C35006, Thermo Fisher Scientific, USA) The 1x dye solution was 
prepared by adding the CyQUANT® NF dye to 5x HBSS buffer (provided with the kit) to distil 
water in a ratio of 1:100:400. 50µl of the 1x dye solution was added and the plate was kept in the 
incubator for 45 minutes. The fluorescence was measured by the Pherastar plate reader (485 nm 
excitation, 520 nm emission detection) at a gain value of 100, which was fixed in all experiments. 
 
Figure 2.3 The principle of the ATP Detection Assay System.  
The production of light is prompted by the reaction of ATP with added luciferase and d-luciferin. 
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2.11 Cellular fractionation 
2.11.1 Mitochondrial isolation  
The isolation of an enriched mitochondrial fraction was performed using a protocol that was 
adopted from (De Vos et al., 2011). Treated cells in a T175 flask were harvested via trypsinisation, 
as described previously. Consequently, the cells were washed twice in PBS before they were re-
suspended in 250µl of mitochondrial isolation buffer (IB): mannitol (220mM), sucrose (70mM), 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (10mM), ethylenediaminetetraacetic 
acid (EDTA) (1m), Dithiothreitol (DTT) (1mM), BSA (0.1%), 10x Protease Inhibitor Cocktail (5%), 
Phosphatase Inhibitor Cocktail2 (1%) in H2O). Then the cells were homogenised using a IKA® 
dual-speed mixer (Merck). The lysate was centrifuged twice for five minutes at 600 x g to remove 
nuclei and unlysed cells. Afterwards, the supernatant was subjected to a centrifugation at 10000 
x g for ten minutes to separate the mitochondrial fraction (the pellet) from the cytoplasmic fraction 
(the supernatant). 
2.11.2 Mitochondria purification 
Next, the mitochondrial extract was purified via centrifugation through two different concentrations 
of sucrose [Figure 2.4]. The mitochondrial pellet was re-suspended in 1ml of IB and carefully 
transferred into a 5ml tube that was pre-loaded with the sucrose gradient. The tube was pre-
loaded with 1.5ml of 1.6M sucrose (in H2O), followed by 2.5ml of 1.2M sucrose (in H2O). HEPES, 
BSA and EDTA were added to the sucrose preparation at equal concentrations to the IB. 
Afterwards, the tube was subjected to high-speed centrifugation at 95,000 x g for one hour using 
the L-80 Ultracentrifuge (Beckman) (SW 55Ti rotor). During that process, the mitochondrial 
fraction progressed through the 1.2M sucrose and accumulated at the level of the 1.5M sucrose 
[Figure 2.4]. Following the centrifugation, the mitochondrial fraction (250–300µl) was recovered 
from the 1.6M/1.2M interface and was mixed with 600µl of IB. In order to pellet the mitochondria, 
the mix was subjected to centrifugation at 10000 x g for ten minutes. The samples and reagents 
were kept at 4°C at all steps of the fractionation. The mitochondrial pellet was lysed and prepared 




Figure 2.4 Purification of mitochondria by sucrose step density gradient centrifugation. 
 The image shows the 5ml centrifugation tube loaded with the sample and the sucrose gradient before and 
after the centrifugation step. The mitochondria accumulate at the 1.6M/1.2M interface and appear as a thin 
white layer. 
 
2.12 Statistical analysis 
All data analyses and statistical tests were performed using Graphpad prism V7.0 (Graphpad). 
All experiments were performed in triplicates, unless otherwise stated, and all error bars represent 
the standard deviation of the mean (SD). The data were analysed using an unpaired t-test, one-
way ANOVA or two-way ANOVA. Significance values were denoted following the GP formatting 
in Graphpad prism V7.0  : Not statistically significant (ns) = p>0.05, * = p<0.05, ** = p<0.01, *** = 
















Chapter 3. Investigating the effect of 







3 Investigating the effect of UDCA on mitochondrial 
biogenesis in patient fibroblasts 
3.1 Introduction 
3.1.1 Parkinson’s disease and mitochondrial biogenesis 
Several studies have suggested a defect in mitochondrial biogenesis in PD, in particular in the 
context of Parkin deficiency. In SH-SY5Y cells, the transcription and replication of mitochondrial 
DNA is enhanced by Parkin overexpression and attenuated by (siRNA-mediated) Parkin 
repression (Kuroda et al., 2006). The mechanism of action involved was subject to debate until 
the discovery of Parkin interacting substrate (PARIS) (Shin et al., 2011). Parkin binds and 
ubiquitinates PARIS and, consequently, can regulate PARIS level through ubiquitin-mediated 
proteasomal degradation. In line with this, PARIS is expressed at a high level in parkin knockout 
mice, as well as in patients with parkin mutations (Stevens et al., 2015, Dawson and Dawson, 
2014).  
PARIS is a potent selective repressor of PGC-1α (a transcriptional coactivator that coordinates 
the activity of diverse transcription factors involved in mitochondrial biogenesis). The expression 
of PGC1-α is sufficient by itself to facilitate the process of mitochondrial biogenesis (Scarpulla et 
al., 2012). Therefore, the Parkin–PARIS–PGC1-α axis is considered to be an important pathway 
in the pathogenesis of PD in patients with parkin mutations. 
3.1.2 Mechanism of mitochondrial biogenesis 
The process of mitochondrial biogenesis requires both mitochondrial and nuclear proteins to be 
expressed in a multistep, coordinated manner. Therefore, mitochondria are considered “semi-
autonomous” despite the fact that they have their own DNA. mtDNA encodes only eleven 
messenger RNAs, which are translated into 13 respiratory chain proteins, 22 tRNAs and two 
rRNAs (Stewart and Chinnery, 2015, Calvo and Mootha, 2010). While mitochondria contain 
around 1200 proteins, only 90 are required for the synthesis of respiratory chain complexes 
(Gustafsson et al., 2016). Therefore, mtDNA-encoded proteins represent only a fraction of these 
complexes. However, their absence is sufficient to induce OXPHOS dysfunction (Gustafsson et 
al., 2016).  
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mtDNA is a double-stranded, circular molecule that consists of approximately 16.500 bp and is 
usually packed into nucleoids inside the mitochondrial lumen (Kukat and Larsson, 2013). Prior to 
mitochondrial biogenesis, mtDNA must be replicated. Numerous nDNA-encoded proteins are 
translocated to the mitochondrion for this purpose. One of these is DNA polymerase subunit 
gamma-1 (POLG), which contributes to the catalytic subunit of the mitochondrial DNA polymerase 
and possesses a proofreading ability. Mitochondrial DNA polymerase-γ is the only replicative 
polymerase in mitochondria. Other important proteins in mtDNA replication are the Twinkle 
helicase, which unwinds the double-stranded mtDNA, and the mitochondrial single-stranded 
DNA-binding protein (mtSSB), which maintains the integrity of the DNA strand at the replication 
fork, as mitochondrial DNA polymerase-γ is unable to bind double-stranded DNA (Fernández-
Millán et al., 2015) (Akhmedov and Marín-García, 2015).  
The transcription of mtDNA requires the RNA polymerase (POLRMT) and various transcription 
factors, such as mitochondrial transcription factor A (Tfam), mitochondrial transcription factor B2 
(TFB2M), and mitochondrial transcription termination factor 1 (Scarpulla et al., 2012). Nuclear 
respiratory factor-1 and nuclear respiratory factor-2 regulate the transcription of nuclear genes 
that encode for a range of mitochondrial proteins, including cytochrome c and translocase of outer 
mitochondrial membrane 34 (Tom34) (Ploumi et al., 2017). They can also regulate mtDNA 
transcription through their ability to control the transcription of Tfam (Palikaras and Tavernarakis, 
2014). Another important factor is Nrf2, which is mainly concerned with antioxidant response but 
has been found to regulate nuclear respiratory factor-1 in vivo and in vitro (Ploumi et al., 2017). 
To develop the OXPHOS system, both nDNA- and mtDNA-encoded proteins must be translated, 
imported, inserted into the inner mitochondrial membrane and congregated into the five 
complexes (Ploumi et al., 2017). Mitochondrial mRNAs are translated in the cytosol and then 
cross the outer and inner mitochondrial membranes via mitochondrial translocases to be 





Our group previously described increased activity in each of the individual respiratory chain 
enzymes after UCA treatment (Mortiboys et al., 2013). The aim of this chapter is to determine 
whether this is due to a positive effect of UCA/UDCA on mitochondrial biogenesis. The effects of 
each compound on the expression of mitochondrial proteins will be quantified in healthy and 
parkin-mutant fibroblasts, using WB. In addition, relative qPCR for mtDNA copy number will be 
used as a complementary method.  
 
3.2 Experimental design 
The experiments in this chapter aimed to investigate the mechanism of the rescue effect observed 
in previous work by our group (Mortiboys et al., 2013). Therefore, the drug treatment protocol was 
adopted from that study.  
Fibroblasts were grown in regular glucose-containing medium until two days before the assay. 
Subsequently, they were switched to galactose-containing medium, and treated with the drugs. 
Growing fibroblasts in galactose medium instead of regular glucose medium should increase their 
dependence on mitochondrial OXPHOS. Hence, any mitochondrial defect in patient fibroblasts 
should be more pronounced. The effect of any mitochondrial rescuing compound should also be 
increased.  
The effective doses in the Mortiboys paper (2013), of 100 nM for both UCA and UDCA in 24-hour 
treatment, were used in all experiments reported in this chapter. Skin fibroblasts from three parkin 
patients and three age-matched controls were used, grouped into pairs: pair1 (GM07924 and 
ND37731), pair2 (GM23967 and ND30171) and pair3 (GM02189 and ND30618). Information 





3.3 Quantifying the expression of mitochondrial respiratory 
complexes via western blotting in patient fibroblasts 
An increase in mitochondrial biogenesis should lead to an increase in the expression of the 
principal proteins involved in energy production. Therefore, we decided to use antibodies against 
proteins in each of the mitochondrial respiratory chain complexes [Figure 3.1]. WB and data 
analysis were performed as described in the methods section. In each round of these 
experiments, samples under different conditions for a given patient and its age-matched control 
were loaded onto a single WB gel and probed with the antibody mixture. This approach minimises 
variability and allows direct comparison between different treatment conditions in the patient and 
the control.  
 
Figure 3.1  Total OXPHOS Human Antibody Cocktail proved to be efficient in detecting its target 
proteins in each mitochondrial respiratory complex.  
The figure shows WB images of fibroblast extracts probed with the Total OXPHOS Human WB Antibody 
[Table 2.5], which binds to a protein from each respiratory chain complex. The figure shows that the 
antibody successfully binds to all target proteins at the predicted locations. Both control and patient 
fibroblasts were treated with 100 nM UCA or 100 nM UDCA for 24 hours, or with 25 µM resveratrol for 48 




3.4 Positive control testing 
There are many compounds reported to enhance mitochondrial biogenesis, such as nitric oxide, 
valproic acid, epigallocatechin-3-gallate and resveratrol. The latter was chosen as a positive 
control in this study because it upregulates mitochondrial biogenesis in various types of cells 
including human liver cancer cells (HepG2), Coronary artery endothelial cells (CAEC), human 
umbilical vein endothelial cells (HUVEC), human neuroblastoma cells SH-SY5Y, mouse myoblast 
cells (C2C12) and human skin fibroblasts of patients with inborn respiratory chain deficiency (de 
Oliveira et al., 2016, Costa et al., 2014).  
More importantly, resveratrol has been proposed to increase mitochondrial biogenesis in 
fibroblasts obtained from PD patients with parkin mutations (Ferretta et al., 2014). In the study by 
Ferretta and colleagues, WB quantification of PGC-1α showed increased levels in all patients and 
controls (2+2) after treatment with resveratrol. RT-qPCR of PGC-1α downstream genes, such as 
Tfam, cytochrome c, cytochrome c oxidase I and superoxide dismutase 2 (SOD2), also revealed 
increased expression. Resveratrol is considered a candidate treatment for PD as it showed a 
neuroprotective effect in vivo and in vitro (Peng et al., 2016, Lofrumento et al., 2014). Resveratrol 
is an important component of red wine, but It is also present in a wide range of plants, such as 
grape, peanut, cocoa, tomato, blueberry and cranberry (de Oliveira et al., 2016).  
In the literature, resveratrol has been applied to human skin fibroblasts in a wide range of doses 
[Table 3.1]. In this chapter, initial testing of resveratrol employed two doses (25 µM and 50 µM) 
and two treatment times (48 hours and 72 hours). The data show an increase in three complexes 
with the highest dose and the longest treatment time [Figure 3.2]. Therefore, we decided to repeat 
the experiment with the application of higher concentrations (50 µM, 75 µM and 100 µM) [Figure 
3.3]. However, no increase in the expression of mitochondrial respiratory complexes was seen. 
In addition, the small increase that was previously observed with 50 µM was not reproducible 
[Figure 3.3]. These results indicate that resveratrol treatment is variable in its effects. 
Nevertheless, we chose to retain the resveratrol condition in our drug treatment experiments.   
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Table 3.1 Resveratrol doses in human fibroblasts.  
Assessment Dose Cell line Technique 
Respiration rates 
25 μM for 48 
hours 






25 μM for 48 
hours 
Primary fibroblasts from 
parkin patients 
Activity assay 
Citrate synthase activitiy 
25 μM for 48 
hours 




25 μM for 24 
hours 




25 μM for 24 
hours 





75 μM 48 hours 
CI- and CIV-deficient 
human fibroblasts 
WB 
Citrate synthase activity 75 μM 48 hours 





75 μM 72 hours 
CI- and CIV-deficient 
human fibroblasts 
Activity assay 
Mitochondrial content 75 μM 48 hours 




Autophagy - LC3 
(12.5–100 μM) 
for 8 hours 
Human dermal fibroblasts WB 
Mitochondrial enzyme 
activities 
100 μM for 48  
hours 
CII- and CIV-deficient 
human fibroblasts 
Activity assay 
Resveratrol application to human fibroblasts showing the dosages used and the techniques performed. 







Figure 3.2 Resveratrol increased the expression of proteins from three mitochondrial respiratory 
complexes in a pilot test.  
(a) A pilot WB test using extracts of control fibroblasts (OB064). The cells were treated with 25 µM or 50 
µM for either 48 or 72 hours, in galactose medium. WB membranes were probed with the Total OXPHOS 
Human WB Antibody [Table 2.5], which binds to a protein from each respiratory chain complex. (b) 
Quantification of WB images, showing increased expression of complex I-, complex II- and complex IV-
targeted proteins upon treatment with 50 µM resveratrol for 72 h. The graph bars represent data from a 






Figure 3.3 The positive effect of resveratrol on the expression of mitochondrial proteins was not re-
producible despite the trial of higher doses. 
 (a) A WB test using extracts of control fibroblasts (OB064) treated with high resveratrol doses (50 µM, 75 
µM and 100 µM for 72 hours, in galactose medium). WB membranes were probed with the Total OXPHOS 
Human WB Antibody [Table 2.5], which binds to a protein from each respiratory chain complex. (b) 
Quantification of WB images, showing no change in the expression of the proteins except for a small 
increase in complex III with 50 µM and 75 µM resveratrol. The graph bars represent data from a single pilot 





3.5 Assessing the effect of drug treatment on the expression of 
mitochondrial respiratory complexes in patient fibroblasts  
Comparing the expression of the mitochondrial respiratory complexes in fibroblasts between the 
patients and the controls suggests a general increase in those of patients (not statistically 
significant) [Figure 3.4]. The only exception observed was in the expression of complex V protein, 
in which no difference was seen between the patient and the control in all three pairs. Treatment 
with either UCA, UDCA or resveratrol had no significant effect in all patient-control pairs. 
 
Figure 3.4 Neither UCA nor UDCA treatment altered the expression of mitochondrial respiratory 
proteins in control and patient fibroblasts. 
 These graphs quantify WB images that were obtained from three pairs of patients and age-matched 
controls. For each pair, means were obtained from three independent experiments. The data for each pair 
were normalised against β-actin and against the untreated control prior to combination. The cells were 
treated with 100 nM UCA or 100 nM UDCA for 24 hours, or 25 µM resveratrol for 48 hours, in galactose 
medium. The graphs show that UCA and UDCA treatment did not increase the expression of the targeted 
mitochondrial components in the patients or controls. The error bars represent SD. Two-way ANOVA test.  
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3.6 Quantifying mtDNA via qPCR    
Quantitative analysis of mtDNA copy number by qPCR is an established method for studying 
mitochondrial mass and biogenesis. The principle of the experiment is that each human cell has 
only two copies of any nuclear gene and multiple copies of mitochondrial genes, depending on 
the number of mitochondria within the cell. The readings at the end of qPCR cycles can be used 
to calculate the average mtDNA copy number per cell in a given sample. Further details on this 
approach can be found in the method chapter [2.6.3].  
In this set of experiments, the primers used were previously tested and employed in human cells 
by our group and others (Cree et al., 2008, Samuels et al., 2017). Beta-2-microglobulin (B2M) 
was targeted as the nuclear reference gene and NADH dehydrogenase subunit 1 (ND1) was 
targeted to deduce the mtDNA copy number. Upon testing, the standard curve and the melt 
peaks, which were obtained from a serial tenfold dilution of the untreated sample, demonstrated 






Figure 3.5 B2M and ND1 primers have high efficiency and specificity in qPCR reactions.  
Efficiency and specificity were assessed using tenfold serial dilution of untreated samples. The standard 
curves (a and b) were obtained following the generation of the amplification curves (c and d), and reveal 
an efficiency of 102% for B2M and 105.2% for ND1. Melt peak graphs (e and f) show single peaks with all 
dilutions of the sample indicating high specificity. 
  





3.7 Assessing the effect of drug treatment on mtDNA copy number in 
patient fibroblasts 
During cell culture, a fraction of the treated cells that were allocated for WB was separated and 
subjected to DNA extraction and subsequent qPCR. Quantitative analysis of mtDNA copy number 
by qPCR did not show a difference between patients and controls in any of the three pairs [Figure 
3.6]. In addition, Drug treatments had no effect on mtDNA copy number. 
 
Figure 3.6 Neither UCA nor UDCA treatment altered mtDNA copy number in control and patient 
fibroblasts.  
Data analysis of qPCR results for three pairs of patients and age-matched controls. For each pair, means 
were obtained from three independent experiments. The data for each pair were normalised against β-actin 
and against the untreated control prior to combination. The cells were treated with 100 nM UCA or 100 nM 
UDCA for 24 hours, or 25 µM resveratrol for 48 hours, in galactose medium. The graph shows that UCA 
and UDCA treatment did not increase mtDNA copy number in the patients or the controls. The error bars 






A wide range of methods and techniques have been used to study mitochondrial biogenesis. The 
most common is direct visualisation of mitochondria via microscopic examination. The 3D nature 
of mitochondria should be taken into account when using microscopy; otherwise, the results could 
be misleading. This issue was avoided in our study through the use of WB to quantify the 
expression of mitochondrial proteins. This is an indirect method which was used to confirm 
whether or not mitochondrial biogenesis had increased.  
More direct approaches involve targeting the key proteins and transcripts that are usually 
upregulated in mitochondrial biogenesis, such as POLG, and PGC-1α. However, the regulation 
of these factors is tight and their expression is frequently transient. Moreover, their expression 
levels in fibroblasts in particular are generally low (Scarpulla et al., 2012, Garcıa-Giménez et al., 
2011). Mitochondrial DNA quantification through Southern blotting or qPCR, as performed in this 
chapter, should also help to confirm increased mitochondrial biogenesis. However, this should 
not be considered as definitive readout because the mtDNA copy number varies within each 
mitochondrion, ranging between two and ten. 
The expression of the mitochondrial respiratory complexes in parkin fibroblasts has been 
assessed previously. Pacelli and colleagues found that the expression of complex I, complex II, 
complex IV, complex V and mitochondrial outer membrane protein, porin, is lower in patients in 
comparison to controls (Pacelli et al., 2011). Conversely, the expression of PGC-1α was higher 
in patients. The authors postulated a compensatory mechanism behind this unexpected elevation. 
However, there was no increase in the expression of PGC-1α downstream targets (Pacelli et al., 
2011).  
The results in this chapter do not show a decrease in the expression of mitochondrial respiratory 
complexes. Instead, there was a non-significant trend toward increased expression. The 
fibroblasts in Pacelli’s study were grown in regular glucose medium, while in this project the 
fibroblasts were grown in galactose medium. It is possible that an induced increased dependency 
on mitochondrial respiratory complexes led to a decrease in the removal of mitochondrial proteins. 
The effect was more prominent in patient cells, since they have lower ATP levels (Mortiboys et 
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al., 2013). Additionally, these are parkin-mutant cells and therefore it is expected that they have 
primary mitophagy impairment, though this has not been studied in patient fibroblasts. The data 
does not suppot that the increased expression of mitochondrial respiratory complexes in the 
patients is due to increased mitochondrial biogenesis, since both patients and controls showed 
comparable mtDNA copy numbers.  
The effects of UCA and UDCA on the expression of mitochondrial respiratory complexes and 
mtDNA content have never been assessed before. Our results do not show significant changes 
in either controls or in patients. Therefore, these findings suggest that UCA/UDCA treatment does 
not enhance mitochondrial biogenesis. However, it is important to point out that only two methods 
were used to investigate mitochondrial biogenesis and that there were no positive results after 
treatment with the positive control. Additionally, the applied doses, treatment protocol, and type 
of culture medium might not be optimal to induce mitochondrial biogenesis, even though they 
were associated with increased mitochondrial function (Mortiboys et al., 2013). Therefore, more 
work is needed in the future to verify the findings in this chapter. Experiments should additionally 
include alternative models, as fibroblasts might not be the best choice for studying mitochondrial 
biogenesis. Since fibroblasts are metabolically and energetically less active than neurons, it is 
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4 Investigating the beneficial effect of UCA and UDCA on 
oxidative stress, ATP and cytotoxicity in ARE reporter cell 
line 
4.1 Introduction 
4.1.1 Nrf2 pathway 
According to the ‘oxidative stress hypothesis’ (proposed by Fahn and validated by subsequent 
experimental data), oxidative stress is one of the main drivers for neuronal degeneration in PD 
(Fahn and Cohen, 1992, Blesa et al., 2015). The mechanism through which this occurs is 
explained in detail in the introduction chapter [Heading 1.3]. Accordingly, drugs that ameliorate 
oxidative stress can be novel treatments for PD. The most important antioxidant pathway in 
cellular biology, the Nrf2 pathway, will be briefly discussed in this section. 
4.1.2 Nrf2 structure 
The Nrf2 pathway is regulated by a highly conserved transcription factor called nuclear factor 
(erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2 (Buendia et al., 2016). Other members 
of the Nrf family include Nrf1 and Nrf3. Nrf1 and Nrf2 are ubiquitously expressed, while the 
expression of Nrf3 is limited to certain tissues such as the placenta, B-cells and monocytes. In 
contrast to Nrf2 and Nrf3, Nrf1 is essential for development and knockout (K/O) embryos die at 
early stages. However, the function of Nrf1 is still unknown (Tebay et al., 2015). Human Nrf2 
consists of 605 amino acids and is composed of seven different distinct domains called the Nrf2-
ECH homology (Neh) domains (Canning et al., 2015) [Figure 4.1]. The Neh1 domain has the Cnc-
basic leucine zipper (Cnc-bZIP) region that is unique to Cap 'n' Collar (Cnc) proteins, and 
possesses a DNA-binding ability, which is an important characteristic of transcription factors (Itoh 
et al., 1999). The Neh2 domain plays a role in regulating the activity of Nrf2 and will be addressed 
in the next section. The Neh3 domain regulates the function of domain 1 and thus controls the 
transcriptional activity of Nrf2 (Nioi et al., 2005). Neh4 and Neh5 enhance the transcriptional 
activity via their binding to the coactivator CREB-binding protein (CBP) (Katoh et al., 2001). 
Inversely, Neh6 has the ability to downregulate Nrf2 activity through a mechanism that will be 
addressed later. Neh7 is the most recent and least described domain. However, it has been 
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suggested that it might control transcriptional activity through binding to different regulatory 
proteins (Wang et al., 2013, Tebay et al., 2015) [Figure 4.1].  
4.1.3 Regulation of Nrf2 activity 
It is believed that the net balance between Nrf2 synthesis and degradation is one of the main 
determinants of its activity. Although most of the work investigating Nrf2 regulation focuses on 
degradation, some interesting findings about Nrf2 regulation have been obtained from studying 
Nrf2 at its transcriptional level. The Nrf2 gene has a xenobiotic response element sequence. This 
sequence promotes the transcription of the genes when exposed to potentially harmful 
xenobiotics through the action of the aryl hydrocarbon receptor. Interestingly, the activation of the 
Nrf2 consequently downregulates aryl hydrocarbon receptor. These findings indicate that 
regulatory feedback loops play a role in Nrf2 control (Tebay et al., 2015). 
The degradation of Nrf2 is regulated via its binding to the Kelch-like ECH-associated protein 1 
(Keap1) (Buendia et al., 2016). More specifically, the Neh2 domain of Nrf2 has two sites (ETGE 
and DLG) where two molecules of Keap1 can bind. Keap1 has the ability to ubiquitinate the lysine 
residues in the Neh domain with the aid of a specific protein adaptor, Ligase Cullin-3. The 
ubiquitination mediates proteasomal degradation (Suzuki and Yamamoto, 2015). Therefore, 
Keap1 acts as a down-regulator of Nrf2. Importantly, Keap1 activity is tightly linked to the level of 
xenobiotic and oxidative stress. This association is attributed to the high number of cysteine 
residues within Keap1 that can be modified by different stressors. The cysteine code hypothesis 
suggests that each group of Nrf2 activators has a preferable specific cysteine residue. The 
modification of these residues breaks the bond between Keap1 and the DLG motif in Nrf2, but 
not ETGE (Huang et al., 2015). This allows structural changes in the Keap1-Nrf2 complex (hinge 
and latch), which consequently prevent Nrf2 ubiquitination [Figure 4.1].  
The regulation of Nrf2 activity is complex and extends beyond the discussed Keap1-ubiquitin 
interactions. For example, there is evidence that Nrf2 itself can regulate the transcription of Keap1 
and Cullin-3 (Kaspar and Jaiswal, 2010). More importantly, several different protein kinases 
increase the levels of Nrf2 via a mechanism that is not clear, but involves the direct 
phosphorylation of Nrf2 residues. These kinases include PKCι, casein kinase II, PI3K, c-Jun N-
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terminal kinase (JNK), ERK and MAPKs (Sun et al., 2009, Numazawa et al., 2003, Pi et al., 2007, 
Nakaso et al., 2003, Keum et al., 2006). In contrast, phosphorylation of Nrf2 residues by certain 
kinases, such as glycogen synthase kinase 3 beta (GSK3β), facilitates Nrf2 degradation. GSK3β 
phosphorylates the DSGIS motif in Neh6. Then, The degradation follows via direct recognition of 






Figure 4.1 Overview of the structure and the regulation of Nrf2.  
(a) The identified domains within the Nrf2 protein. (b) The proteasomal-mediated degradation of Nrf2 in the 
basal condition is facilitated by the ubiquitination by Keap1 and Cullin-3. (c) In the case of oxidative stress, 
the Keap1-DLG bond breaks and the ubiquitination stops. The increased amount of Nrf2 in the nucleus 
stimulates the transcription of ARE in the targeted genes.  
Abbreviations: Neh: Nrf2-ECH homology, Nrf2: Nuclear factor erythroid 2-like 2, Keap1: Kelch-like ECH-
associated protein 1, ARE:  antioxidant response element.  
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4.1.4 Nrf2 genes and the mechanism of action 
In the nucleus, Nrf2 binds to Maf proteins to form dimers. Subsequently, the dimers recognise the 
cis-acting elements (commonly known as the antioxidant response elements (ARE)) within the 
promotors of Nrf2 downstream genes and facilitate their transcription (Suzuki and Yamamoto, 
2015, Tebay et al., 2015). Besides defending the cells against oxidative stress, the Nrf2-targeted 
genes, also called Nrf2 regulon, have other protective functions that include homeostasis, efflux 
and drug metabolism [Table 4.1] (Tufekci et al., 2011).  
Table 4.1 Examples of Nrf2 target genes 








GST (Glutathione-S-transferase) Cellular detoxification 
Gcl (Glutamate cysteine ligase) 
Catalyses glutathione 
synthesis 
Gcl (Glutamate cysteine ligase) 
GS (Glutathione Synthetase) 
GPx (Glutathione Peroxidase) 
Catalyses reduction of 
H2O2 
GR (Glutathione Reductase) 
Catalyses reduction of 






reduction of quinones 
Ugt (UDP-
glucuronosyltransferases) 
Catalyses endogenous and 
exogenous substances with 
glucuronic acid 
mEH (Microsomal epoxide 
hydrolase) 
Inactivates epoxides 






Iron-binding protein having 
role in iron oxidative stress 




The main response to the Nrf2 activation is the expression of the antioxidant genes. However, the table 
demonstrates that the Nrf2 is involved in various other functions as well. Source: (Tufekci et al., 2011)  
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Oxidative stress occurs when the production of ROS exceeds their physiological levels. The 
utilisation of glucose to produce energy via OXPHOS is one of the major sources of physiological 
cellular ROS. The insufficient oxidation and the electron leak that occurs during aerobic 
respiration leads to the formation of several ROS, such as superoxide anions (O2-.), hydrogen 
peroxide (H2O2), and hydroxyl radical (HO-). ROS are neutralised by several basally expressed 
proteins. For example, GSH, which is the most abundant synthesised antioxidant in the central 
nervous system (CNS) (present in millimolar concentration), serves as an electron donor in a 
reaction that oxidises the free thiol groups into disulphide bonds: H2O2 + 2 GSH = GS-SG + 2H2O 
(Gandhi and Abramov, 2012). Another example is superoxide dismutase, which catalyses the 
reduction of superoxide anions into hydrogen peroxides, which is consequently converted into 
oxygen and water molecules (Bauer, 2014). In addition to the direct antioxidant mechanism, there 
is an indirect mechanism that involves the induction of gene expression and is considered as a 
secondary line of defense. The induced genes are not only involved in the synthesis of new 
antioxidant molecules but also in the reactivation of certain antioxidants that possess redox-active 
properties. For example, the restoration of the reduced GSH is achieved via the action of 
glutathione reductase (Jozefczak et al., 2012). Other members of the indirect antioxidants family 
include NAD(P)H:quinone oxidoreductase-1(NQO1) and glutathione S-transferase (GST) (Tebay 
et al., 2015). Of note, all of the aforementioned antioxidant-related proteins are expressed upon 
Nrf2 activation, which demonstrates why Nrf2 is considered to be one of the most important 
antioxidant pathways in cells (Tebay et al., 2015). 
4.1.5 Objectives 
In this chapter, the ability of UDCA to activate the Nrf2 pathway will be assessed via the use of 
reporter cell lines that were specifically developed for this purpose. As mentioned in the method 
chapter [Heading 2.7], the ARE-CHO reporter cell line was designed to express green fluorescent 
protein (GFP) only when the transcription of the ARE sequence is stimulated. The TK-CHO cell 
line lacks the ARE sequence in the construct, and therefore it was used to demonstrate that the 
expression of GFP is strictly linked to the activation of the ARE sequence and not to any other 
part of the inserted construct. To validate the effect of UCA/UDCA on the Nrf2 pathway, qPCR for 
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Nrf2 downstream genes was performed. Moreover, the ability of UDCA to reduce oxidative stress 
was investigated in CuSO4-stressed cells.  
UDCA rescued mitochondrial function in genetic models of PD (Mortiboys et al., 2013). To 
determine whether this beneficial effect is not just limited to patient tissue or genetically induced 
models, the effect of UDCA on ATP level and viability was investigated in CHO cells with 
mitochondrial dysfunction, which was induced via the application of commonly used toxins.  
 
4.2 Investigating the effect of UCA and UDCA on the Nrf2 pathway in 
CHO cells 
4.2.1 Assessing the effects of UCA/UDCA on ARE expression in CHO cells  
Testing positive controls and the CHO-ARE reporter  
Dimethyl fumarate (BG12) – the methyl ester of fumaric acid – has a robust, Nrf2-mediated 
antioxidant effect (Lastres-Becker et al., 2016). A pilot test showed that treating ARE-CHO 
reporter cells with BG12 significantly increased the expression of GFP [Figure 4.2].  
    
Figure 4.2 BG12 significantly increased ARE expression in CHO reporter cells. 
 (a) GFP readings of ARE reporter cell lines (ARE-CHO) treated with BG12, and showing a significant 
increase in ARE expression. By contrast, no increase was observed in the CHO reporter that lacks the ARE 
sequence in construct (TK-CHO) (b). The cells were treated with 100 µM BG12 for 24 hours in a serum-










Subsequently, increasing concentrations of BG12 (0.1 µM–100 µM) as well as another known 
Nrf2 activator, RTA 408 (a synthetic oleanane triterpenoid compound), were tested. Both BG12 
and RTA408 showed a dose-dependent response that follows the classical drug response curve 
[Figure 4.3]. RTA408 was more potent than BG12 but had a higher toxicity, which was apparent 
when the cells were examined under the optic microscope. The cells were not able to tolerate 
more than 1 µM, and as a result, there was a massive decrease in ARE expression readings at 
this concentration and above [Figure 4.3]. Therefore, it was decided to use BG12 only as a 
positive control in drug treatment experiments.    
  
 
Figure 4.3 BG12 and RTA408 induced a dose dependant increase in ARE expression in CHO reporter 
cells.  
(a) GFP readings of ARE reporter cell lines (ARE-CHO) treated with two positive controls, BG12 and 
RTA408. RTA408 was more potent but the signal dropped significantly at 1 µM due to cytotoxicity, which 
was apparent when the cells were examined via optic microscope. (b) As expected, BG12 and RTA408 did 
not increase the GFP readings in the (TK-CHO) cell line which lack the ARE sequence in the construct 
[Heading 2.7]. The lowest starting concentrations on the graphs represent the vehicle-treated condition. 






Determining the effect of UCA/UDCA on ARE expression in CHO cells   
UCA and UDCA treatment was tested at various concentrations (1 µM–300 µM) and time points 
(2 hours, 16 hours, 24 hours and 48 hours) to assess possible Nrf2 activation by these 
compounds. The results suggest a small but dose-dependent increase in the GFP readings with 
UCA and UDCA [Figure 4.4]. The increase in the readings appeared at two hours of treatment 
and was stable between 16 and 24 hours of treatment. As expected, all the readings of the TK-
CHO line of the corresponding conditions remained unchanged, regardless of the increasing 
concentrations or treatment time [Figure 4.4].  
  
Figure 4.4 UCA and UDCA induced a dose dependant increase in ARE expression at different time 
points.  
GFP readings of CHO reporter cell lines treated with UCA (a), DUCA (b), and BG12 (c). The upper group 
of lines in each figure represent data obtained from the ARE reporter cell line (ARE-CHO) and the lower 
groups of lines represent data obtained from the TK-CHO cell line (ARE-deficient reporter). The cells were 
treated for 2,16, 24 and 48 hours in a serum-free medium. The graphs show a small dose-dependent 
increase in ARE expression with UCA and UDCA treatment, and a remarkable dose-dependent increase 
with BG12 treatment. As expected, GFP readings remained unchanged in all treatment conditions. The 
lowest starting concentrations on the graphs represent the vehicle-treated condition. Drug treatment was 





To confirm the effect of the drugs on ARE expression, three independent experiments were 
performed using a wider concentration range (0.1 µM – 1000 µM) of UCA and UDCA for 24 hours 
[Figure 4.5]. Two conjugated forms of UDCA; TUDCA and GUDCA, were added as well for 
comparison since most of the UDCA in human is conjugated. The results showed that all the 
tested UDCA derived compounds exerted a positive effect on ARE expression [Figure 4.5 a]. 
Although the effect was small in comparison to the positive control, it was statistically significant 
and positively correlated with the treatment doses. 
 
     
Figure 4.5 24 hours of treatment with increasing concentrations of UCA, UDCA, TUDCA and GUDCA 
induced a small increase in ARE expression. 
(a) GFP readings of ARE reporter cell line (ARE-CHO) treated with increasing concentrations of BG12, 
GUDCA, TUDCA, UDCA and UDCA. The graph demonstrates a comparable dose-dependent increase in 
ARE expression in all treatment conditions except for BG12 which had a pronounced effect on ARE 
expression. (b) Equally treated TK-CHO cell lines (ARE-deficient reporter) showed no increase in GFP 
readings as expected. (c) and (d) Data from the 10 µM and 100 µM conditions in column graphs to elucidate 
the effect of drugs on ARE expression. The lowest starting concentrations in (a) and (b) represent the 
vehicle-treated conditions. The cells were treated with 100 µM BG12 for 24 hours in a serum-free medium 
The results were obtained from three independent experiments. The error bars represent the SD. ** p < 






4.2.2 Assessing the effect of the UCA/UDCA on the expression of Nrf2 genes in 
CHO cells   
Initial testing of the primers 
To verify/confirm the results obtained from the ARE-CHO reporter experiments, the expression of 
the Nrf2 downstream genes was assessed via RT-qPCR using RNA extracts of the treated cells. 
Primers for four Nrf2 genes were designed (NQO1, FTH1, GCLC and HMOX1), and different 
concentrations of the forward and the reverse primers were tested as described in the method 
chapter [Heading 2.6.3] in order to find the optimum combination. All tested concentrations 
produced similar amplification curves and melt peaks except for HMOX1 [a and b in Figure 4.6 – 
Figure 4.10]. To assess the specificity and the efficiency of the reaction, the standard curve and 
the melt peak were obtained from a serial of ten-fold dilution of the samples. The results revealed 
a high efficiency and specificity for all primers with the exception of HMOX1 [d and e in Figure 4.6 
– Figure 4.10]. Standard curves of FTH1 revealed an efficiency of 80%, which is lower than 
accepted minimum in this project (90%). However, the FTH1 primers were used in drug treatment 
experiments because the positive control, BG12, significantly increased the expression of this 
gene in initial testing [f in Figure 4.8].  Pilot tests also showed that BG12 significantly increased 
the expression of NQO1, and to a lesser extent GCLC [f in Figure 4.7 and Figure 4.9]. However, 
the expression of HMOX1 was not increased [f in Figure 4.10]. Since HMOX1 primers showed 





Figure 4.6 GAPDH primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 89.6 %. The melt peak graph showed single peaks with all dilutions of the sample 
indicating high specificity. (f) Analysed qPCR results of BG12 treated samples. As expected, the treatment 
did not increase the expression of GAPDH. The error bars represent the SD of a technical triplicate. ns p > 










Figure 4.7 NQO1 primers have high efficiency and specificity in qPCR reactions. 
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 100.3 %. The melt peak graph showed single peaks with all dilutions of the sample 
indicating high specificity. (f) Analysed qPCR results of BG12 treated samples. BG12 significantly increased 












Figure 4.8 FTH1 primers have sub-optimal efficiency and high specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 82.2 %. The melt peak graph showed single peaks with all dilutions of the samples 
indicating high specificity. (f) Analysed qPCR results of BG12 treated sample. BG12 significantly increased 










Figure 4.9 GCLC primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 94.5 %. The melt peak graph showed single peaks with all dilutions of the sample 
indicating high specificity. (f) Analysed qPCR results of BG12 treated samples. BG12 treatment resulted in 
a small non-significant increase in GCLC expression. The error bars represent the SD of a technical 









Figure 4.10 HMOX1 primers have low efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. The results showed variable amplification curves and double peaks in the melt peak graphs. (c), (d) 
and (e) Assessing the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The 
standard curves revealed an efficiency of 204.5 %. The melt peak graph showed multiple peaks with all 
dilutions of the sample indicating that the reaction is not specific. (f) Analysed qPCR results of BG12 treated 
samples. Unexpectedly, BG12 treatment resulted in a decrease in HMOX1 expression. The error bars 








Assessing the effect of UCA and UDCA on the expression of Nrf2 downstream genes in 
CHO cells   
Based on the previously obtained result using the ARE reporter cell line [Figure 4.5], it was 
decided to treat the cells with 10 µM of the drugs for 24 hours. The results showed that the 
response to drug treatment was not comparable in these three genes. Upon treatment with UCA, 
there was a significant increase in the expression of GCLC and FTH1, and a decrease in the 
expression of NQO1. UDCA, on the other hand, only increased the expression of NQO1. BG12 
treatment significantly increased the expression of NQO1 and induced a small non-significant 
increase in FTH1 [Figure 4.11].  
 
Figure 4.11 UCA and UDCA exert variable effect on the expression of Nrf2 downstream genes. 
 Assessing the effect of the drugs on the Nrf2 downstream genes in CHO cells was performed by qPCR. 
Data analysis revealed that UDCA significantly increased the expression of NQO1 (a) but did not increase 
the expression of GCLC (b) and FTH1 (c). The cells were treated with 10 µM of the drugs for 24 hours in a 
serum-free medium. The graphs represent data of three independent experiments. The error bars represent 






4.3 Assessing the ability of UCA and UDCA to ameliorate oxidative 
stress in CHO cells   
4.3.1 Optimising DCF concentrations and assessing the effect of different 
stressors 
The effect of the drugs on ROS levels in stressed cells was assessed through the use of DCF 
reagent, which transforms into a fluorescent molecule upon exposure to hydroxyl radicals. 
Different stressors were tested as ROS inducers in this pilot experiment, but the increase in 
fluorescence was only seen with CuSO4 (40% - 50% increase) [Figure 4.12 a, b, c,]. The 
stressors were added one hour before the application of the DCF. Notably, upon stressing the 
cells with CuSO4, the signals of stressed and unstressed conditions were simultaneously 
positively correlated with the concentrations of the DCF [Figure 4.12 b]. 20 µM of DCF was 
selected as the default for all experiments in this chapter. Negative control conditions in Figure 
4.12 d indicate that the DCF produced signals only when it was within the cells and that there 





Figure 4.12 DCF readings are significantly increased in CuSO4 stressed CHO cells.  
The CHO cells were serum starved for 24 hours and the stressor was added one hour prior to the application 
of the DCF. (a), (b) and (c) Evaluating the effect of rotenone (20 nM), H2O2 (400 µM) and CuSO4 (400 µM) 
on oxidative stress levels using different DCF concentrations (10 µM, 20 µM and 30 µM). Only CuSO4 
treatment induced a significant increase in green fluorescent readings (indicating DCF conversion due to 
ROS exposure), which was apparent in all tested DCF concentrations. (d) A comparison between the 
readings of unstressed and stressed cells to the background conditions. Auto fluorescence represents the 
reading of untreated cells unexposed to DCF. Culture medium + DCF represent cell-free wells with 20 µM 
DCF. The culture medium condition contains the medium only, without cells and DCF. The error bars 







4.3.2 Assessing the effect of UCA/UDCA on CuSO4 stressed CHO cells 
The effect of the drugs on the ROS level was assessed in unstressed and CuSO4-stressed cells. 
The results showed that treatment with UCA, UDCA and BG12 induced 20% increase in DCF 
readings in unstressed cells [Figure 4.13]. The application of CuSO4 increased the signals by 
30% in comparison to the unstressed conditions. However, both UDCA and BG12 treatment failed 
to ameliorate the increase in DCF readings in stressed cells. Notably, UCA treatment induced a 
significant increase in DCF readings.  
 
   
Figure 4.13 Initial experiments showed that UCA and UDCA do not decrease DCF readings in CuSO4-
stressed cells.  
(a) A diagrammatic representation of the experiment design. The CHO cells were treated and serum starved 
for 24 hours, and the stressor was added 1 hour prior to the application of the DCF. (b) and (c) Green 
fluorescent readings of ROS-exposed DCF in unstressed (a) and stressed (b) cells. UDCA treatment failed 
to reduce DCF readings in the stressed cells. In contrast, UCA significantly increased DCF signals in the 
stressed cells. The cells were treated with 10 µM of each drug in serum-free medium according to the 
experiment design. Cells were stressed with 400 µM CuSO4. The graphs represent data of three 







4.3.3 Evaluating the effect of CuSO4 using a second stressing method (protocol 
B) 
The aim of this experiment was to assess the ability of UCA and UDCA to decrease oxidative 
stress using an alternative stressing method. In this protocol, the stressor and the drug were 
applied for one hour. Then the stressor was removed and the drug was kept for a certain time 
before the application of the DCF [Figure 4.14 a]. Prior to performing the drug treatment 
experiments, many different concentrations of CuSO4 were tested with various recovery times 
[Figure 4.14 b]. The results generally showed that there is no statistically significant difference 
between unstressed and stressed cells except for the 24 hours’ conditions with 200 µM CuSO4 
(27%) and 300 µM CuSO4 (30%) [Figure 4.14 b].   
 
Figure 4.14 Testing a second stressing method (protocol B) demonstrated an increase in DCF 
reading with 24h recovery time.  
(a) A diagrammatic representation of the experiment design. The CHO cells were serum starved for 24 
hours. CuSO4 was applied for one hour and cells were allowed to recover for a certain time (2, 5, 8 or 24 
hours) before the application of the DCF. (b) Evaluating the effect different recovery times on oxidative 
stress levels in cell treated with increasing concentrations of CuSO4. The results showed an increase in 
DCF readings when CuSO4 (200 µM and 300 µM) was removed 24 hours prior the application of the DCF. 





4.3.4 Assessing the effect of UCA/UDCA on CuSO4-stressed CHO cells (protocol 
B) 
In accordance with the results in the previous section, it was decided to test the drugs with two 
concentrations of CuSO4: 200 µM and 300 µM. However, the small increase that was observed 
in the previous test was not present when the experiment was repeated [Figure 4.15 c, d]. 
Nevertheless, the UCA and UDCA did not decrease DCF readings in all conditions [Figure 4.15]. 
Since the BG12 did not show a positive effect in the previous experiments, it was decided to add 
Trolox as an alternative positive control. Trolox is an analogue of vitamin E that has been used in 
biological and biochemical applications to reduce oxidative stress. Multiple concentrations of 
Trolox were tested but there was no decrease in DCF levels in stressed and unstressed cells 
[Figure 4.15]. 
 
Figure 4.15 UCA and UDCA had no positive effect in CuSO4-stressed cells (protocol B).  
A diagrammatic representation of the experiment design. The CHO cells were serum starved for 24 hours. 
CuSO4 was applied for one hour and cells were allowed to recover for 24 hours before the application of 
the DCF. (b), (c) and (d) Green fluorescent readings of ROS-exposed DCF in unstressed and stressed 
cells. The cells were treated with Trolox as an additional antioxidant positive control. All treatments failed 
to reduce DCF readings in the stressed cells. The cells were treated with 10 µM of each drug in serum-free 
medium according to the experiment design. The graphs represent data of three independent experiments. 






4.3.5 Evaluating the effect of CuSO4 using a third stressing method (protocol C) 
Since CuSO4 failed to demonstrate consistent results in the previous experiments, it was decided 
to test a third stressing method. In this protocol, the stressor and the drug were applied 
simultaneously for 24 hours before the application of the DCF [Figure 4.16 a]. Testing different 
concentrations of CuSO4 revealed a clear dose-dependent increase in DCF signals [Figure 4.16 
b]. Examining the cells under light microscopy showed that high doses, 500 µM and – to some 
extent – 400 µM, had a negative effect on cell morphology and viability, which was not noticed in 
the previous experiments. Therefore, it was decided to use 200 µM and 300 µM CuSO4 in the 
drug treatment experiment. 
 
Figure 4.16 Testing a third stressing method (protocol C) demonstrated clear dose-dependent 
increase in DCF reading. 
 (a) A diagrammatic representation of the experiment design. The CHO cells were serum starved and 
treated with CuSO4 for 24 hours before the application of the DCF. (b) Evaluating the effect of increasing 
CuSO4 doses on converted DCF signals (green fluorescent readings) revealed a clear dose-dependent 
response. The graphs represent data of three independent experiments. The error bars represent SD. * p 





4.3.6 Assessing the effect of UCA/UDCA on CuSO4-stressed CHO cells (protocol 
C) 
As shown in the previous experiment, the third stressing method proved to be reliable in 
increasing the DCF readings. The application of 200 µM CuSO4 increased DCF readings by 55%, 
while the application of 300 µM CuSO4 increased DCF readings by 65% [Figure 4.17 c, d]. 
However, UCA and UDCA treatment failed to reduce DCF readings. Similar findings were also 
seen with BG12 and Trolox [Figure 4.17]. 
 
Figure 4.17 UCA and UDCA had no positive effect in CuSO4-stressed cells (protocol C).  
A diagrammatic representation of the experiment design. The CHO cells were serum starved and treated 
with CuSO4 and the drugs for 24 hours before the application of the DCF. (b) (c) and (d) Green fluorescent 
readings of ROS-exposed DCF in unstressed cells (b) and in cells stressed with either 200 µM CuSO4 (c) 
or 300 µM CuSO4 (d). The cells were treated with Trolox as an additional antioxidant positive control. 
Although CuSO4 significantly increased DCF signals, all treatment conditions did not reduce DCF readings 
in the stressed cells. The cells were treated with 10 µM of each drug in serum-free medium according to 
the experiment design. The graphs represent data of three independent experiments. The error bars 






4.4 Investigating the ability of UCA/UDCA to rescue mitochondrial 
function in stressed CHO cells 
4.4.1 Optimisation experiments for rotenone treatment  
Optimisation of culture medium 
The initial rotenone-dosing experiment showed that rotenone (up to 10 µM) had no effect on 
cytotoxicity [Figure 4.18 a]. Assessing ATP reduction after rotenone treatment showed 45% 
decrease in ATP level with 0.1 µM rotenone. However, this percentage did not change with the 
application of higher rotenone doses (up to 10 µM) [Figure 4.18 a]. Similar findings regarding ATP 
levels were observed when the experiment was repeated using a different mitochondrial inhibitor, 
antimycinA [Figure 4.18 b].  
 
 
Figure 4.18 Rotenone and antimycinA did not show a dose-dependant effect on LDH and ATP 
readings in regular culture medium. 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [2.9.1, 2.10]. The CHO cells were stressed with increasing concentrations of either rotenone (a) or 
antimycinA (b) for 48 hours in regular culture medium. The results did not show a dose-dependent decrease 





It might be possible that higher concentrations of the toxins are needed to produce a greater drop 
in ATP levels. However, a more plausible explanation is that the cells were able to compensate 
for the rotenone/antimycinA-induced ATP reduction. Since rotenone and antimycinA interfere with 
OXPHOS by inhibiting complex I and complex III of the mitochondrial respiratory chain, the cells 
probably relied on glycolysis to produce energy. When the glucose in the medium was replaced 
by galactose to force the cells to depend on oxidative phosphorylation, there was a dramatic 
increase in the sensitivity towards the rotenone [Figure 4.19 a]. The lowest tested rotenone 
concentration (0.1 µM) was sufficient to induce marked cytotoxicity. To verify the results, the 
experiment was repeated using a regular culture medium supplemented with 2-Deoxy-D-Glucose, 
a glucose analogue that inhibits glycolysis via its actions on hexokinase. As expected, the results 
were comparable to what was observed with the galactose medium [Figure 4.19 b].  
 
Figure 4.19 The sensitivity toward rotenone was significantly increased in galactose and 2-Deoxy-
D-Glucose medium. 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. The CHO cells were stressed for 48 hours with increasing concentrations of 
rotenone in either galactose medium (a) or 2-Deoxy-D-Glucose medium (b). The results showed a 
remarkable increase in the sensitivity towards the rotenone as the lowest tested concentration (0.1 µM) 





Optimisation rotenone dose and treatment time 
The CHO cells became highly sensitive to rotenone when they were cultured in galactose 
medium. Lower concentrations of rotenone needed to be tested since the lowest concentration 
(0.1 µM) in the previous experiment was lethal to the cells. In this experiment a range of low 
rotenone concentrations at the scale of nanomolar (20 nM -120 nM) were tested at different time 
points (24 hours and 48 hours). The results showed that treatment with 20 nM of rotenone did not 
induce LDH leakage in the 24 hour condition but was associated with a massive reduction in ATP 
levels [Figure 4.20].  
 
 
Figure 4.20 Low rotenone doses had massive effects on LDH and ATP readings when the cells were 
culture in galactose medium.  
Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method chapter 
[Heading 2.9.1, 2.10]. The CHO cells were stressed for either 24 hours (a) or 48 hours (b) with increasing 
concentrations of rotenone in galactose medium. The results showed that the lowest tested concentration 







Accordingly, the experiment was repeated with the addition of lower rotenone concentrations (15 
nM, 10 nM and 5 nM). Treatment with 10 nM and 20 nM rotenone induced approximately a 75% 
and 85% reduction in ATP levels when applied for 24 hours, and a 70% and 85% reduction when 
applied for 48 hours [Figure 4.21]. For drug treatment experiments, it was decided to stress the 
cells with 20 nM of rotenone for 24 hours and 10 nM rotenone for 48 hours. 
 
 
Figure 4.21 Assessing the effect of extra low rotenone doses on LDH and ATP readings at different 
time points in galactose medium. 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. The CHO cells were stressed for either 24 hours (a) or 48 hours (b) with 
increasing concentrations of rotenone in galactose medium. The results revealed a 70–85 % reduction in 





4.4.2 Assessing the effect of UCA/UDCA on rotenone-stressed CHO cells  
The stressing conditions were determined according to the results of the previous optimisation 
experiments. In the first drug treatment experiment, both rotenone and UCA/UDCA were applied 
simultaneously for 24 hours [Figure 4.22]. As expected, there was no significant change in LDH 
readings when the cells were stressed with rotenone but there was a significant decrease in ATP 
levels. UCA and UDCA treatment had no positive effect despite the trial of various doses (1 µM, 
10 µM and 100 µM) [Figure 4.22].  
 
Figure 4.22 Multiple concentrations of UCA and UDCA did not induce a positive effect in unstressed 
and rotenone-stressed CHO cells (24h rotenone). 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. The rotenone and the drugs were applied simultaneously for 24 hours. The 
results showed that none of the tested UDCA and UCA doses increased ATP levels in rotenone-stressed 
cells. The error bars represent the SD of three independent experiments. *** p < 0.001, **** p < 0.0001, 





Subsequently, an alternative treatment method was tested. In this method, the CHO cells were 
stressed for 24 hours before the addition of UCA/UDCA, which were kept for 24 hours [Figure 
4.23]. Again, UCA and UDCA failed to increase ATP levels in the stressed cells.  
 
  
Figure 4.23 Multiple concentrations of UCA and UDCA did not induce a positive effect in unstressed 
and rotenone-stressed CHO cells (48h rotenone). 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. The rotenone was applied for 24 hours. Then the CHO cells were treated 
with the drugs for 24 hours. The results showed that none of the tested UDCA and UCA doses increased 
ATP levels in rotenone-stressed cells. The error bars represent the SD of three independent experiments. 






Finally, the rescue effect of UCA and UDCA was assessed by a third treatment method. In this 
method, the CHO cells were pre-treated with the drugs for 24 hours and the rotenone was added 
afterwards for a further 24 hours [Figure 4.24]. UCA and UDCA treatment had no positive effect 
with this treatment method as well. Taken together, these results suggest that neither UCA nor 
UDCA can restore ATP levels in rotenone-stressed CHO cells. 
 
 
Figure 4.24 pre-treatment with UCA and UDCA did not induce a positive effect in unstressed and 
rotenone-stressed CHO cells. 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. The CHO cells were pre-treated with 10 µM UCA and 10 µM UDCA for 24 
hours. Then the rotenone was added and kept for 24 hours. The results showed that neither UDCA nor 
UCA were able to increased ATP levels in rotenone-stressed cells. The error bars represent the SD of three 





4.4.3 Optimisation experiments for CCCP treatment 
Optimising culture medium and CCCP concentration  
Since the UCA/UDCA failed to rescue mitochondrial function in rotenone-stressed CHO cells it 
was decided to repeat the experiments using an alternative toxin, CCCP (mitochondrial 
uncoupler), which is a known inducer of mitochondrial dysfunction. Initial testing of CCCP in 
regular culture medium showed similar findings to what was previously observed with rotenone 
[Figure 4.18]; the cells were able to resist the CCCP-induced ATP depletion via glycolysis when 
cultured in glucose-containing medium [Figure 4.25].  
 
     
Figure 4.25 CCCP did not show a dose-dependant effect on LDH and ATP readings in regular culture 
medium.  
Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method chapter 
[Heading 2.9.1, 2.10]. The CHO cells were stressed with increasing concentrations of CCCP for 48 hours 
in regular culture medium. The results did not show a significant dose dependant decrease in ATP levels. 





Consequently, galactose medium was also used in CCCP experiments. A wide range of doses 
were tested. As expected, the sensitivity of the cells to CCCP was dramatically increased when 
galactose medium was used [Figure 4.26]. There was a clear dose-dependent increase in LDH 
readings and a clear decrease in ATP levels with increasing doses of CCCP [Figure 4.26]. In 
accordance with these results, concentrations of 3 µM and 4 µM were selected for the drug 
treatment experiments. 
 
     
Figure 4.26 Wide range of CCCP concentrations induced a clear dose-dependant effect on LDH and 
ATP readings in galactose medium.  
Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method chapter 
[Heading 2.9.1, 2.10]. The CHO cells were stressed with increasing concentrations of CCCP for 48 hours 
in galactose medium. The results showed a clear dose-dependent decrease in ATP levels. The error bars 




4.4.4 Assessing the effect of UCA/UDCA on CCCP-stressed CHO cells 
The aim of this experiment was to assess the ability of UCA/UDCA to rescue mitochondrial 
function when CCCP is used as an alternative stressor to rotenone. However, the drugs did not 
show positive results either in cells stressed with 3 µM or in cells stressed with 4 µM of CCCP 
[Figure 4.27].  
  
Figure 4.27 UCA and UDCA did not induce a positive effect in unstressed and CCCP-stressed CHO 
cells (48h CCCP). 
 Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method 
chapter [Heading 2.9.1, 2.10]. Two concentrations of CCCP: 3 µM (a) and 4 µM (b) were applied for 24 
hours. Then the CHO cells were treated with 10 µM UCA and 10 µM UDCA for 24 hours. The drugs failed 







The previously applied pre-treatment protocol was also used with CCCP but the drugs failed to 
restore the ATP levels [Figure 4.28]. Taken together, the data suggest that UCA and UDCA are 
unable to rescue mitochondrial function in toxin-stressed CHO cells. 
 
  
Figure 4.28 Pre-treatment with UCA and UDCA did not induce a positive effect in unstressed and 
CCCP-stressed CHO cells. 
Cytotoxicity and ATP levels were measured using LDH and ATP assays as described in the method chapter 
[Heading 2.9.1, 2.10]. The CHO cells were pre-treated with 10 µM UCA and 10 µM UDCA for 24 hours. 
Then 3 µM (a) and 4 µM (b) CCCP was added and kept for 24 hours. The results showed that neither UDCA 
nor UCA were able to increase ATP levels in CCCP-stressed cells. The error bars represent the SD of three 







The beneficial effect of Nrf2 activation has been reported in multiple models of PD. For example, 
Nrf2 activation alleviated DA neuronal death in a α-synuclein Drosophila model of PD (Barone et 
al., 2011, Todorovic et al., 2016). In addition, the treatment with BG12 alleviated 6-OHDA-induced 
toxicity in SH-SY5Y cells and mice models (Jing et al., 2015). The Nrf2-meditated response 
included reduced cytotoxicity, oxidative stress levels, DA neuron loss and locomotor dysfunction. 
This is in agreement with a previously conducted study which demonstrated that tert-
butylhydroquinone – an alternative Nrf2 activator – had a significant protection against 6-OHDA-
induced damage in vitro mouse model (rat DA neuron cell line) (Jakel et al., 2007).  
There is also increasing evidence of the involvement of the Nrf2 in mitochondrial function and 
biology. Complex I activity as well as mitochondrial membrane potential were reduced in Nrf2-KO 
neurons, and were increased when the Nrf2 was upregulated (Holmström et al., 2013). Enhanced 
production of mitochondrial substrates such as pyruvate seems to be the main mechanism by 
which Nrf2 influences mitochondrial function (Holmström et al., 2013). Studies also suggested 
that Nrf2 enhances OXPHOS efficiency and alters mitochondrial bioenergetics (Dinkova-Kostova 
and Abramov, 2015). In wild type neurons, the application of OXPHOS inhibitor, oligomycin, 
significantly reduced ATP levels. However, this effect was not reproducible in Nrf2-KO cells where 
the ATP production was only blocked upon the application of glycolysis inhibitor (iodoacetic acid) 
(Holmström et al., 2013). This suggests that Nrf2 pressures the cells to rely on OXPHOS instead 
of glycolysis. 
The use of CHO-ARE reporter cell line [Heading 2.7] allowed us to determine the increase in ARE 
expression effectively via measuring the GFP fluorescence. The selected positive control, BG12, 
demonstrated the classical drug curve response and proved to be an efficient ARE inducer [Figure 
4.3]. The cytoprotective effect of BG12 via Nrf2 activation is well characterised and BG12 itself is 
a candidate treatment for PD (Lastres-Becker et al., 2016). Although the results showed that UCA 
and UDCA exerted a positive effect on ARE expression, the increase was minor compared to 
BG12. This suggests that the mechanism of action of UCA and UDCA may not mainly depend on 
ARE activation. UDCA has been reported to activate Nrf2 in unstressed and ferric nitrate-stressed 
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hepatic cells (Okada et al., 2008, Arisawa et al., 2009). The activation was associated with an 
increase in the expression of Nrf2 genes such as GSH and GCLC, and a decrease in the 
production of ROS. This effect was abolished when the activation of Nrf2 was inhibited (Arisawa 
et al., 2009). However, the inhibition of the Nrf2 was achieved via blocking the AKT pathway which 
raises the possibility of an alternative AKT-related pathway responsible for this antioxidant 
response. Nonetheless, UDCA treatment in other types of cells such as smooth muscle cells has 
been found to ameliorate oxidative stress in a Nrf2-dependent manner, which was demonstrated 
via the use of Nrf2-siRNA (Liu et al., 2016).  
Since most of the secreted UDCA in bile is conjugated (predominantly with taurine), it was decided 
to compare the effect of conjugated forms of UDCA with the unconjugated ones. However, the 
results were similar with regard to ARE expression [Figure 4.5]. Therefore, it was decided to use 
UDCA only in the subsequent experiments. To confirm the UCA/UDCA-meditated activation of 
the Nrf2 pathway, we quantified the copy number of the Nrf2 regulated transcripts of three genes, 
which are either directly or indirectly involved in the antioxidant mechanism: NQO1, GCLC and 
FTH1. NQO1 is one of the most extensively investigated phase 2 enzymes. NQO1 mediates the 
reduction of quinones via the use of NADH/NADPH as cofactors (Yang et al., 2015). GCLC acts 
as an antioxidant via facilitating the formation of the glutathione precursor, γ-glutamyl cysteine 
(Park et al., 2017). FTH1 is involved in the synthesis of ferritin, which controls free iron levels and 
iron redox reaction via sequestering iron into protein complexes (Kerins and Ooi, 2017). The 
results showed that UCA significantly increased the expression of FTH1 and GCLC. However, 
UCA treatment reduced the expression of NQO1, which is the only gene that showed a consistent 
response to the positive control. On the other hand, no significant change was seen with UDCA 
other than a small increase in NQO1 expression.  
The expression of Nrf2 downstream genes depends on a complex signaling network and might 
be influenced by cell type, metabolic state and even by the structure of the activator compound. 
Therefore, it is not expected that a given Nrf2 activator should upregulate all of the Nrf2 genes. 
This might explain why treatment with the positive control was not associated with an increase in 
all of the investigated genes. Taken all together, it is difficult to conclude that UCA and UDCA are 
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potent Nrf2 activators, at least in CHO cells. Nonetheless, it was decided to assess the ability of 
the UCA and UDCA to ameliorate oxidative stress, not only because both increased ARE 
expression but also because they might lessen oxidative stress by a mechanism independent of 
Nrf2. 
Three oxidative stress inducers were tested in this chapter: H2O2, rotenone and CuSO4. H2O2 
itself is a member of the ROS family [Figure 4.29]. It is endogenously generated from superoxide 
anions, which are produced as a result of a one-electron reduction of molecular oxygen. Usually, 
superoxide anions are immediately converted by SOD1 and SOD2 into H2O2. Rotenone inhibits 
complex I, and therefore results in an increase in the electron leak and the production of 
superoxide and H2O2. Importantly, only free radicals (not H2O2 by itself) are capable of oxidising 
H2DCF into DCF (Karlsson et al., 2010). Hydroxyl radicals can indistinguishably damage lipids, 
proteins and DNA (Schieber and Chandel, 2014). Typically, hydroxyl radicals are generated from 
H2O2 in the presence of ferrous ions during Fenton-type reactions [Figure 4.29 b], or – to a lesser 
extent – through unspecific enzymatic oxidation by cytochrome C (Karlsson et al., 2010). Despite 
the availability of H2O2, heavy metals like Fe or Cu are crucial for the Fenton-type reactions. Our 
results showed that there was no increase in DCF readings when the cells were stressed with 
H2O2 and rotenone, but there was a significant increase when the cells were stressed with CuSO4 
[Figure 4.12].  
The hydroxyl radicals are extremely reactive. However, they have a short lifespan (9–10 seconds) 
(Jomova et al., 2012). This might explain why there was no increase in DCF readings when the 
CuSO4 was removed two hours and five hours before the application of the DCF (protocol B) 
[Figure 4.14]. in addition, the cells might be able to eliminate the hydroxyl radicals via the 
antioxidant mechanisms during the CuSO4-free period. Only a small increase in DCF signals was 
seen when CuSO4 was removed eight hours and 24 hours before the application of the DCF 
[Figure 4.14]. However, this increase was not reproducible in drug treatment experiments [Figure 
4.15]. In contrast, the DCF readings were significantly increased in the experiments where the 
CuSO4 was present in the medium until the application of DCF (protocol C) [Figure 4.16]. In the 
literature, only a few studies have investigated ROS production in CHO cells via the DCF. 
140 
 
However, in these studies, the stressor was removed only at the time of the application of the 
DCF (Orhan et al., 2006, Kang et al., 2006).  
Although BG12 had a significant positive effect on the ARE activation, it failed to reduce DCF 
signals in CuSO4-stressed CHO cells. BG12 has not been reported to alleviate copper-induced 
oxidative stress. However, it has been reported to ameliorate oxidative stress induced by various 
toxins such as MPTP, 6-OHDA, H2O2 (Campolo et al., 2017, Linker et al., 2011, Wang et al., 
2015, Jing et al., 2015). Consequently, it was decided test Trolox as an alternative antioxidant 
control. Trolox has a well-known radical scavenging activity and has been used as a reference 
for the antioxidant capacity of other compounds (Wang et al., 2016, Lee et al., 2016). Despite the 
different tested concentrations and stressing protocols, there was no decrease in DCF readings 
[Figure 4.15] [Figure 4.17]. Similarly, UCA and UDCA did not reduce DCF readings in all 
experiments. Since the BG12 and Trolox showed no effect, it is difficult to conclude that UCA and 
UDCA are ineffective against oxidative stress. The usage of DCF might obscure the effect of the 
positive controls, UCA and UDCA since it only detects one type of ROS. Therefore, assessing 
oxidative stress using an alternative reagent is recommended for future work. 
In this chapter, the rescue effect of UCA and UDCA was assessed in cells stressed with two 
mitochondrial toxins, rotenone, which has been associated with increased risk of PD, and CCCP, 
which is a mitochondrial uncoupler commonly used in PD-related research. The results showed 
that the cells were able to compensate for the induced ATP reduction via glycolysis. 
Consequently, the cells were cultured in galactose medium to force them to rely on OXPHOS, 
which makes them metabolically closer to the neurons (Bolaños et al., 2010). The ability of UCA 
and UDCA to increase ATP levels in rotenone-stressed cells was investigated using different 
experimental designs and different treatment times and doses. However, no significant rise in 
ATP levels was seen [Figure 4.22] [Figure 4.23] [Figure 4.24]. Notably, the decrease in ATP 
readings with rotenone was rather abrupt and did not show a gradual decrease with increasing 
concentrations of rotenone [Figure 4.21]. Further experiments were performed to assess the 
effect of the drugs using CCCP as an alternative stressor. CCCP dosing experiments showed a 
clear dose-dependent decrease in ATP levels [Figure 4.26]. Accordingly, two CCCP doses that 
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induced two different degrees of ATP reduction were selected for drug treatment experiments. 
However, no increase in ATP levels was seen after the application of the drugs, regardless of the 
different tested protocols and CCCP concentrations [Figure 4.27] [ Figure 4.28].  
In this chapter, a LDH-based cytotoxicity assay was used to assess the degree of cytotoxicity 
induced by rotenone and CCCP, and to investigate whether the drugs are able to ameliorate this 
toxicity. In comparison to ATP readings, the effect of the stressors on LDH levels was generally 
smaller, especially when rotenone was used. Despite the occasionally observed variability, the 
drugs did not show a significant cytoprotective effect in all experiments. Collectively, our results 
showed that neither UCA nor UDCA were able to rescue mitochondrial function nor to decrease 
cytotoxicity in rotenone and CCCP-stressed CHO cells. It is appreciated that the used cell line 
and the introduced defects are different from those in the drug screening paper (Mortiboys et al., 
2013) and, therefore, might contribute to these negative results. In an attempt to tackle these 
limitations, the ability of the drugs to rescue mitochondrial function will be assessed in a cell line 
of human origin in the next chapter. 
 
 
Figure 4.29 An overview of the reactive oxygen species.  
(a) Shows common types of ROS and their production pathway. (b) The Fenton-type reaction and the 
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5 Investigating the beneficial effect of UDCA on ATP levels 
and cytotoxicity in SH-SY5Y cells 
5.1 Introduction 
5.1.1 SH-SY5Y Origin 
The neuroblastoma-derived SH-SY5Y cell line is commonly used in the field of PD research. 
These cells were obtained after a series of sub-cloning of bone marrow biopsies of neuroblastoma 
patients. In this process, the most neuron-like cells were selected and isolated for further 
expansion. The cells were initially named SK-N-SH, then SH-SY and finally SH-SY5Y (Biedler et 
al., 1973, Biedler et al., 1978). 
5.1.2 SH-SY5Y characteristics 
The genetic characterisation of SH-SY5Y showed that most of the PD-related genes and 
pathways are unimpaired, which is important given the nature of the origin of these cells (Krishna 
et al., 2014). The initial characterisation of SH-SY5Y revealed modest levels of dopamine-β-
hydroxylase and a small amount of choline acetyl-transferase, acetylcholinesterase, 
noradrenaline and TH (Biedler et al., 1978, Påhlman et al., 1984, Ross and Biedler, 1985). The 
expression of these proteins indicates that SH-SY5Y has a catecholaminergic phenotype and 
therefore it is important to note that these cells are not exclusively dopaminergic. Xicoy and 
colleagues performed a systematic review of published papers that have used SH-SY5Y cells to 
study PD and found that almost half of the published papers stated that they used DA cells without 
providing or citing previous experimental evidence (Xicoy et al., 2017). The other half of the 
papers did not provide any information about the phenotype of SH-SY5Y, and only 5% of the 
papers investigated the dopaminergic characteristics of the used cells. In less than 1% of the 
papers, the noradrenergic and the cholinergic phenotypes were reported (Xicoy et al., 2017).  
5.1.3 SH-SY5Y differentiation 
SH-SY5Y can be differentiated into more neuron-like cells, which makes them more relevant for 
PD-related research. There are several published methods and protocols to differentiated SH-
SY5Y cells. RA is the most commonly used substance to drive the differentiation. Studies have 
shown that terminally differentiated cells by RA express a higher level of DA markers and are 
more sensitive to toxins (Korecka et al., 2013, Lopes et al., 2010). However, these findings are 
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not consistent with other reports where no increase in DA markers have been observed (Cheung 
et al., 2009). Additionally, an increase in cholinergic markers has been reported (Hashemi et al., 
2003). Since RA is used at different concentrations for different time periods, it is possible that 
this variation could affect the final phenotype of the cells. In addition, the type of culture medium 
might also play a role, as well as the percentage and the type of added supplements such as 
FBS. The variation might also arise from the difference in cell source and passage number. 
Therefore, it is not surprising to know that more than 80% of papers used only undifferentiated 
SH-SY5Y (Xicoy et al., 2017). It has been proposed that RA acts via the activation of nuclear 
retinoic acid receptors and retinoid X receptors. Consequently, RA upregulates the transcription 
of various differentiation-related genes that harbour retinoic acid response elements (RARE) in 
their promotors (Das et al., 2014). Additionally, the RA mechanism involves non-genomic 
pathways such as ROS-mediated signalling (Kunzler et al., 2017). 
Alternatively, sequential treatment with RA and brain-derived neurotrophic factor (BDNF) has also 
been used to differentiate SH-SY5Y (Xicoy et al., 2017). This method should give a more 
homogenous population. However, the characterisation of the outcome is also controversial as it 
has shown a sympathetic / cholinergic phenotype in some reports and a DA phenotype in others 
(Goldie et al., 2014, Mastroeni et al., 2009). Other compounds that have been used in combination 
with RA include 12-O-tetradecanoylphorbol-13-acetate (TPA), dibutyryl cyclic adenosine 
monophosphate (dbcAMP) and tissue plasminogen activator (Xicoy et al., 2017). Furthermore, 
SH-SY5Y can be differentiated by the use of other compounds such as growth/differentiation 
factor 5 (GDF5), recombinant bone morphogenetic protein 2 (BMP2) and glial cell line-derived 








In the previous chapter, UDCA failed to rescue toxin-stressed CHO cells regardless of different 
tested conditions. Although toxin-induced mitochondrial dysfunction might be relevant to PD in 
terms of modelling, CHO cells are not an appropriate cell line for investigating treatments for PD 
since they are non-human and are not neuronal in nature. Therefore, SH-SY5Y cells were 
selected to investigate the rescue effect of UDCA further. In this chapter, an RA-based protocol 
will be used to differentiate the SH-SY5Y into more neuron-like cells. The differentiation will be 
evaluated through studying cell proliferation, morphology and expression of neuronal-specific 
markers. The effect of UDCA on ATP and cytotoxicity will be determined in both undifferentiated 
and differentiated SH-SY5Y cells. Subsequently, the mechanism of action of UDCA will be 




5.2 Assessing the ability of UCA/UDCA to rescue mitochondrial 
function in stressed undifferentiated SH-SY5Y cells 
5.2.1 Optimisation of culture medium and rotenone concentration  
Initial rotenone-dosing experiment showed an increase in cytotoxicity at 1 µM, which remained 
unchanged regardless of subsequent treatment with increasing rotenone doses (up to 10 µM) 
[Figure 5.1 a]. Similarly, assessing ATP reduction after rotenone treatment showed that the 
decrease in ATP levels was comparable regardless of the applied rotenone doses (1 µM–10 µM) 
[Figure 5.1 b]. This trend is comparable to what was previously observed in CHO cells. The 
sensitivity of SH-SY5Y cells to rotenone was significantly increased when they were cultured in 
galactose medium [Figure 5.1 c, d]. This indicates that SH-SY5Y cells also utilise glycolysis to 
produce energy. For the drug treatment experiments, it was decided to test multiple rotenone 
concentrations (15 nM - 40 nM), which induced a decrease in ATP levels that ranged between 
20% and 80%. 
 
Figure 5.1 Rotenone induced a dose-dependant effect on cytotoxicity and ATP readings in galactose 
culture mediums.  
Cytotoxicity and ATP levels were measured using trypan blue staining and ATP assay, as described in the 
method chapter [Heading 2.9.1, 2.10]. The SH-SY5Y cells were stressed for 24 hours in either regular 
culture medium (a, b) or galactose medium (c, d). Stressing the cells in galactose medium significantly 
increased their sensitivity to rotenone and induced a clear dose-dependent effect. The error bars represent 







5.2.2 Assessing the effect of UCA and UDCA in rotenone-stressed SH-SY5Y cells 
The cells were pre-treated with 10 µM of each drug for 24 hours prior to the addition of rotenone. 
The changes in cytotoxicity and ATP readings in rotenone-stressed cells were comparable to 
what was previous observed in the rotenone-dosing experiments. UCA and UDCA treatment had 
no positive effect in all conditions [Figure 5.2].   
 
Figure 5.2 UCA and UDCA did not induce a positive effect in unstressed and rotenone-stressed SH-
SY5Y.  
Cytotoxicity and ATP levels were measured using trypan blue staining and ATP assay as described in the 
method chapter [Heading 2.9.1, 2.10]. The cells were pre-treated with 10 µM of the drug for 24 hours. Then 
the rotenone was added and kept for 24 hours. Rotenone significantly increased cytotoxicity (a) and 
decreased ATP levels (b) but no rescue effect was seen with UCA and UDCA treatment in all conditions. 
The error bars represent the SD of three independent experiments. The error bars represent SD. * p < 0.05, 





5.2.3 Assessing the effect of UCA and UDCA in CCCP-stressed SH-SY5Y cells 
In this set of experiments, the dosing and the treatment times of the CCCP and the drugs were 
adopted from a recently published paper (Fonseca et al., 2017), in which TUDCA exerted a 
positive effect on ATP and cytotoxicity in CCCP-stressed SH-SY5Y (Fonseca et al., 2017). 
Accordingly, the cells were stressed with two CCCP concentrations (25 µM and 50 µM), and were 
treated with 100 µM UDCA and 100 µM TUDCA in addition to the previously tested conditions (10 
µM UCA and 10 µM UDCA) [Figure 5.3]. Both CCCP concentrations increased cytotoxicity (155% 
with 25 µM CCCP, 227% with 50 µM CCCP) and decreased ATP levels (50% with 25 µM CCCP, 
70% with 50 µM CCCP). No positive effect was observed with 10 µM UCA/UDCA and 100 µM 
TUDCA. However, there was a notable insignificant positive effect with 100 µM UDCA, which was 
apparent in ATP levels and cytotoxicity in the 50 µM CCCP condition.  
 
Figure 5.3 UDCA induced a small non-significant positive effect in CCCP-stressed SH-SY5Y. 
Cytotoxicity and ATP levels were measured using trypan blue staining and ATP assays as described in the 
method chapter [Heading 2.9.1, 2.10]. The SH-SY5Y cells were pre-treated for 12 hours with the drugs and 
then were further incubated with either 25 µM CCCP (a, b) or 50 µM CCCP (c, d) for 24 hours. The results 
showed a small insignificant rescue effect with 100 µM UDCA. The error bars represent the SD of three 





Accordingly, higher doses of UDCA were tested [Figure 5.4 a, b]. The results showed significant 
positive changes in cytotoxicity (25% decrease) and ATP levels (65% increase) when the cells 
were treated with 300 µM UDCA [Figure 5.4 a, b]. Higher UDCA doses, 600 µM and 900 µM, 
increased the toxicity in unstressed cells. The rescue effect of treatment with 300 µM UDCA was 
also apparent when the cells were examined under the optic microscope [Figure 5.4 c].  
     
Figure 5.4 A UDCA dose of 300 µM induced a significant positive effect on ATP and LDH levels in 
CCCP-stressed SH-SY5Y.  
(a), (b) Cytotoxicity and ATP levels were measured using trypan blue staining and ATP assays as described 
in the method chapter [Heading 2.9.1, 2.10]. The cells were pre-treated for 12 hours with UDCA before the 
addition of 50 µM CCCP, which was kept for 24 hours. The results showed a significant rescue effect with 
300 µM UDCA (a, b). (c) Bright field microscopy images showing the surviving cells in the UDCA-treated 
condition (VI). The white arrows point to some of the healthy-looking cells which are not present in the 
CCCP-only condition (V). The error bars represent the SD of three independent experiments. ** p < 0.01, 
*** p < 0.001, **** p < 0.0001, two-way ANOVA test. Scale bar = 50µm.  






























5.3 Assessing the ability of UDCA to rescue mitochondrial function in 
stressed differentiated SH-SY5Y cells 
5.3.1 Characterisation of differentiated SH-SY5Y 
Proliferation assay: The differentiation of SH-SY5Y cells alters their transcription profile to 
transform them into neuron-like cells. In this process, the cells do not only express higher levels 
of neuronal markers but also become non-proliferative. To assess cell growth, the cell count was 
determined regularly using an automated counter throughout the differentiation course. The cells 
were plated in a 24-well plate at equal densities and the differentiation protocol was commenced 
as described in the method section. Every two days, the contents of three wells were collected 
separately in order to conduct a cell count. An identical parallel culture plate was prepared to 
compare the cell count to undifferentiated cells grown in regular culture medium. As expected, 
the results showed that the increase in the total cell count with time was significantly lower in the 
differentiating cells [Figure 5.5]. Yet the presence of increasing total cell count with time in 
differentiated cells indicates a non-homogenously differentiated population, which is one of the 
limitations of the protocol used. Although the total number of growing undifferentiated cells was 
higher than the differentiated cells, the number of dead cells was comparable, indicating that there 
were a number of differentiating cells that died throughout the process, which was also noticed 
when the plate was examined under the optic microscope [Figure 5.6 a]. Of note, the number of 
viable undifferentiated cells dropped significantly towards the end of the second week due to the 







Figure 5.5 Differentiating SH-SY5Y cells have lower growth rate and higher cell death rate in 
comparison to the undifferentiated cells.  
The readings were obtained by the use of an automated counter and trypan blue staining [Heading 2.9.1], 
which enables the determination of total cell count (a), viable cell count (b) and dead cell count (c). The 
graphs show that the proliferation of differentiating cells was reduced as the total cell count and the viable 








Morphological analysis: Differentiated SH-SY5Y demonstrated a remarkable change in 
morphology in terms of neurite growth [Figure 5.6 a]. Immunocytochemistry (ICC) staining showed 
that these neurites expressed the Neuron-specific class III β-tubulin (TuJ1) [Figure 5.6 b]. The 
images were analysed using the ‘Find Neurites’ building block on the Harmony software 
(PerkinElmer). This analysis protocol can identify neurites growing from cell bodies and 
consequently measures various parameters such as maximum neurite length, total neurite length, 
number of extremities and number of roots. Since undifferentiated cells have no dendritic 
structure, only the total neurite length was used to assess neurite growth and was significantly 
increased in differentiated cells. 
 
Figure 5.6 Differentiated SH-SY5Y cells exhibited remarkable change in their morphology.  
(a) Optic microscopy images of SH-SY5Y cells pre/post differentiation. Differentiated SH-SY5Y cells 
showed a significant increase in neurite growth. (b) Confocal microscopy images of SH-SY5Y cells pre/post 
differentiation stained with Tuj1. The images showed that the neurites of the differentiated cells were 
positively stained with Tuj1. (c) Analysis of Tuj1 images showed a significant increase in neurite growth. 
ICC and imaging were performed as described in the method section. * p < 0.05, unpaired t-test.  Scale bar 










Neuronal markers: The differentiated SH-SY5Y cells showed a significant increase in the 
expression of microtubule-associated protein 2 (MAP2), which is a protein that stabilises 
microtubules in the dendrites and post-mitotic cells (Poulain and Sobel, 2010) [Figure 5.7 a]. The 
DA phenotype of the differentiated cells was determined via staining with FOXA2, which is a 
member of the forkhead/winged helix transcription factor family that has a significant role in the 
development and maintenance of DA neurons (Stott et al., 2013) [Figure 5.8 a]. Notably, FOXA2 
staining was not as intense in the nucleus as was expected. However, the increase in the 
expression of FOXA2 in differentiated cells was observed in both cytoplasmic and nuclear 
regions. In addition, WB revealed a significant increase in the expression of TH, a rate-limiting 
enzyme in dopamine synthesis, which further confirmed the DA phenotype of the differentiated 
cells [Figure 5.8 c]. 
 
 
Figure 5.7 The expression of the neuronal marker MAP2 is significantly higher in differentiated SH-
SY5Y cells.  
ICC was performed as described in the method section and the images were captured using a confocal 
microscope. The cells were probed with MAP2 (a) antibody and the images were analysed using the 
Harmony software (b). The images show a significant increase in the expression of MAP2 in differentiated 
SH-SY5Y cells. The error bars represent the SD of three independent experiments. * p < 0.05, unpaired t-
test. Scale bar = 50µm.  































Figure 5.8 The expression of the dopaminergic markers is significantly higher in differentiated SH-
SY5Y cells.  
(a) ICC was performed as described in the method section and the images were captured using a confocal 
microscope. The cells were probed with FOXA2 antibody and the images were analysed using the Harmony 
software (b). Marker-specific positive cells were selected according to a pre-set intensity threshold. The 
images show a significant increase in the expression of both markers in differentiated SH-SY5Y cells. (c) 
WB images showing a marked increase in TH levels in differentiated cells. WB was performed using total 
cell lysates as described in the method section. (d) Densitometric analysis of WB images. The expression 
of TH was remarkably increased in the differentiated cells. The error bars represent the SD of three 




































5.3.2 Optimising CCCP concentration 
Differentiated SH-SY5Y cells are more vulnerable to toxins (Forster et al., 2016). Therefore, 
CCCP doses need to be optimised before the application of the UDCA. As expected, the 
previously used dose of CCCP (50 µM) was highly toxic to the differentiated cells [Figure 5.9]. 
The results also showed high basal cytotoxicity in differentiated cells (more than 50%). This is 
probably attributed to the presence of dead cells that accumulated during the differentiation 
process, which were consequently included in the counting process, and in the ATP assay as 
well.  
  
Figure 5.9 A pilot experiment to optimise CCCP concentration demonstrated high basal toxicity 
readings in unstressed differentiated SH-SY5Y. 
 Cytotoxicity and ATP levels were measured using trypan blue staining and ATP assays, as described in 
the method chapter [Heading 2.9.1, 2.10]. The cells were stressed with CCCP for 24 hours in regular culture 
medium. The graphs showed a significant increase in basal cytotoxicity levels (a) and marked reduction in 
ATP levels with the lowest tested CCCP concentration, 10 µM (b). The error bars represent the SD of three 
technical replicates. 
 
To minimise the effect of dead cells on the results in the following experiments, the wells were 
routinely washed with differentiation medium during the course of the differentiation. In addition, 
the cytotoxicity was assessed via ICC as an alternative method. The cells were probed with 
cleaved caspase-3 antibody and imaged using confocal microscopy [Figure 5.10]. The image 
analysis protocol was programmed to exclude dead cells based on the size and the intensity of 





Figure 5.10 Cleaved caspase 3 staining is an efficient approach to assess cytotoxicity in 
differentiated SH-SY5Y. 
 ICC images of caspase stained cells as an alternative approach to assess CCCP cytotoxicity. The cells 
were stressed with 10 µM CCCP for 24 hours. ICC was performed as described in the method section, and 
images were captured using confocal microscopy. Images of the first column (I and V) show staining with 
cleaved caspae-3 (yellow). Images of the second column (II and VI) show staining with Tuj1 (green). Images 
of the third column (III and VII) show staining with Hoechst (blue). Images of the forth column (IV and VIII) 
show the merged image. The images show a significant increase in caspase staining in CCCP-stressed 
differentiated cells. Scale bar = 50µm. 
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Figure 5.11 Image analysis software can detect and exclude dead cells co-stained with Hoechst and 
caspase-3. 
 An illustration of the protocol used to analyse caspase staining. Untreated differentiated SH-SY5Y cells 
were probed with cleaved caspase-3 antibody and were stained with Hoechst. The images were captured 
by confocal microscopy, as described in the method section, and then were analysed using the Harmony 
software. (a) Hoechst staining to visualise the nuclei. White arrows point to some of dead cells with 
condensed shrunken nuclei. (b) Shows the viable nuclei that were selected by the software for subsequent 
analysis (enclosed within coloured circles). (c) Cleaved caspase-3 staining of untreated differentiated cells. 
(d) Shows caspase spots identified by the analysis software (the coloured areas). Only caspase spots of 
viable cells were analysed by the software. (e) A merged image of Hoechst and caspase staining. (f) The 
cells were also probed with Tuj1 to determine the cytoplasmic regions. Scale bar = 50µm.  
50 µm 
a) Hoechst b) Hoechst (analysis) 
c) Caspase-3 d)  Caspase-3 (analysis) 
e)  Hoechst + Caspase-3 f)  Tuj1 
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Consequently, image analysis of caspase staining was set to calculate different parameters 
[Figure 5.12] [Figure 5.13]. Those were labelled as follows: number of spots / cell count = the 
average number of caspase spots per cell, number of spots per area of cells = the average 
number of detected spots divided by the area of the cell region, total spot area / cell count = the 
average of the area of all spots detected per cell, spot area = the average area of individual spot, 
relative spot intensity = the fraction of stain aggregated in spots compared to total amount of stain 
in the cell, region intensity = the mean intensity of the spot search region where the particular spot 
is located. 
Testing low CCCP doses revealed a dose-dependent increase in caspase spot numbers and the 
total caspase spot areas [Figure 5.12]. The tested CCCP doses also increased the readings of 
other parameters of caspase analysis [Figure 5.13], and collectively demonstrated a clear effect 
of CCCP treatment on the amount of cleaved caspase-3. With regard to ATP levels, the lowest 
tested CCCP concentration had no effect, while both 5 µM and 10 µM CCCP induced around a 
40% decrease [Figure 5.14]. Notably, differentiated cells had higher basal ATP levels (almost 
double) in comparison to the undifferentiated cells. In accordance with the ATP and cytotoxicity 





Figure 5.12 Multiple CCCP concentrations induced a dose-dependent effect on several parameters 
of caspase-3 spots analysis (1/2).  
The results of image analysis of caspase staining of CCCP-stressed cells. Undifferentiated and 
differentiated SH-SY5Y cells were treated with 1 µM, 5 µM and 10 µM of CCCP for 24 hours. ICC was 
performed as described in the method section, and images were captured using confocal microscopy. The 
cells were co-stained with Tuj1 to determine the cell boundaries, and with Hoechst to determine the cell 
counts. Analysis of caspase spots was performed by the Harmony software to determine the number of 
spots per cell (a), the number of spots per area (b) and the total spot area per cell (c). The results showed 
a dose dependant increase in the number of spots and total spot area in differentiated cells. All readings 








Figure 5.13 Multiple CCCP concentrations induced a dose-dependent effect on several parameters 
of caspase-3 spots analysis (2/2). 
 The results of image analysis of caspase staining of CCCP-stressed cells. The cells were treated with 
1 µM, 5 µM and 10 µM of CCCP for 24 hours. ICC was performed as described in the method section, and 
images were captured using confocal microscopy. The cells were co-stained with Tuj1 to determine the cell 
boundaries, and with Hoechst to determine the cell counts. Analysis of caspase spots was performed by 
the Harmony software to determine the average spot area (a), relative spots intensity (b) and region spots 
intensity (c). The results showed a significant increase in spot area and relative spot intensity in CCCP-
stressed differentiated cells. All readings were normalised to the undifferentiated control. The error bars 







Figure 5.14 Assessing the effect of multiple CCCP doses on ATP readings demonstrated 
comparable responses with 5 µM and 10 µM. 
 ATP levels were measured using ATP assays as described in the method chapter [Heading 2.10]. The 
cells were stressed with CCCP for 24 hours. 5 µM and 10 µM CCCP induced approximately a 40% decrease 
in ATP level in differentiated SH-SY5Y cells. The error bars represent the SD of three independent 
experiments. 
 
5.3.3 Assessing the effect of UDCA in CCCP-stressed differentiated SH-SY5Y  
Differentiated SH-SY5Y cells have an altered transcription profile and a higher sensitivity to 
CCCP. Therefore, the effective UDCA dose in these cells might differ from that of the 
undifferentiated cells. Accordingly, three doses of UDCA were tested in this experiment (10 µM, 
100 µM and 300 µM). The assay window of a 40% decrease in ATP levels was reproducible; 
however, none of the tested UDCA doses ameliorated the cytotoxicity of CCCP [Figure 5.15] 
[Figure 5.16]. Similarly, UDCA treatment failed to increase ATP levels [Figure 5.17]. The 
difference between the stressed and unstressed cells was statistically insignificant due to the 
variation between the replicates, which make it difficult to interpret the data. Although there was 
an increase of 35% with 10 µM UDCA in comparison to the untreated control, the variability 
between control conditions (CCCP-untreated and CCCP-Vehicle) and long error bars made it 
difficult to conclude that this increase was real. Overall, the results suggest that the previously 






Figure 5.15 Multiple doses of UDCA did not induce a positive effect on cleaved caspase 3 staining 
in CCCP-stressed differentiated SH-SY5Y cells (1/2). 
 Image analysis of caspase staining of treated SH-SY5Y cells. The cells were pre-treated for 12 hours with 
UDCA. Then, they were further incubated with 10 µM CCCP for 24 hours. The results show that UDCA 
treatments did not ameliorate cytotoxicity in stressed cells. The cells were co-stained with Tuj1 to determine 
the cell boundaries, and with Hoechst to determine the cell counts. Analysis of caspase spots was 
performed by the Harmony software to determine the number of spots per cell (a), the number of spots per 
area (b) and the total spot area per cell (c). All readings were normalised to the unstressed control. The 







Figure 5.16 Multiple doses of UDCA did not induce a positive effect on cleaved caspase 3 staining 
in CCCP-stressed differentiated SH-SY5Y cells (2/2). 
 Image analysis of caspase staining of treated SH-SY5Y cells. The cells were pre-treated for 12 hours with 
UDCA. Then, they were further incubated with 10 µM CCCP for 24 hours. The results show that UDCA 
treatments did not ameliorate cytotoxicity in stressed cells. The cells were co-stained with Tuj1 to determine 
the cell boundaries, and with Hoechst to determine the cell counts. Analysis of caspase spots was 
performed by the Harmony software to determine the average spot area (a), relative spots intensity (b) and 
region spots intensity (c). All readings were normalised to the unstressed control. The error bars represent 








Figure 5.17 Multiple doses of UDCA did not induce a significant positive effect on ATP levels in 
CCCP-stressed differentiated SH-SY5Y cells. 
 ATP levels were measured using ATP assays as described in the method chapter [Heading 2.10]. The 
cells were pre-treated for 12 hours with UDCA. Then they were further incubated with 10 µM CCCP for 24 
hours. The results show that UDCA treatments did not increase ATP readings in stressed cells. The error 
bars represent the SD of three independent experiments. 
 
5.4 Evaluating the effect of UDCA on the expression of Nrf2 genes in 
stressed undifferentiated SH-SY5Y cells 
5.4.1 Initial testing of the primers 
Since UDCA increased ARE expression in unstressed CHO cell [Figure 4.5], it was decided to 
investigate if the rescue effect in CCCP-stressed SH-SY5Y cells was mediated via the Nrf2 
pathway. To assess Nrf2 activation, we quantified the expression of Nrf2 target genes via RT-
qPCR using RNA extracts of treated cells. Primers of six Nrf2 genes were designed and tested, 
as described in the method section. Upon testing different concentrations of the forward and the 
reverse primers, HMOX1 and NQO1 showed double peaks on the melt peak curves and therefore 
were excluded from the subsequent experiments [Figure 5.22]. The primers of the other genes 
(GAPDH, GST2A, GCLC and FTH1) produced similar amplification curves and melt peaks in all 
tested concentrations [(a) and (b) in Figure 5.18 to Figure 5.21]. Subsequently, standard curves 
and melt peaks were obtained from a serial of ten-fold dilution of the samples. The results reveal 





Figure 5.18 GAPDH primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 95.1 %. The melt peak graph showed single peaks with all dilutions of the sample 








Figure 5.19 GST2A primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 108.6 %. The melt peak graph showed single peaks with all dilutions of the sample 









Figure 5.20 GCLC primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 108.9 %. The melt peak graph showed single peaks with all dilutions of the sample 










Figure 5.21 FTH1 primers have high efficiency and specificity in qPCR reactions.  
(a) and (b) Testing combinations of different concentrations of the forward and the reverse primers [Heading 
2.6.3]. All combinations showed comparable amplification curves and melt peaks. (c), (d) and (e) Assessing 
the reacting efficiency and specificity using a ten-fold serial dilution of the sample. The standard curves 
revealed an efficiency of 100.4 %. The melt peak graph showed single peaks with all dilutions of the sample 










Figure 5.22 HMOX1 and NQO1 primers showed secondary peaks in melt peak graphs in qPCR 
reactions.  
Testing combinations of different concentrations of the forward and the reverse primers [Heading 2.6.3]. 
Secondary peaks were observed with all combinations of HMOX primers (b) and NQO1 primers (d). 









5.4.2 Assessing the effect of UDCA and BG12 on the expression of Nrf2 
downstream genes in undifferentiated SH-SY5Y cells 
The SH-SY5Y cells were treated with 300 µM UDCA as this was the most effective dose in 
CCCP-stressed cells (undifferentiated SH-SY5Y) [Figure 5.4]. In addition, the cells were 
treated with different concentrations of the positive control, BG12 (2 µM, 10 µM and 30 µM). 
Notably, CCCP significantly increased the expression of GCLC (140%) and FTH1 (680%) but 
had no effect on GST2A [Figure 5.23]. The results showed that UDCA treatment did not 
increase the expression of Nrf2 genes in CCCP-stressed cells (undifferentiated SH-SY5Y). In 
contrast, there was a decrease in the expression of GST2A (20%), and a statistically significant 
decrease in the expression of FTH1 (25%) [Figure 5.23]. Despite the treatment with different 
concentrations of BG12, none of them significantly increased the expression of the selected 
Nrf2 genes. 
 
Figure 5.23 UDCA treatment induced variable effects on the expression of Nrf2 downstream genes 
in undifferentiated SH-SY5Y cells.  
Determining the effect of UDCA on the Nrf2 downstream genes was performed by qPCR. The cells were 
pre-treated with 300 µM UDCA for 12 hours before the addition of 50 µM CCCP, which was kept for 24 
hours. Data analysis revealed that UDCA reduced the expression of GST2A (a) and FTH1 (c), but did not 
affect the expression of GCLC (b). The graphs represent data of three independent experiments. The error 






The objective of this chapter is to demonstrate the rescue effect of UDCA in a human cell line of 
neuronal nature. As performed with the CHO cells, toxin-induced (rotenone/CCCP) mitochondrial 
dysfunction was used to model PD pathology. The results of the initial rotenone testing in the 
regular culture medium using SH-SY5Y cells were comparable to what was previously observed 
in CHO cells, where CHO cells were able to compensate the inhibition of OXPHOS via 
upregulating glycolysis [Figure 4.18]. Since SH-SY5Y cells originate from tumors, they are 
expected to have increased glycolytic activity due to the Warburg effect (Aminzadeh et al., 2015). 
Culturing SH-SY5Y cells in galactose medium significantly increased their vulnerability to the 
rotenone. However, treatment with 10 µM UCA and UDCA failed to rescue cells stressed with 
various doses of rotenone [Figure 5.2]. Prior to starting the CCCP experiments, Fonseca et al. 
(2017) published a paper that showed a significant TUDCA-mediated rescue effect in CCCP-
stressed SH-SY5Y cells (Fonseca et al., 2017). Notably, higher doses of both CCCP and the drug 
were used in her paper (50 µM CCCP, 100 µM TUDCA), and the experiments were performed 
using glucose-containing medium. Accordingly, it was decided to adopt their treatment protocol 
in the CCCP experiment in this chapter. The previously used 10 µM UCA and 10 µM UDCA 
conditions were kept, and 100 µM UDCA and 100 µM TUDCA were added. The cells were also 
stressed with a lower CCCP dose, 25 µM. While the TUDCA effect was not reproducible, UDCA 
treatment with doses up to 300 µM significantly increased ATP levels and ameliorated cytotoxicity 
[Figure 5.4].  
Possible explanation for the absence of the TUDCA-mediated positive effect on undifferentiated 
SH-SY5Y cells might be the difference in the culturing mediums. In this project, SH-SY5Y cells 
were cultured in DMEM medium supplemented with 10% FBS [Table 2.2], while in the paper the 
cells were grown in Ham’s F12:EMEM (1:1) supplemented with 15% FBS in addition to 1% non-
essential amino acids. Providing the cells with more supportive nutrition might enable the cells to 
respond positively to the TUDCA treatment. Treatment with higher UDCA doses (>300 µM) was 
toxic to the unstressed cells [Figure 5.4]. Therefore, the 300 µM UDCA was used as standard in 
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all subsequent experiments investigating the mechanism of action of UDCA in undifferentiated 
SH-SY5Y. 
In this project, the RA-based differentiation protocol was adopted from published studies that 
demonstrated successful SH-SY5Y differentiation (Lopes et al., 2017, Popova et al., 2017). The 
differentiated cells in this project showed significant morphological changes that were associated 
with an increase in the expression of the neuronal marker, MAP2. The transformation into a 
terminal post-mitotic state (deduced from reduced cell growth) and the presence of Tuj1 in the 
neurites of differentiated cells further confirms successful differentiation. More than one third of 
the published papers declare that the differentiated SH-SY5Y cells in use have a DA phenotype 
without providing supportive evidence (Xicoy et al., 2017). In this chapter, the DA nature of the 
differentiated cells was determined by assessing the expression of two DA markers, FOXA2 and 
TH [Figure 5.8]. Although the expression of TH is commonly used to identify DA cells, it is 
important to point out that this is an indirect method. An example of the direct approach would be 
the detection of dopamine using the ELISA technique, which allows the quantification of 
synthesised dopamine within the cells and the released dopamine in the culture medium. 
Throughout the course of the differentiation, a significant percentage of the cells failed to tolerate 
this process and died in the wells, which negatively affected the accuracy of the cytotoxicity 
assessment via trypan blue staining. Even with the repetitive washing procedure, some of these 
cells stuck to the well floor and were subsequently included in cell counting. Using an LDH assay 
would not improve the results, as accumulated dying cells would have contributed to the total LDH 
released in the medium. To overcome this limitation, ICC was used to assess cytotoxicity as it 
enables the exclusion of dead cells in image analysis. The cells were probed with cleaved 
caspase-3 antibody, which is mainly produced in the apoptotic cells via the action of initiator 
caspases, such as caspase 8 and caspase 9 on pro-caspase-3 (Maes et al., 2015, Kiraz et al., 
2016). Unlike cleaved caspase-3 staining, tryban blue staining does not differentiates between 
apoptotic and necrotic cells. Therefore, cleaved caspase-3 staining, is superior since necrosis is 
not implicated in cell death in PD.  
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Differentiated SH-SY5Y cells are vulnerable to toxins that elevate oxidative stress, such as H2O2 
and 6-OHDA (Lopes et al., 2017, Forster et al., 2016, Piras et al., 2017). Equally, caspase staining 
in this chapter showed that CCCP induced a dose-dependent effect on cytotoxicity in 
differentiated SH-SY5Y [Figure 5.12]. Notably, the basal cytotoxicity in differentiated cells was 
higher than in undifferentiated cells. This is consistent with previously published studies that 
showed increased cleaved caspase-3 levels in retinoic acid-differentiated SH-SY5Y (Mak et al., 
2010). Research shows that RA-mediated elevation in ROS and oxidative stress is critical for SH-
SY5Y differentiation (Kunzler et al., 2017). The basal ATP levels in differentiated cells were higher 
than in undifferentiated cells. This finding has been previously reported (Lopes et al., 2017). Since 
RA enhances the expression of glucokinase (an enzyme responsible for the conversion of glucose 
into glucose-6-phosphate) (Cabrera-Valladares et al., 2001), it is plausible that the increase in 
ATP is achieved via upregulation in glycolysis. However, experimental data suggest that 
differentiated SH-SY5Y cells have enhanced OXPHOS instead. The oxygen consumption rate 
was found to be significantly increased in RA-treated SH-SY5Y cells, and this increase was not 
affected by the inhibition of glycolysis, indicating increased dependency on OXPHOS (Xun et al., 
2012). This increase is proposed to be mediated via elevated levels of metabolic substrates such 
as Acetyl-CoA or via the utilisation of a different pathway such as fatty acid catabolism (Xun et 
al., 2012). Since brain neurons are predominantly oxidative, these changes in bioenergetics in 
differentiated SH-SY5Y cells make them better models of mature neurons (Raefsky and Mattson, 
2017).  
According to the cytotoxicity and ATP results of CCCP-stressed differentiated SH-SY5Y cells, it 
was decided to use 10 µM CCCP in the drug treatment experiments. Three different 
concentrations of UDCA were tested. The results showed an occasional inconsistency between 
the untreated and vehicle conditions as well as variability between replicates, which made it 
difficult to interpret the data. This variability might have risen from non-homogenous differentiation 
of the cells as well as differences between independent experiments. Nonetheless, the results 
suggest that none of the tested UDCA doses had a positive effect on cytotoxicity or ATP levels. 
One of the possible explanations for these negative results is that the used differentiation protocol 
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is inappropriate for studying the rescue effect of UDCA. In the used protocol, the cells were grown 
in a serum-free medium. This might have induced a significant stress load on the cells and 
rendered them unable to respond properly to drug treatment. In line with that notion, the 
differentiation of SH-SY5Y cells was associated with a significant degree of cell death [Figure 5.6 
a]. Therefore, it is recommended that the protocol is optimised in future experiments, which was 
not accomplished in this project due to the time limit. Possible adjustments include the use of 
alternative differentiation medium and the addition of a small percentage of FBS (1–5%) to 
support the health of differentiating cells. The addition of BDNF to the medium helps to induce a 
homogenous cell culture (Shipley et al., 2016), which should help to reduce the variability in the 
results. It is also recommended to increase the number of technical replicates in each round of 
drug treatment, and to use alternative methods such as flow cytometry (to assess caspase 
activation) to improve the accuracy of the results. 
Although the results were inconsistent in differentiated SH-SY5Y experiments, UDCA significantly 
increased ATP levels and viability in CCCP-stressed undifferentiated SH-SY5Y cells at a dose of 
300 µM [Heading 5.2.3]. Consequently, we investigated whether this beneficial effect was 
associated with activation of the Nrf2 pathway, since UDCA showed a dose-dependent increase 
in ARE expression in CHO cells [Figure 4.5]. Notably, the results showed that CCCP significantly 
increased the expression of 2/3 Nrf2 genes (GCLC and FTH1) [Figure 5.23]. This upregulation is 
expected since CCCP treatment damages the mitochondria and increases oxidative stress levels 
in the cells (Fonseca et al., 2017). In addition, CCCP directly reacts with Keap1 thiol groups, 
resulting in breaking the bond between Keap1 and Nrf2, and consequently increasing Nrf2 content 
in the nucleus (Kane et al., 2017). The mechanism of Nrf2 activation was previously discussed in 
Chapter 4 [Heading 4.1.3].  
The results in this chapter show that UDCA treatment did not increase the expression of the 
selected Nrf2 genes in CCCP-stressed SH-SY5Y cells. In contrast, there was an unexpected 
decrease in the expression of GST2A and FTH1. This does not rule out the possibility of UDCA-
mediated antioxidant effect as it could be achieved via other adaptive stress response pathways 
such as AP-1 and JNK.  
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It is also possible that UDCA triggered an alternative cytoprotective pathway that decreased 
oxidative stress levels and, as a result, the expression of the Nrf2 genes was not increased as 
much as in the untreated CCCP-stressed condition. According to the literature, the activation of 
the AKT pathway is one of the most plausible mechanisms of the UDCA-mediated cytoprotective 












Chapter 6. Investigating the effect of 





6 Investigating the effect of UDCA on the AKT pathway  
6.1 Introduction to the AKT pathway 
6.1.1 Background 
Protein kinase B, more commonly known as AKT, is a serine/threonine kinase that plays a key 
role in multiple physiological processes, including cardiovascular homeostasis, glucose 
metabolism, synaptic signalling, apoptosis, and cellular growth and proliferation. Abnormal AKT 
signalling has been linked to various pathologies that include cancer, diabetes, cardiomyopathy 
and vascular diseases (Risso et al., 2015).  
AKT dysregulation is implicated in PD. Immunostaining of post-mortem tissue demonstrates that 
AKT phosphorylation is considerably decreased in the DA neurons of PD patients (Greene et al., 
2011). In addition, activation of the AKT pathway has been beneficial in various PD-related 
models (Zhang et al., 2013a, Castro-Caldas et al., 2012, Gong et al., 2012). The activation of 
AKT induced axonal growth and re-innervation is associated with partial improvement in motor 
functions in a 6-OHDA mouse model (Kim et al., 2011). 
AKT was discovered in 1987 following the isolation of the transforming retrovirus from an AKR 
mouse T-cell lymphoma (Staal, 1987). Afterwards, it was possible to clone and sequence the viral 
oncogene v-AKT and to find the human homologue, which was given the name AKT (Toker and 
Marmiroli, 2014) (Testa and Tsichlis, 2005).  
6.1.2 Activation and regulation of the AKT pathway 
The AKT protein consists of three highly conserved domains (hydrophobic, catalytic and pleckstrin 
homology (PH) domains), which are critical for its regulation and function [Figure 6.1] (Hanada et 
al., 2004, Song et al., 2005). The activation of AKT is dependent on the phosphoinositide 3 (PI3) 
kinase signalling pathway [Figure 6.1]. G protein-coupled receptors and membrane-associated 
receptor tyrosine kinases activate the PI3 kinase via phosphorylation. The activated PI3 kinase 
in turn phosphorylates the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to 
produce phosphatidylinositol 3,4,5 trisphosphate (PIP3) (Hers et al., 2011). This process is 
controlled by phosphatase and tensin homologue (PTEN), which has the ability to 
dephosphorylate the 3-OH position of PIP3 (Song et al., 2005). PIP3 is crucial for AKT activation, 
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as it localises AKT to the cell membrane, along with pyruvate dehydrogenase kinase (PDK1), and 
mediates changes to the structure of AKT to expose its activating sequence [Figure 6.1].  
The binding of AKT to the cell membrane is achieved via the interaction between the membrane 
lipids and the PH domain. The latter is an N-terminal domain that consists of 100 amino acids and 
is named after the protein that PKC targets in platelets, pleckstrin (Song et al., 2005).  
The phosphorylation of a threonine residue within the catalytic domain by the action of PDK1 
results in a 100-fold increase in the activity of AKT. However, this is only a partial activation of 
AKT. To reach its fully activated state, serine 473 in the hydrophobic domain must be 
phosphorylated as well. The primary kinase for this step is mechanistic target of rapamycin 
(mTOR) complex 2 (mTORC2) [Figure 6.1] (Hers et al., 2011, Toker and Marmiroli, 2014). Other 
possible Ser473 phosphorylators include MAPKAP kinase 2, an isoform of PDK1, integrin-linked 
kinase (ILK) and AKT itself (Hers et al., 2011). Once phosphorylated, AKT can interact with 
different substrates in either the cytoplasm or the nucleus. 
The regulation of AKT function is a highly complex process. It requires the phosphorylation of 
other residues on AKT as well as different types of PTM, for instance acetylation, ubiquitination 
and glycosylation. It has been suggested that these PTMs modulate AKT’s activity, specificity and 
movement inside cells. Cells also have the means to deactivate AKT. As mentioned previously, 
PTEN can interfere with PIP3 formation, which is an upstream activator of AKT. Src homology 
domain 2 (SH2)-containing inositol phosphatase (SHIP) also interferes with PIP3 formation, which 
could be labelled as an indirect mechanism to deactivate AKT by reducing its phosphorylation 
rate. However, there are proteins, such as protein phosphatase 2A (PP2A) and PH-domain 
leucine-rich repeat protein phosphatases (PHLPPs), which are capable of dephosphorylating AKT 







Figure 6.1 Overview of the structure and activation of AKT.  
AKT activation depends mainly on the action of several kinases, such as RTK, PIK3 and PDK1. Two sites 
need to be phosphorylated in order to achieve the fully activated state. Once activated, AKT can interact 
with a vast number of substrates to control various biological functions.  
Abbreviations: IGF-1: Insulin-like growth factor 1; RTK: receptor tyrosine kinase; GPCR: G protein-coupled 
receptor; PIP2: Phosphatidylinositol 4,5-bisphosphate or PtdIns(4,5); PIP3: Phosphatidylinositol (3,4,5)-
triphosphate; PIK3: Phosphatidylinositol-4,5-bisphosphate 3-kinase; PTEN: Phosphatase and tensin 






6.1.3 AKT downstream 
A number of AKT targets that are relevant to mitochondria and PD were investigated in this 
chapter. They are briefly overviewed below.  
CREB 
cAMP response element binding (CREB) is a transcription factor that is implicated in diverse brain 
functions. It consists of multiple domains that enable it to dimerise and bind to either DNA or other 
transcriptional complexes (Sakamoto et al., 2011). CREB is activated when the Ser133 residue 
in its kinase-inducible domain (KID) is phosphorylated (Wen et al., 2010). Activated CREB binds 
to the KID-interacting domain (KIX) or CREB-binding domain in the p300-CBP coactivator family, 
which enables the induction of CREB-mediated transcription (Wen et al., 2010). 
Besides its role in the synthesis of proteins that regulate neuronal plasticity and memory formation 
(Barco and Marie, 2011) (Kandel, 2012), CREB is involved in neuronal development and survival. 
It has been previously reported that the cortical expression of dominant negative CREB (CREB 
S133A) results in significant neurodegeneration in adult mice (Ao et al., 2006). CREB protects 
neurons against ROS, as it enhances the expression of antioxidant genes such as HMOX1 (Lee 
et al., 2009). In a recent study, hydrocortisone significantly increased Parkin expression and 
protected cells against oxidative stress in a CREB-dependent manner. Remarkably, knocking out 
endogenous CREB abolished the hydrocortisone-mediated Parkin induction and consequent 
protection (Ham et al., 2017). 
mTOR 
mTOR is a serine/threonine protein kinase that regulates multiple cellular functions, for instance 
gene transcription and translation, metabolism, proliferation and survival (Saxton and Sabatini, 
2017). mTOR is present in cells within two distinct complexes, mTORC1 and mTORC2. AKT has 
been reported to activate mTOR via direct phosphorylation at serine 2448, although it has been 
proposed that this phosphorylation is achieved indirectly via a positive feedback loop downstream 
of mTOR involving the ribosomal protein S6 kinase beta-1 (S6K1) (also known as p70S6 
kinasep70S6 kinase) (Chiang and Abraham, 2005). AKT also activates mTORC1 via 
phosphorylating tuberous sclerosis complexes (TSC) 1 and 2 (Inoki et al., 2002). The resulting 
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inactivation of TSC1/2 leads to an increase in the concentration of Ras homolog enriched in the 
brain (RHEB), the main activator of mTORC1. 
Neurotoxins that are commonly used in modelling PD such as MPTP and 6-OHDA were 
associated with reduced mTOR signaling in mice DA nerons (Malagelada et al., 2008, Rieker et 
al., 2011, Bockaert and Marin, 2015). By contrast, increased mTORC activity is protective in 
stressed DA neurons (Choi et al., 2010, Kim et al., 2012). In addition, it has been reported that 
the activation of mTOR signalling in toxin-treated DA neurons can promote the regeneration of 
axons (Kim et al., 2012, Kim et al., 2011).  
FOXO1 
FOXO1 belongs to the forkhead box O (FOXO) family of transcription factors that functions in 
various intracellular processes, including apoptosis, oxidative stress, cell cycle and metabolism 
(Golson and Kaestner, 2016). The activation of AKT results in its translocation into the nucleus, 
where it phosphorylates FOXO1 at three conserved residues (Thr24, Ser256 and Ser319) 
(Xiangshan et al., 2004). This phosphorylation drives the binding of FOXO1 to the 14-3-3 
regulatory protein and consequently inhibits FOXO1, as it becomes localised in the cytoplasmic 
region of the cell (Eijkelenboom and Burgering, 2013). When cells are stressed, the activation of  
JNK overrides the effect of AKT and dissociates FOXO1 from the 14-3-3 regulatory protein 
(Eijkelenboom and Burgering, 2013). Nonetheless, the regulation of FOXO is complex as various 
other signalling pathways and PTM are involved. 
Although the activation of AKT is cytoprotective, the consequent inhibition of FOXO1 seems to 
be disadvantageous to cells. FOXOs are considered an important determinant in human ageing 
and longevity (Martins et al., 2016). It has been suggested that FOXOs regulate ageing and age-
related disorders by increasing the antioxidant capacity of cells, depending on posttranslational 
modifications (Storz and signaling, 2011). In line with this, FOXO1 levels are positively correlated 
with ageing in the human brain (Hwang et al., 2018). The protective role of this upregulation has 
been demonstrated in FOXO1 knockout mice, which display accelerated age-associated axonal 




Hexokinase is a constitutively active kinase that facilitates the first reaction of glucose metabolism 
(Irwin and Tan, 2014). Hexokinase phosphorylates glucose into glucose-6-phosphate (G6P), 
which serves as a glycolysis precursor (Irwin and Tan, 2014). Hexokinase ll maintains close 
contact with mitochondria through binding to the mitochondrial outer membrane protein VDAC 
(Pastorino and Hoek, 2008), which couples glycolysis to oxidative phosphorylation. 
Mitochondrion-bound hexokinase has preferential access to the generated ATP, which is used to 
phosphorylate glucose molecules (Roberts and Miyamoto, 2015). An increased amount of G6P 
in turn inhibits hexokinase-mitochondrion binding (Roberts and Miyamoto, 2015). In addition, such 
binding can be prevented via the phosphorylation of VDAC by GSK3β (Sutherland, 2011). When 
AKT is activated, it inhibits GSK3β via phosphorylation and thus indirectly increases mitochondrial 
hexokinase ll binding (Manning and Toker, 2017). It has also been reported that AKT directly 
phosphorylates hexokinase ll at Thr473 and facilitates mitochondrion-hexokinase binding 
(Roberts et al., 2013).  
6.1.4 Objectives 
The first objective of this chapter is to to determine if UDCA treatment can lead to increase AKT 
phosphorylation in CHO cells. The second objective is to assess if UDCA treatment can lead to 
increase AKT phosphorylation in CCCP-stressed SH-SY5Y cells, in which UDCA exerted a 
cytoprotective effect. The third objective is to investigate the role of AKT activation in the UDCA-
mediated effect, which will be determined via the use of an AKT inhibitor. To determine if the 
mitochondrial rescue effect of UDCA is mediated via direct interaction between the mitochondria 
and either the AKT or its downstream protein, the hexokinase, the translocation of AKT and 
hexokinase into mitochondria will be examined through cellular fractionation. Finally, the effect of 
UDCA treatment on phosphorylated and total CREB, mTOR and FOXO1 will be assessed via WB 





6.2 Determining the ability of UCA and UDCA to activate AKT in CHO 
cells 
6.2.1 Testing AKT antibodies and IGF as a positive control in CHO cells 
The level of AKT activation within cells is positively correlated with the ratio of (phos) AKT to (total) 
AKT. To assess AKT phosphorylation, we performed ICC and probed the CHO cells with (phos) 
AKT, as described in the methods chapter [Heading 2.5]. Parallel wells matching each treatment 
condition were prepared and probed with (total) AKT antibody. In addition, the ratio between 
(phos) AKT intensity and (total) AKT intensity was used as an indicator of AKT activation.  
Prior to starting UCA and UDCA treatment experiments, the specificity of the AKT antibodies was 
assessed through the application of various controls, including isotype control and (phos) AKT 
blocking peptide [Figure 6.2]. The isotype control is an antibody of the same class and host as 
the primary antibody that lacks specificity to the target. Therefore, it reveals the non-specific 
interactions of the immunoglobulin with the sample. The utilised (phos) AKT and (total) AKT 
antibodies were both rabbit IgG and applied at different concentrations. The results show that the 
corresponding concentrations of the isotype produced minor signals in ICC [Figure 6.2 a]. 
The (phos) AKT blocking peptide was also used to confirm that the (phos) AKT antibody is highly 
specific. The (phos) AKT blocking peptide resembles the epitope recognised by the primary 
(phos) AKT antibody. Pre-incubation of the (phos) AKT blocking peptide with the (phos) AKT 
antibody should block the targeting site of the (phos) AKT antibody. Consequently, no signals 
should be detected when ICC is performed unless the (phos) AKT antibody has an element that 
binds non-specifically.  
The results show that the use of (phos) AKT blocking peptide significantly decreased the detected 
signals [Figure 6.2 a (III)] in comparison to (phos) AKT probing of untreated cells [Figure 6.2 b 
(I)], indicating high specificity of the (phos) AKT antibody. Non-specific binding of the secondary 
antibody was also tested and found to be insignificant [Figure 6.2 a (IV)]. 
As expected, treating the cells with IGF significantly increased the intensity of (phos) AKT but not 
of (total) AKT, which implies increased AKT activation [Figure 6.2 b]. Taken together, these results 




Figure 6.2 pilot test of AKT antibodies and IGF as a positive control in CHO cells. 
 (a) Representative images of the conditions used to assess the specificity of the AKT antibodies. Cells in 
(l) and (ll) were probed with the isoantibodies, cells in (lll) were probed with the (phos) AKT antibody mixed 
with (phos) AKT blocking peptide, and cells in (lV) were probed only with the secondary antibody. All images 
show signals with low intensities, indicating high specificity of the AKT antibodies. (V–Vlll) show nuclei 
under the corresponding conditions. (b) Assessment of IGF as a positive control revealed a significant 
increase in (phos) AKT intensity (ll) in comparison to the untreated condition (l). As expected, the intensity 
of (total) AKT remained unchanged (lll and lV). (V–Vlll) show nuclei under the corresponding conditions. (c) 
Analysis of ICC images. The images were captured by confocal microscopy, as described in the method 
section. The error bars represent the SD of the data, obtained from five random fields per cover slip. Scale 
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6.2.2  Assessing the effect of UCA and UDCA on AKT activation in CHO cells 
CHO cells were treated following the treatment protocol that was previously used in the ARE 
experiments [Heading 4.2.1]. Although UCA and UDCA treatment increased the expression of 
ARE [Figure 4.5], it seems that this increase is not associated with activation of AKT. Analysis of 
images obtained via confocal microscopy revealed a significant increase in the (phos) AKT / (total) 
AKT ratio when the cells were treated with IGF (25%) but no increase was observed with UCA 
and UDCA treatment [Figure 6.3]. 
 
Figure 6.3 UCA and UDCA treatments did not induce significant effects on AKT phosphorylation in 
unstressed CHO cells. 
 Analysis of (phos) AKT (a) and (total) AKT (b) images obtained via confocal microscopy. (c) AKT activation 
levels were calculated as the ratio between (phos) AKT and (total) AKT. The cells were treated with 10 µM 
UCA and 10 µM UDCA for 24 hours in serum-free culture medium. IGF (100nM) was applied for 10 minutes 
before the fixation process. IGF significantly activated AKT but no effect was seen with UCA and UDCA 
treatment. ICC and imaging were performed as described in the methods section. The error bars represent 
the SD of three independent experiments. In each experiment, at least 20 fields per condition were captured 





6.3 Determining the ability of UDCA to activate AKT in SH-SY5Y cells 
6.3.1 Optimisation experiments 
In the previous chapter, the positive effect of UDCA on ATP and cytotoxicity was only observed 
at a high UDCA concentration (300 µM). Therefore, we decided to investigate the ability of UDCA 
to activate AKT using the exact treatment protocol of that experiment.  
However, while the ATP/cytotoxicity experiments were performed in regular culture medium, the 
AKT experiments in this chapter were performed in serum-free medium. Serum contains various 
types of growth factors and cytokines that might induce negative feedback mechanisms and 
render cells unable to respond to an exogenous activator. In addition, serum starvation 
synchronises cells to arrest at the G0 phase, which decreases variability in AKT activation level, 
which varies according to cell cycle stage (Liu et al., 2014).  
Accordingly, we chose to assess the effect of increasing concentrations of serum on AKT 
activation in unstimulated and IGF-stimulated cells prior to the drug treatment experiments. 
Unexpectedly, the results show that the addition of serum had no significant effect on basal levels 
of (total) AKT and (phos) AKT [Figure 6.4]. Additionally, IGF-stimulated cells revealed that the 
level of AKT activation was not significantly dependent of the concentration of the serum in the 
culture medium. Taken together, these results confirm that AKT activation can be assessed in 







Figure 6.4 The addition of serum to the culture medium has no effect on IGF-mediated AKT 
activation. 
 (a, b and c) Representative images obtained via confocal microscopy showing the effect of IGF treatment 
on AKT phosphorylation in SH-SY5Y cells grown in culture medium with 0% FBS (a), 5% FBS (b) and 10% 
FBS (c). The SH-SY5Y cells were also treated with IGF (100 nM) for 10 minutes prior to the fixation process. 
ICC and imaging were performed as described in the methods section. The cells were probed either with 
(phos) AKT or (total) AKT (both in yellow) and co-stained with Hoechst (in blue). Analysis of (phos) AKT (d) 
and (total) AKT (e) images shows that the addition of serum to the culture medium did not affect the basal 
AKT phosphorylation level nor alter the response to IGF treatment. (f) AKT activation levels ((phos) AKT / 
(total) AKT). The error bars represent the SD of three technical replicates. In each replicate, at least 25 
fields per condition were captured and the average of the intensity measures was used as a readout. ** p 




























CCCP-stressed cells were easily detached from the well floor during the washing steps in ICC, 
which made ICC an unsuitable technique for this experiment. We therefore decided to use WB to 
assess AKT activation as an alternative. The AKT antibodies used in ICC were also reliable in 
WB [Figure 6.5]. Assessing the levels of AKT activation in CCCP-stressed cells revealed 
significantly higher basal readings in comparison to the unstressed cells (700%). This probably 
attributed to the stimulation of the survival pathway in stressed cells, which is mainly dependent 
on the activation of the AKT pathway. The IGF-induced activation of AKT was observed in 
unstressed (380%) and – to a much lesser extent (60%) with more variability – in CCCP-stressed 
cells [Figure 6.5]. 
 
Figure 6.5 The AKT antibodies are usable in western blotting experiments. 
 (a) WB images showing increased levels of (phos) AKT after treatment with IGF in both unstressed and 
stressed cells. (b), (c) Densometric analysis of (phos) AKT and (total) AKT WB images. (d) AKT activation 
levels calculated as the ratio between (phos) AKT and (total) AKT. The cells were treated with IGF (100 nM) 
for 10 minutes. WB and imaging were performed as described in the methods section. The cells were 
probed with (phos) AKT antibody (mouse), and then the membrane was stripped and re-probed with (total) 
AKT (rabbit). The error bars represent the SD of three independent experiments. * p < 0.05, ** p < 0.01, 





6.3.2  Drug treatment experiments 
The SH-SY5Y cells were stressed and treated following the protocol used in the previous chapter 
[Figure 5.4]. In addition to the condition found to improve ATP and cytotoxicity (300 µM UDCA for 
24 hours with 12 hours of pre-treatment), a lower concentration of UDCA (10 µM) was added in 
order to check whether AKT activation was present in conditions that were not associated with a 
cytoprotective effect [Figure 6.6]. This could   indicate that AKT activation is not the driver of the 
observed rescue effect. UDCA was also applied for shorter periods to detect transient AKT 
activation (if present). While AKT activation was not significantly increased under these new 
conditions, the results showed a significant increase in AKT activation (85%) when the stressed 




Figure 6.6 300 µM UDCA significantly increased AKT phosphorylation in CCCP-stressed SH-SY5Y 
cells (western blot images). 
 WB images show an increased level of (phos) AKT after treatment with 300 µM UDCA for 24 hours. The 
cells were pre-treated with UDCA for 12 hours before the addition of 50 µM CCCP, which was kept for 24 
hours. For the 10-minute treatment conditions, the cells were pre-treated with the vehicle for 12 hours 
before the addition of 50 µM CCCP, which was applied for 24 hours, and the drug was applied 10 minutes 
prior to collecting the cells for WB. WB and imaging were performed as described in the methods section. 
The cells were probed with (phos) AKT antibody (mouse), and then the membrane was stripped and re-




Figure 6.7 300 µM UDCA significantly increased AKT phosphorylation in CCCP-stressed SH-SY5Y 
cells (data analysis).  
(a), (b) Densometric analysis of (phos) AKT and (total) AKT WB images. (c) AKT activation levels calculated 
as the ratio between (phos) AKT and (total) AKT. The cells were pre-treated with UDCA for 12 hours before 
the addition of 50 µM CCCP, which was kept for 24 hours. For the 10-minute treatment conditions, the cells 
were pre-treated with the vehicle for 12 hours before the addition of 50 µM CCCP, which was kept for 24 
hours, and the drug was applied 10 minutes prior to collecting the cells for WB. The graphs show significant 
activation of AKT in CCCP-stressed cells treated with 300 µM UDCA (24 hours). WB and imaging were 
performed as described in the methods section. The error bars represent the SD of three independent 






6.4 Investigating the role of AKT activation in the UDCA-mediated 
rescue effect in SH-SY5Y cells 
The rescue effect of UDCA in CCCP-stressed SH-SY5Y cells was associated with significant AKT 
activation. To examine whether the rescue effect is dependent on the activation of AKT, we 
decided to repeat the experiment in cells in which AKT was pharmacologically inhibited via the 
use of triciribine, a selective inhibitor of AKT phosphorylation. Upon testing, triciribine was able to 
inhibit IGF-induced AKT phosphorylation in unstressed and CCCP-stressed cells [Figure 6.8]. 
As expected, triciribine significantly reduced AKT activation in CCCP-stressed cells that were 
treated with UDCA [Figure 6.8]. Consequently, ATP and cytotoxicity assays were performed with 
the application of triciribine. On examination with an optic microscope, it appeared that the rescue 
effect of UDCA was not eliminated upon the addition of triciribine [Figure 6.9 a]. Equally, 
cytotoxicity assessment showed that the reduction in cytotoxicity induced by UDCA was not 
altered when the triciribine was applied [Figure 6.9 b]. On the other hand, triciribine significantly 
reduced ATP levels in UDCA-treated cells to match those of untreated controls [Figure 6.9 c]. 
e to untreatedThe application of triciribin  cells resulted in a decrease in ATP levels but did not 
affect their viability.  
These findings demonstrate that the rescue effect of UDCA is not entirely dependent on the AKT 
pathway. They also support a direct relation between AKT and mitochondria. Accordingly, in the 




Figure 6.8 Triciribine treatment inhibited AKT phosphorylation in UDCA/IGF treated cells. 
 (a) WB images demonstrating the effect of triciribine on AKT phosphorylation in SH-SY5Y cells treated 
with UDCA and IGF. The cells were pre-treated with 300 µM UDCA and 0.5 µM triciribine for 12 hours 
before the addition of 50 µM CCCP, which was applied for 24 hours. IGF (100mM) was applied for 10 
minutes prior to the collection of the cells. WB and imaging were performed as described in the methods 
section. The cells were probed with (phos) AKT antibody (mouse) and then the membrane was stripped 
and re-probed with (total) AKT (rabbit). The images show that triciribine significantly inhibited AKT 
phosphorylation in IGF- and UDCA-treated cells (under CCCP conditions). (b), (c) Densometric analysis of 
(phos) AKT and (total) AKT WB images. (d) AKT activation levels calculated as the ratio between (phos) 
AKT and (total) AKT. The error bars represent the SD of three independent experiments. * p < 0.05, two-







Figure 6.9 AKT inhibition abolished the UDCA-mediated rescue effect on ATP level in CCCP-
stressed SH-SY5Y cells. 
 (a) Optic microscopy images of treated SH-SY5Y cells with and without triciribine (all stressed with CCCP). 
Red arrows point to some healthy-looking cells, which were not present under the untreated/vehicle 
conditions. The healthy-looking cells were seen under UDCA conditions regardless of the presence or 
absence of triciribine. The cells were pre-treated with 300 µM UDCA and 0.5 µM triciribine for 12 hours 
before the addition of 50 µM CCCP, which was applied for 24 hours. (b), (c) Cytotoxicity and ATP levels 
under different treatment conditions. Triciribine did not affect the cytotoxicity level of UDCA-treated cells 
(a). However, it abolished the UDCA-mediated effect on ATP level (b). The error bars represent the SD of 





6.5 Investigating AKT translocation into the mitochondria in UDCA-
treated SH-SY5Y cells 
6.5.1 Cellular fractionation 
To assess the efficiency of the fractionation protocol that was used to extract the mitochondrion-
enriched fraction, an untreated sample was fractionated and probed with various mitochondrial 
and cytoplasmic markers. The results demonstrated significant enrichment of the mitochondrial 
fraction with mitochondrion-specific proteins (Tom20, Tim23 and NDUFS2) [Figure 6.10 a]. 
While equal amounts of protein were loaded into the gel for WB (12µg), the mitochondrial fraction, 
in comparison to the total lysate, displayed an increase of approximately 400% in the amount of 
Tom20, 650% for Tim23, and 7000% for NFUFS2 [Figure 6.10 (b), (c) and (d)]. On the other hand, 
the obtained cytoplasmic fraction showed an approximately 90% decrease in its amount of Tom20 
in comparison to the total lysate, 50% less Tim23, and 30% less NFUFS2 [Figure 6.10 (b), (c) 
and (d)]. 
As expected, this picture was inverted upon probing the membranes for cytoplasmic proteins (β-
actin, α-tubulin and GAPDH). The mitochondrial fraction showed an approximately 60% decrease 
in its amount of β-actin relative to the total lysate, 60% less α-tubulin, and 45% less GAPDH 
[Figure 6.10 (e), (f) and (g)]. Conversely, in comparison to the total lysate, the extracted 
cytoplasmic fraction had an approximately 55% increased amount of β-actin, 25% more α-tubulin, 
and 20% more GAPDH [Figure 6.10 (e), (f) and (g)]. 









Figure 6.10 The fractionation protocol proved to be efficient in producing mitochondrial enriched 
extracts. 
 (a) WB images of fractionated untreated samples probed with various mitochondrial and cytoplasmic 
markers. Following the BSA assay, equal protein quantities (12µg) from the total lysate, mitochondrial 
fraction and cytoplasmic fraction were loaded into the gel to allow direct comparison. WB and imaging were 
performed as described in the methods section. The images show significant enrichment of mitochondrial 
proteins in the extracted mitochondrial fraction. The lower panel shows the results of WB image 
quantification of (b) Tom20, (c) Tim23, (d) NDUFA2, (e) β-actin, (f) α-tubulin, and (g) GAPDH. The graphs 
represent the data from a pilot WB experiment. 
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6.5.2 The effect of UDCA on AKT translocation into the mitochondria in SH-SY5Y 
cells 
As performed in the previous chapter [Figure 5.4], the SH-SY5Y cells were pre-treated with 
300 µM UDCA for 12 hours before the addition of 50 µM CCCP, which was applied for 24 hours. 
IGF (100 nM) was applied as a positive control for 10 minutes before collecting the cells for the 
fractionation process. Prior to probing the blotted fractionated samples with AKT antibodies, 
Tom20 and β-actin antibodies were applied to confirm that the fractionation was successful 
[Figure 6.11, Figure 6.12]. WB images of the total lysate showed that the cells responded to IGF 
treatment, with a significant increase in AKT phosphorylation [Figure 6.11]. WB images reveal 
that the expression of AKT in the mitochondrial fraction was remarkably low relative to the other 
compartments.  
 
Figure 6.11 Fractionation of treated SH-SY5Y cells (unstressed). 
 (a) WB images of treated samples probed with β-actin, Tom20, (phos) AKT and (total) AKT (all unstressed). 
The images show no increase in mitochondrial (phos) AKT or (total) AKT upon UDCA treatment. WB and 
imaging were performed as described in the methods section. (b), (c) WB image quantification of β-actin 
and Tom20 confirm successful fractionation of all treated conditions. The graphs represent the data from 
three independent experiments.  
a)  




Figure 6.12 Fractionation of treated SH-SY5Y cells (CCCP-stressed). 
 WB images of treated samples probed with β-actin, Tom20, (phos) AKT and (total) AKT (all stressed with 
CCCP). The images show no increase in mitochondrial (phos) AKT or (total) AKT upon UDCA treatment. 
WB and imaging were performed as described in the methods section. (b), (c) WB image quantification for 
β-actin and Tom20 confirmed successful fractionation of all treated conditions. The graphs represent the 
data from three independent experiments.  
a)  
b)  c)  
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Quantification of WB images of the mitochondrial fractions reveals that UDCA treatment increased 
the amount of (total) AKT and (phos) AKT in CCCP-stressed cells [Figure 6.13]. However, the 
increase was not significant due the variability between the replicate. 
 
 
Figure 6.13 UDCA treatment did not induce a significant change in the expression of AKT in the 
mitochondrial fraction of SH-SY5Y cells. 
 (a) and (b) show the results of WB image quantification for (phos) AKT and (total) AKT in mitochondrial 
fractions of unstressed and CCCP-stressed cells. Raw intensity readings for (phos) AKT and (total) AKT 
were normalised against the corresponding Tom20 readings. UDCA increased mitochondrial (phos) AKT 
and (total) AKT but this increase was associated with significant variability between the replicates. (c) AKT 
activation levels calculated as the ratio between (phos) AKT and (total) AKT. The graphs represent the data 









In the cytoplasm, UDCA treatment increased (phos) AKT level but had no effect on (total) AKT 
level [Figure 6.14]. the  Again, the increase was not significant due the variability between
together, it is difficult to conclude that AKT translocates into mitochondTaken . eplicatesr ria as a 
result of UDCA treatment in CCCP-stressed SH-SY5Y.  
 
  
Figure 6.14 UDCA treatment did not induce a significant change in the expression of AKT in the 
cyoplasmic fraction of SH-SY5Y cells.  
(a) and (b) show the results of WB image quantification for (phos) AKT and (total) AKT in the cytoplasmic 
fractions of unstressed and CCCP-stressed cells. Raw intensity readings for (phos) AKT and (total) AKT 
were normalised against the corresponding Tom20 readings. UDCA increased cytoplasmic (phos) AKT but 
this increase was associated with significant variability between the replicates. (c) AKT activation levels 
calculated as the ratio between (phos) AKT and (total) AKT. The graphs represent the data from three 
independent experiments.




Investigating the effect of UDCA on AKT downstream targets in SH-
SY5Y cells 
In this set of experiments, UDCA treatment was performed on SH-SY5Y cells following the 
previously used protocol that was associated with significant rescue effect (pre-treatment with 
300 µM for 12 hours followed by 24 hours’ treatment with 50 µM CCCP) [Figure 5.4]. The 
assessment was performed using two techniques, WB and ICC. The application of CCCP was 
reduced to six hours in plates for ICC to prevent the detachment of cells during the washing steps. 
The cells were probed with antibodies against the total and phosphorylated forms of the targets 
simultaneously because the antibodies were raised in different species (mouse, rabbit). In WB, 
the membrane was probed with the (phos) antibody, stripped and then probed with the (total) 
antibody. WB and ICC were conducted as described in the methods section.  
6.6.1 Assessing the effect of UDCA on CREB phosphorylation  
WB results show that the phosphorylation of CREB was significantly lower in CCCP-stressed SH-
SY5Y cells (an 85% decrease) [Figure 6.15]. H s treatment cowever, variou conditions with UDCA 
failed to increase CREB phosphorylation in either unstressed or stressed cells [Figure 6.15]. 
Equally, WB results showed that IGF treatment was not associated with an increase in CREB 
phosphorylation. The 85% decrease in CREB phosphorylation in the untreated stressed cells was 
not observed in the ICC results [Figure 6.17]. The response of the cells to UDCA and IGF 





Figure 6.15 UDCA treatment had no significant effect on CREB phosphorylation in CCCP-stressed 
SH-SY5Y cells (via western blotting). 
 (a) WB images showing the expression levels of (phos) CREB and (total) CREB under different treatment 
conditions. The cells were pre-treated with UDCA for 12 hours before the addition of 50 µM CCCP, which 
was applied for 24 hours. For the 10-minute treatment conditions, the cells were pre-treated with the vehicle 
for 12 hours before the addition of 50 µM CCCP, which was applied for 24 hours, while the drugs were 
applied 10 minutes prior to collecting the cells for WB. WB and imaging were performed as described in 
the methods section. The cells were probed with (phos) CREB antibody (rabbit) and then the membrane 
was striped and re-probed with (total) CREB (mouse) antibody. The lower panel shows the results of WB 
image analysis for (b) (phos) CREB and (c) (total) CREB. (d) CREB activation levels calculated as the ratio 
between (phos) CREB and (total) CREB. The graphs show that all UDCA treatment conditions had no effect 
on CREB phosphorylation. The graphs represent the data from three independent experiments. ** p < 0.01, 







Figure 6.16 Immunocytochemistry images of UDCA-treated SH-SY5Y cells probed with 
phosphorylated and total CREB antibodies. 
 These are representative images obtained via confocal microscopy showing CREB staining in unstressed 
(a) and CCCP-stressed cells (b). The images show no difference between the vehicle and UDCA-treated 
conditions. The cells were probed with Hoechst (in blue (I, V)), (phos) CREB (in yellow (II, VI)) and (total) 
CREB (in green (III, VII)). (c) shows background signalling in cells that were probed with only the secondary 






Figure 6.17 UDCA treatment had no significant effect on CREB phosphorylation in CCCP-stressed 
SH-SY5Y cells (via immunocytochemistry). 
 Analysis of (phos) CREB (a) and (total) CREB (b) images obtained via confocal microscopy. (c) AKT 
activation levels calculated as the ratio between (phos) AKT and (total) AKT. The cells were pre-treated 
with UDCA for 12 hours before the addition of 50 µM CCCP, which was applied for 6 hours. For the 10-
minute treatment conditions, the cells were pre-treated with the vehicle for 12 hours before the addition of 
50 µM CCCP, which was applied for 6 hours, while the drug was applied 10 minutes prior to the fixation 
process. The graphs show that all UDCA treatment conditions had no effect on CREB phosphorylation. ICC 
and imaging were performed as described in the methods section. The error bars represent the SD of three 
independent experiments. In each experiment, at least 20 fields per condition were captured, and the 
average of the intensity readings was used as a readout. ** p < 0.01, two-way ANOVA test. 
 
6.6.2 Assessing the effect of UDCA on mTOR phosphorylation  
Analysis of WB images of (phos) mTOR and (total) mTOR showed no significant difference 
between the unstressed and stressed conditions [Figure 6.18]. No treatment condition had any 
significant effect on (total) mTOR levels or mTOR phosphorylation [Figure 6.18]. Similar findings 
were observed in ICC results [Figure 6.19, Figure 6.20], except for a minor – but statistically 
significant – decrease in the mTOR phosphorylation ratio in stressed cells in comparison to 
unstressed ones [Figure 6.20 c]. However, this decrease was due to an increase in the intensity 






Figure 6.18 UDCA treatment had no significant effect on mTOR phosphorylation in CCCP-stressed 
SH-SY5Y cells (via western blotting). 
 (a) WB images showing the expression levels of (phos) mTOR and (total) mTOR under different treatment 
conditions. The cells were pre-treated with UDCA for 12 hours before the addition of 50 µM CCCP, which 
was applied for 24 hours. For the 10-minute treatment conditions, the cells were pre-treated with the vehicle 
for 12 hours before the addition of 50 µM CCCP, which was applied for 24 hours, while the drugs were 
applied 10 minutes prior to collection of the cells for WB. WB and imaging were performed as described in 
the methods section. The cells were probed with (phos) mTOR antibody (rabbit) and then the membrane 
was striped and re-probed with (total) mTOR (mouse) antibody. The lower panel shows the results of WB 
image analysis for (b) (phos) mTOR and (c) (total) mTOR. (d) mTOR activation levels calculated as the 
ratio between (phos) mTOR and (total) mTOR. The graphs show that all UDCA treatment conditions had 








Figure 6.19 Immunocytochemistry images of UDCA-treated SH-SY5Y cells probed with 
phosphorylated and total mTOR antibodies. 
 Representative images obtained via confocal microscopy showing mTOR staining in unstressed (a) and 
CCCP-stressed cells (b). The images show no difference between the vehicle and the UDCA-treated 
conditions. The cells were probed with Hoechst (in blue (I, V)), (phos) mTOR (in yellow (II, VI)) and (total) 
mTOR (in green (III, VII)). (c) shows background signalling in cells that were probed only with the secondary 





Figure 6.20 UDCA treatment had no significant effect on mTOR phosphorylation in CCCP-stressed 
SH-SY5Y cells (via immunocytochemistry). 
 Analysis of (phos) mTOR (a) and (total) mTOR (b) images obtained via confocal microscopy. (c) mTOR 
activation levels calculated as the ratio between (phos) mTOR and (total) mTOR. The cells were pre-treated 
with UDCA for 12 hours before the addition of 50 µM CCCP, which was applied for 6 hours. For the 10-
minute treatment conditions, the cells were pre-treated with the vehicle for 12 hours before the addition of 
50 µM CCCP, which was applied for 6 hours, while the drug was applied 10 minutes prior to the fixation 
process. The graphs show that all UDCA treatment conditions had no effect on mTOR phosphorylation. 
ICC and imaging were performed as described in the methods section. The error bars represent the SD of 
three independent experiments. In each experiment, at least 20 fields per condition were captured, and the 
average of the intensity readings was used as a readout. ** p < 0.01, two-way ANOVA test. 
 
6.6.3 Assessing the effect of UDCA on FOXO1 phosphorylation  
In initial testing experiments, no bands were observed upon probing WB membranes with (total) 
FOXO1 antibody. (total) FOXO1 bands were only observed when the WB protocol was optimised 
by doubling both the loading quantity of the sample (40µg/lane) and the concentration of the 
applied (total) FOXO1 antibody (1:500 titre) [Figure 6.21]. 
In ICC, (total) FOXO1 signals (unlike (phos) FOXO1) were remarkably weak, close to the level of 
the background, despite trials of various concentrations [Figure 6.22]. Therefore, it was decided 
to omit ICC for drug treatment experiment for FOXO1. The assessment of the drug treatment 
experiment by WB showed variable results and it was difficult to establish any significant 






Figure 6.21 UDCA treatment had no significant effect on FOXO1 phosphorylation in CCCP-stressed 
SH-SY5Y cells (via western blotting) . 
 (a) WB images showing the expression levels of (phos) FOXO1 and (total) FOXO1 under different 
treatment conditions. Cells were pre-treated with UDCA for 12 hours before the addition of 50 µM CCCP, 
which was applied for 24 hours. For the 10-minute treatment conditions, the cells were pre-treated with the 
vehicle for 12 hours before the addition of 50 µM CCCP, which was applied for 24 hour, while the drugs 
were applied 10 minutes prior to collection of the cells for WB. WB and imaging were performed as 
described in the methods section. The cells were probed with (phos) FOXO1 antibody (rabbit) and then the 
membrane was striped and re-probed with (total) FOXO1 (mouse) antibody. The lower panel shows the 
results of WB image analysis for (b) (phos) FOXO1 and (c) (total) FOXO1. (d) FOXO1 inhibition levels 
calculated as the ratio between (phos) FOXO1 and (total) FOXO1. The graphs show variable results and it 
is difficult to assert if UDCA treatment had an effect on FOXO1 phosphorylation The graphs represent the 








Figure 6.22 Total FOXO1 antibody is not effective in immunocytochemistry experiments. 
 (a) ICC images of various dilutions of (phos) FOXO1 antibody (in yellow, l–lll) and corresponding Hoechst 
staining (in blue, lV–Vl). (b) ICC images of various dilutions of (total) FOXO1 antibody (in green, l–lll) and 
corresponding Hoechst staining (in blue, lV–Vl). (c) Analysis of (phos) FOXO1 and (total) FOXO1 images 
obtained by confocal microscopy. The images and the graphs indicate that the (total) FOXO1 antibody is 
not reliable for detecting (total) FOXO1 in cells. The right panels show background signalling in cells that 
were probed only with the secondary antibodies. The graphs represent the data from a sinle pilot 
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6.6.4 Assessing the effect of UDCA on the mitochondrial hexokinase level  
Following drug treatment, mitochondrion-enriched fractions were obtained using the fractionation 
protocol described in the methods chapter [Heading 2.11]. Evaluation of this protocol was 
previously performed [Heading 6.5.1]. Figure 6.23 shows WB membranes of treated fractionated 
samples probed with hexokinase as well as mitochondrial and cytoplasmic markers.  
 
 
Figure 6.23 Assessing the effect of UDCA on mitochondrial hexokinase content in CCCP-stressed 
SH-SY5Y cells by western blotting. 
 WB images of fractionated unstressed (a) and CCCP-stressed (b) samples probed with mitochondrial 
markers, cytoplasmic markers and hexokinase. The cells were pre-treated with 300 µM UDCA for 12 hours 
before the addition of 50 µM CCCP, which was applied for 24 hours. IGF (100 nM) was applied as a positive 
control for 10 minutes before collection of the cells for the fractionation process. Equal quantities of protein 
(12 µg) from the total lysate, mitochondrial fraction and cytoplasmic fraction were loaded in WB to allow 
direct comparison. The images show successful fractionation of the mitochondrial compartment but UDCA 
treatment did not increase the hexokinase content in the mitochondria fraction. Cellular fractionation, WB 







Analysis of WB images revealed that the amount of hexokinase was approximately three times 
higher in the mitochondrial fraction of stressed cells in comparison to the unstressed cells [Figure 
6.24]. However, neither UDCA nor IGF increased hexokinase levels in the mitochondrial fraction.  
 
 
Figure 6.24 UDCA treatment did not induce a significant change in the expression of hexokinase in 
the mitochondrial fraction of SH-SY5Y cells. 
 The results of WB image analysis for various treatment conditions. UDCA treatment had no effect on 










To assess mitochondrial hexokinase via ICC, cells were co-stained with Tom20 to determine their 
mitochondrial regions. An image analysis protocol was set to calculate hexokinase intensity both 
within the area occupied by mitochondria and in the remaining area of the cell. Consequently, the 
ratio between the hexokinase intensities in the mitochondrial and cytoplasmic regions was used 
as a measure of hexokinase localisation to the mitochondria.  
Analysis of ICC images revealed an increase of approximately 10% in mitochondrial hexokinase 
in stressed cells in comparison to unstressed cells [Figure 6.25, Figure 6.26]. Both WB and ICC 






Figure 6.25 Immunocytochemistry images of UDCA-treated SH-SY5Y cells probed with hexokinase 
and Tom20 antibodies. 
 These are representative images obtained via confocal microscopy showing hexokinase staining (in green 
(I, V)) in unstressed (a) and CCCP-stressed (b) cells. The cells were also co-stained with Tom20 (in yellow 
(III, VII)) to determine mitochondrial regions and Hoechst (in blue (I, V)) to show nuclei. The images show 
that hexokinase areas of high intensities colocalise with mitochondrial areas as indicated by the white 
arrows. (c) shows background signalling in cells that were probed with only the secondary antibodies. Scale 




   
Figure 6.26 UDCA treatment had no significant effect on mitochondrial hexokinase content in CCCP-
stressed SH-SY5Y cells (via immunocytochemistry) . 
 Analysis of hexokinase images obtained via confocal microscopy. The intensity of hexokinase in the 
mitochondrial region is expressed relative to hexokinase intensity in the cytoplasmic region. The graph 
show that mitochondrial hexokinase was significantly increased after the application of CCCP but UDCA 
treatment did not affect its levels. The cells were pre-treated with UDCA for 12 hours before the addition of 
50 µM CCCP, which was applied for 6 hours. For the 10-minute treatment conditions, the cells were pre-
treated with the vehicle for 12 hours before the addition of 50 µM CCCP, which was kept for 6 hours, while 
the drug was applied 10 minutes prior to the fixation process. ICC and imaging were performed as described 
in the methods section. The error bars represent the SD of three independent experiments. In each 
experiment, at least 20 fields per condition were captured, and the average of the intensity readings was 





As mentioned in the introduction chapter [Heading 1.6], AKT and Nrf2 are putative pathways 
through which UDCA exerts its beneficial effects. These two pathways are not considered 
separate entities since AKT regulates Nrf2 activity via one of its downstream targets, GSK3β 
(Manning and Toker, 2017). The suppression of AKT activity is sufficient to abolish Nrf2 activation 
and the subsequent antioxidant effects (Wu et al., 2013, Cui et al., 2016, Ryu et al., 2014). 
Although UDCA and UCA treatments did not rescue mitochondrial function in toxin-stressed CHO 
cells in Chapter 4 [Heading 4.4], they were associated with a small but significant induction of 
ARE expression. Therefore, we planned to determine whether that increase was associated with 
AKT activation. The results in this chapter [Figure 6.3] demonstrated that neither UDCA nor UCA 
were able to activate AKT in CHO cells, even though the treatment protocol was identical to the 
one used in ARE experiments.  
There are several possible explanations for this outcome. First, the observed ARE induction was 
small and it is possible that the AKT activation required to induce this effect is small and beyond 
the detectable level in the experiment performed. Second, AKT activation may have occurred 
transiently following the application of the drugs and become undetectable by the time of ICC. 
Third, it is possible that Nrf2 activation was achieved via AKT-independent mechanisms, since 
GSK3β is a downstream target of other kinases including MAPK (Bryan et al., 2013). Additionally, 
ROS can directly modify subsets of the cysteine residues in Keap1, resulting in a conformational 
change that disturbs the Keap1-Nrf2 interaction and consequently increases the level of Nrf2 in 
the nucleus (Taguchi et al., 2011). The activation mechanism of Nrf2 was discussed in detail in 
Chapter 4 [Heading 4.1.3].  
Because the CHO cell line is not relevant to PD, we decided to conduct the subsequent 
experiments using SH-SY5Y cells. As predicted, the UDCA-mediated rescue effect observed in 
CCCP-stressed cells was associated with a significant increase in AKT activation. Since UDCA 
was used in high doses (300 µM) in the SH-SY5Y cells, it is possible that the doses applied in the 
CHO experiments (10 µM) were insufficient to activate AKT. Further, the discrepancy between 
the results in CHO and SH-SY5Y cells might be attributed to the differences in type and origin of 
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these cells. In addition, the effect of UDCA on AKT activation in CHO cells was only tested in 
unstressed conditions since no rescue effect was observed in toxin-stressed cells. On the other 
hand, AKT activation was triggered in SH-SY5Y cells in association with the rescue effect 
observed in CCCP-stressed cells, suggesting that UDCA-mediated AKT activation might only 
occur as a response to abnormal biological states. In line with this notion, the results in the study 
previously undertaken in the Bandmann group showed clearly that UCA was able to increase 
AKT phosphorylation only in parkin patient fibroblasts and not in healthy control fibroblasts 
(Mortiboys et al., 2013).  
The role of AKT activation in the UDCA-mediated rescue effect was investigated further via the 
use of the AKT inhibitor triciribine. This is a tricyclic nucleoside originally developed as a potential 
anticancer therapy, though it has been also investigated as an antiviral agent against HIV. 
Although initial clinical trials were not promising (Hoffman et al., 1995, Feun et al., 1993), further 
investigation suggested that triciribine could be beneficial against tumours with hyperactivated 
AKT, such as cancers of the breast, ovary and pancreas (Yang et al., 2004, Garrett et al., 2011).  
Within cells, triciribine is phosphorylated into a monophosphate active analogue. This is the active 
form of the compound that interacts with the PH domain of AKT and interferes with its localisation 
to the membrane, consequently preventing AKT phosphorylation and activation (Sampath et al., 
2013). Triciribine is superior to other commonly used AKT inhibitors (for instance LY294002), as 
it directly inhibits AKT phosphorylation (Nitulescu et al., 2016). In contrast, LY294002 is an indirect 
AKT inhibitor that blocks PI3K, which is an upstream of AKT. Moreover, LY294002 mediates 
PI3K-independent events, such as inhibition of NF-κB and Ca2+ signalling (Gharbi et al., 2007), 
which might negatively affect the interpretation of data.  
Unexpectedly, our results uncovered a discrepancy between the cytotoxicity and ATP findings 
when the AKT pathway was inhibited. Triciribine inhibited the UDCA-mediated increase in ATP 
but did not affect cytotoxicity [Figure 6.9]. This observation has not been reported before. In a 
previously published study, the application of triciribine inhibited a UDCA-mediated increase in 
viability in sodium nitroprusside-stressed SH-SY5Y cells (Chun and Low, 2012). However, that 
assessment of viability was performed using the MTT assay, which primarily reflects mitochondrial 
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activity (van Meerloo et al., 2011). Our results suggest that the observed UDCA-mediated rescue 
effect is not entirely dependent on the AKT pathway.  
The mechanism by which UDCA mediates its AKT-independent rescue effect might involve direct 
interaction between UDCA and AKT downstream targets. For example, it has been reported that 
UDCA has high affinity for BAX (a pro-apoptotic protein), and that its binding prevents BAX 
translocation within cells, allowing anti-apoptotic proteins to prevail (Sousa et al., 2015).  
Further, it is possible that UDCA exerts its rescue effect in part via alternative pathways. 
Hepatobiliary system-related study has found that the anti-apoptotic effect of TUDCA involves the 
activation of protein kinase A (PKA) and consequent phosphorylation and inhibition of CD95 (a 
receptor that leads to programmed cell death via the extrinsic pathway of apoptosis (Le Gallo et 
al., 2017, Sommerfeld et al., 2015). Arguably, the mechanism of cell death in the study could be 
irrelevant due to the use of hydrophobic bile acid as an inducer of apoptosis. Nonetheless, reports 
have shown previously that treating cells with a mitochondrial uncoupler such as CCCP also 
enhances the activity of CD95 (Vier et al., 2004).  
Our results show that activation of AKT was associated with an increase in ATP level in CCCP-
stressed SH-SY5Y cells [Figure 6.9]. Therefore, we decided to investigate whether UDCA 
treatment was associated with spatial translocation of AKT into mitochondria. Although this had 
never been assessed in UDCA-treated cells, a previously published study demonstrated that a 
fraction of AKT is inherently present in the mitochondria of SH-SY5Y cells (Bijur and Jope, 2003). 
Specifically, AKT was associated with the inner and outer mitochondrial membranes, while only 
a negligible amount was found in the matrix. More importantly, IGF treatment induced a rapid 
increase in the mitochondrial AKT level, which occurred synchronously with AKT phosphorylation 
in the cytoplasm (Bijur and Jope, 2003). Likewise, our results reveal an increased (total) AKT 
level in the mitochondrial fraction following IGF treatment [Figure 6.13 b]. Although UDCA 
increased (total) AKT content in the mitochondrial fractions of CCCP-stressed cells [Figure 6.13 
b], it is difficult to draw conclusions from this because of the considerable variability between 
replicates. Further research is needed to verify the significance of this increase. 
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The presented work in this chapter supports the assumption that AKT activation plays a significant 
role in the UDCA-mediated rescue effect. Accordingly, the effect of UDCA on AKT downstream 
targets was investigated. The results indicate that UDCA treatment did not affect the 
phosphorylation level of CREB in either unstressed or CCCP-stressed SH-SY5Y cells. The effect 
of UDCA on CREB in CCCP-stressed cells had never been assessed before. However, in biliary 
epithelial cells, TUDCA treatment has previously been reported to activate CREB and protect 
cells from the toxicity of CCI-779 (a specific inhibitor of mTOR) (Wang et al., 2005).  
Notably, the application of CCCP was associated with a significant decrease in CREB 
phosphorylation [Figure 6.15]. Since AKT is significantly activated in CCCP-stressed SH-SY5Y 
cells [Figure 6.5], CREB phosphorylation was expected to increase. In addition, research has 
indicated that CREB can be phosphorylated via the action of AMP-activated protein kinase 
(AMPK) under such conditions (Thomson et al., 2008). Therefore, the decrease in CREB 
phosphorylation reported in this chapter should be interpreted with caution, especially as it was 
observed in WB results and not in ICC results. Further research is needed to verify these findings 
and to investigate the underlying mechanism. Decreased CREB phosphorylation may be 
attributed to several protein phosphatases that are known to dephosphorylate CREB, such as 
serine/threonine protein phosphatase 2A (PP2A) and calcineurin (PP2B) (Johannessen et al., 
2004). 
Similarly, the application of CCCP decreased the level of phosphorylated mTOR in SH-SY5Y 
cells. This decrease was smaller but it was statistically significant and was observed in ICC results 
[Figure 6.20]. Reduced mTOR phosphorylation as a result of CCCP treatment has been assessed 
before, in HEK293 cells, and displayed a similar trend (Park et al., 2014). The mitigation of 
mTORC1 activity is known to be a part of the survival response under stressful conditions via 
AMPK (Kang et al., 2011). By inhibiting mTORC1, AMPK restricts anabolic mechanisms (RNA 
translation and protein synthesis), increases mitophagy and promotes cell survival by enhancing 
the production of ATP via glycolysis (Kang et al., 2011). Of note, the previous study showed that 
complete inhibition of mTOR was associated with increased cell death, indicating that basal 
mTOR activity is equally important to protect cells (Park et al., 2014). Other PD-related toxins 
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(such as 6-OHDA, MPP+ and rotenone) have also been found to decrease mTOR 
phosphorylation in primary neurons (Xu et al., 2014). Therefore, it is plausible that the mechanism 
of the effect observed is relevant to PD as well.  
With regard to FOXO1, it has been reported previously that CCCP and rotenone treatment 
increase FOXO1 expression in the nuclear compartment in adipocytes (Barbato et al., 2014). The 
phosphorylation of FOXO1 is expected to rise in CCCP-stressed cells due to the action of 
activated AKT and AMKP (Eijkelenboom and Burgering, 2013). Nonetheless, in this study, it was 
difficult to assess the effect of CCCP and UDCA on FOXO1 expression and phosphorylation due 
to variability in the results [Figure 6.21]. 
Several lines of evidence suggest that mitochondrial hexokinase opposes apoptosis by interfering 
with BAX-mitochondrion interaction and consequent mitochondrial outer membrane 
permeabilisation (Robey and Hay, 2006). Evidence also indicates that the activation of AKT not 
only increases hexokinase-mitochondrion association but also increases hexokinase expression 
(Roberts and Miyamoto, 2015).  
As mentioned above, the activation of AMPK in stressed cells with reduced ATP levels increases 
their reliance on glycolysis to compensate for energy loss. Since hexokinase catalyses the first 
step of glucose metabolism, its availability becomes more crucial in these conditions. As 
predicted, our results reveal a significant increase in hexokinase content in the mitochondrial 
compartment of CCCP-stressed cells through both WB and ICC results [Figure 6.24, Figure 6.26]. 
This was also previously reported in CCCP-stressed Hela cells (McCoy et al., 2013). The effect 
of UDCA on hexokinase had never been investigated before. The results showed that UDCA 
treatment had no effect on hexokinase expression or localisation [Figure 6.24, Figure 6.26]. 
In conclusion, we could not demonstrate that AKT activation was associated with any significant 
effect on the selected AKT targets. This implies that there are other targets and pathways by 

















7.1 Mitochondrial biogenesis in parkin patients’ fibroblasts 
As aforementioned, previous work in our research group demonstrated a beneficial effect of 
UDCA on parkin and LRRK2 patient fibroblasts; it was plausible to assume that this effect was 
due to enhanced mitochondrial biogenesis. Accordingly, we assessed the effect of UDCA 
treatment on mitochondrial protein expression and mtDNA copy numbers in parkin patient 
fibroblasts. The results obtained in this project did not show evidence of increased mitochondrial 
biogenesis with UDCA treatment [Heading 3.5, 3.7]. However, it is difficult to draw a firm 
conclusion since the tested positive control, resveratrol, did not induce a positive effect, although 
it has been previously reported to increase mitochondrial biogenesis in parkin patients fibroblasts 
(Ferretta et al., 2014).  
In Ferretta and colleague’s study, resveratrol significantly increased mtDNA copy numbers, as 
well as the mRNA level of PGC-1α target genes, such as TFAM, in the fibroblasts of both controls’ 
and patients’ (parkin) fibroblasts (Ferretta et al., 2014). In contrast to Ferretta and colleague’s 
study, where the cells were grown in a regular glucose-containing culture medium, the cells in 
this project were forced to rely on OXPHOS, via the use of a galactose-containing medium 
[Heading 3.2]. In a recent study, in which healthy fibroblasts were cultured in a galactose-
containing medium, resveratrol treatment did not increase the expression of PGC-1α (Sgarbi et 
al., 2018). This suggests that culturing cells in a galactose-containing medium might obscure the 
effects of resveratrol (and possibly UDCA) on mitochondrial biogenesis.  
Several groups have reported that mitophagy is inhibited when cells are grown in a galactose 
medium (Van Laar et al., 2010, MacVicar and Lane, 2014, Allen et al., 2013). One study reported 
that the reliance on OXPHOS prevents Parkin translocation in uncoupled mitochondria (Van Laar 
et al., 2010). In contrast, another study, which was conducted afterward, demonstrated that Parkin 
translocation occurs, but mitophagy is still inhibited, suggesting that a Parkin-independent 
pathway is involved in this inhibition (MacVicar and Lane, 2014). Since mitophagy and 
mitochondrial biogenesis are tightly coupled (Palikaras and Tavernarakis, 2014), it is possible that 
blocking mitophagy would downregulate the mitochondrial biogenesis programme, consequently 
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decreasing the response to mitochondrial biogenesis enhancers, such as resveratrol. 
Nonetheless, UDCA treatment in a galactose-containing medium significantly rescues 
mitochondrial function in parkin patient fibroblasts (Mortiboys et al., 2013). Therefore, the results 
in this project suggest that mitochondrial biogenesis does not play a significant role in the 
mechanism of action of UDCA. 
7.2 Activation of the Nrf2 pathway in ARE reporter cell lines 
The mechanism of action of UDCA has been extensively investigated in the context of 
hepatobiliary diseases. The activation of the Nrf2 pathway is one of the most important 
mechanisms by which UDCA stimulates hepatocellular transport, detoxification and antioxidative 
stress systems (Okada et al., 2008). Evidence shows that the activation of Nrf2 is sufficient to 
stimulate mitochondrial biogenesis via the regulation of Nrf1 and PGC1α (Dinkova-Kostova and 
Abramov, 2015). While the results in this project showed no evidence of enhanced mitochondrial 
abiogenesis following UDCA treatment, this does not necessarily mean that Nrf2 was not 
activated in the treated cells, due to the complex regulatory mechanism of the mitochondrial 
biogenesis programme. Accumulative evidence of the role of oxidative stress in PD (more details 
in the introduction chapter [Heading 1.3]) imply that drugs with an antioxidant effect might be a 
novel treatment for PD. Accordingly, it was decided to investigate the ability of UDCA to activate 
the Nrf2 pathway. 
It is plausible to assume that the beneficial mitochondrial effect observed in parkin patient 
fibroblasts (Mortiboys et al., 2013) was achieved via Nrf2 activation. Evidence shows that Nrf2 is 
closely linked to mitochondrial function. In a previously published report, the basal mitochondrial 
membrane potential, oxygen consumption and ATP levels in Nrf2-KO mouse embryonic 
fibroblasts (MEFs) and cultured primary glioneuronal cells were significantly reduced in 
comparison to the wild type (Holmström et al., 2013). In contrast, mitochondrial function was 
enhanced when Nrf2 was genetically constitutively upregulated via Keap1 knockdown 
(Holmström et al., 2013). These responses were believed to be prompted via changes in the rate 
of utilisation of mitochondrial substrates (Holmström et al., 2013). This proposed mechanism 
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could explain the increase in the activity of mitochondrial respiratory complexes that was 
previously observed in fibroblasts of parkin patients (Mortiboys et al., 2013).  
The availability of the ARE-CHO reporter cell line in-house provided a feasible tool to assess the 
ability of UDCA to activate Nrf2. Our results showed that UDCA treatment was associated with a 
statistically significant increase in ARE expression [Figure 4.5]. However, this increase 
(approximately twofold in comparison to the vehicle) was remarkably lower when compared to 
the positive control, BG12, which increased ARE expression by more than fivefold (at a 
concentration of 10 µm) [Figure 4.5]. The effect of UDCA on ARE expression was comparable 
when the cells were treated either with 10 µM or 100 µM of UDCA [Figure 4.5]. The results clearly 
indicated that the effective UDCA dose in parkin patient fibroblasts, 100 nm (Mortiboys et al., 
2013), would not increase ARE expression in the CHO reporter cell line. Accordingly, we decided 
to pursue the 10 µm UDCA in the subsequent experiments. To confirm that UDCA activated the 
Nrf2 pathway, the expression of multiple Nrf2 downstream genes (NQO1, GCLC and FTH1) was 
quantified via RT-qPCR [Figure 4.11]. The positive control, BG12, increased the expression of 
NQO1, but not GCLC or FTH1. Although there are no studies investigating the effect of BG12 and 
UDCA on the expression of Nrf2 downstream genes in CHO cells, research shows that the 
response to BG12 varies across different type of cells. For example, in hippocampal cells, BG12 
treatment increased the expression of both NQO1 and GCLC, while it only increased the 
expression of NQO1 in cortical neurons and had no effect on the expression of GCLC (Albrecht 
et al., 2012). Notably, our results showed that UDCA increased the expression of NQO1, which 
is the only gene that responded to BG12 [Figure 4.11]. 
Subsequently, we investigated the ability of UDCA to reduce oxidative stress in CuSO4 - stressed 
CHO cells using DCF assay, but no positive results were obtained [Heading 4.3]. Neither UDCA 
nor BG12 were able to reduce DCF readings in CuSO4 – stressed cells. Since the potent 
antioxidant, Trolox, also failed to decrease DCF readings, despite the trials of different 
concentrations, it is likely that the method used was not appropriate to assess oxidative stress. 
This could also explain why the initial trials of toxins known to increase oxidative stress levels, 
H2O2 and rotenone, did not demonstrate an increase in DCF readings. DCF has been widely used 
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as a probe for measuring oxidative stress. Nonetheless, Kalyanaraman and colleagues have 
critically evaluated various oxidative stress detecting probes and concluded that DCF cannot be 
reliably used to detect intracellular reactive oxygen species; however, it may be used as a redox 
indicator that responds to changes in intracellular iron/copper signalling (Kalyanaraman et al., 
2012). Accordingly, the ability of UDCA to ameliorate oxidative stress should be assessed via 
alternative probes in future experiments, such as hydroethidine (HE) and Mito-SOX. The 
assessment of oxidative stress can be achieved through measuring the ROS-mediated damage 
to proteins, lipids, RNA and DNA, which are more stable than ROS, or via quantifying the levels 
of antioxidant enzymes that neutralise ROS, such as superoxide dismutase. 
 Further experiments showed that UDCA was unable to increase ATP levels and reduce 
cytotoxicity in CCCP/rotenone-stressed CHO cells, despite trials of various treatment conditions. 
Treating CHO cells with UDCA was only reported in one study, which investigated its effect on a 
glucocorticoid receptor-dependent pathway (Tanaka et al., 1996). In this study, UDCA was 
applied at a concentration of 100 µM. This dose was also tested in our CHO–rotenone model, but 
did not show a beneficial effect. The absence of a UDCA-mediated rescue effect in CHO cells 
could be attributed to their inherent characteristic as hamster ovarian cells. Yet, it makes it difficult 
to assert that the increase in ARE expression is relevant to the rescue effect of UDCA.  
7.3 Beneficial effects in stressed SH-SY5Y cells  
In SH-SY5Y cells, the ability of UDCA to ameliorate toxicity was investigated initially in rotenone-
stressed cells, but no positive effect was observed. Then, CCCP was applied as an alternative 
toxin following a treatment protocol of a recently published paper (Fonseca et al., 2017). While 
no rescue effect was observed with 10 µM UDCA, the trial of 100 µM UDCA resulted in a minor 
positive effect on ATP and cytotoxicity [Figure 5.3]. Further experiments showed that the 
application of a higher UDCA dose (300 µM) significantly increased ATP levels and decreased 
cytotoxicity in CCCP-stressed cells [Figure 5.4]. Indeed, the response of cells with neuronal 
features, such as SH-SY5Y, to UDCA treatment is important for supporting the applicability of 
UDCA as a treatment for PD. However, since the SH-SY5Y cell line is a derivative of 
neuroblastoma, it inherently has cancerous properties that affect its metabolism and genomic 
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stability. Therefore, the use of primary neuron cultures would be superior, because they are more 
likely to represent the properties of neuronal cells. However, it is obviously extremely difficult to 
obtain, prepare and keep sufficient numbers of primary neurons to perform all experiments 
described in this project. 
To tackle this limitation of the SH-SY5Y cell line, we attempted to reproduce the UDCA-mediated 
rescue effect in terminally differentiated SH-SY5Y cells. Although the differentiation was 
successful, and was associated with a significant increase in neuronal and DA markers [Figure 
5.7, Figure 5.8], UDCA treatment did not ameliorate the CCCP-induced toxicity [Figure 5.15, 
Figure 5.16, Figure 5.17]. Possible causes for the absence of a response in differentiated SH-
SY5Y cells is discussed in chapter 5.  
7.4 Mechanism of action of UDCA in SH-SY5Y cells 
Since UDCA increased ARE expression in CHO cells, the effect of UDCA on the Nrf2 pathway in 
CCCP-stressed SH-SY5Y cells was investigated first. Unlike the previously used CHO cells, the 
SH-SY5Y cell line in this project was not a reporter cell line and, therefore, we only looked at the 
expression of Nrf2 downstream genes. However, the RT-PCR results did not show an 
upregulation in the expression of Nrf2 genes in response to UDCA treatment or to treatment with 
the positive control, BG12 [Figure 5.23]. With regard to BG12, it is possible that the increase in 
mRNA levels was transient, and was not detectable 24 hours after the treatment. However, it has 
been reported that BG12 treatment (2 µm) for 24 hours increased mRNA levels of Nrf2 targets in 
SH-SY5Y cells (including GCLC, which was assessed in this project) (Jing et al., 2015). Notably, 
in a different study, the effect of BG12 treatment (30 µm, 24 hours) on the mRNA levels of GCLC 
in SH-SY5Y cells was particularly minor (Lin-Holderer et al., 2016), indicating that the upregulation 
of Nrf2 targets in response to BG12 might not be consistent in SH-SY5Y cells. In the Nrf2 - SH-
SY5Y experiments, we increased the number of assessed Nrf2 genes and designed primers for 
five genes (FTH1, GCLC, GST2A, HMOX1 and NQO1). Unfortunately, only three of them were 
specific.  
 Due to the lack of a response to the positive control, it is difficult to conclude that UDCA is not a 
Nrf2 activator in our SH-SY5Y model. Recently, Fonseca and colleagues found that the rescue 
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effect of TUDCA on CCCP-stressed SH-SY5Y cells was not associated with an increase in the 
expression of Nrf2 target genes, and did not increase nuclear translocation of Nrf2 (Fonseca et 
al., 2017). However, no positive control was used in the study to validate these findings. 
Unexpectedly, our results showed a decrease in mRNA levels of GST2A and FTH1 with UDCA 
treatment in CCCP-stressed cells, in comparison to vehicle CCCP-stressed cells [Figure 5.23]. 
We postulated that UDCA activated an alternative protective pathway that decreased oxidative 
stress levels and, as a consequence, the expression of the Nrf2 genes. Accordingly, no further 
experiments related to the Nrf2 pathway were conducted.  
AKT kinase is a strong candidate mediator of the UDCA rescue effect. The protective effect of 
UDCA has been attributed to AKT activation in various cell lines, including HepG2 cells, colon 
carcinoma-derived cell lines and cardiomyocytes (Arisawa et al., 2009, Hanafi et al., 2016, Im et 
al., 2005). More importantly, previous work in our group has shown that the UDCA-mediated 
rescue effect in parkin patient fibroblasts is dependent on AKT activation (Mortiboys et al., 2013). 
Indeed, the results in this project showed that UDCA significantly activated AKT in CCCP-stressed 
SH-SY5Y cells [Figure 6.7]. Interestingly, further experiments revealed that the inhibition of AKT 
eliminated the UDCA-mediated increase in ATP levels, but did not affect cytotoxicity. This finding 
suggests a closer relationship between the AKT and the mitochondria.  
It has been previously reported that IGF induces AKT translocation into the mitochondria in SH-
SY5Y cells (Bijur and Jope, 2003). Accordingly, we investigated if UDCA treatment in our SH-
SY5Y cells would induce a similar response, but the results were negative [Figure 6.13]. If AKT 
does not directly interact with the mitochondria, this suggests that the effect of AKT on the 
mitochondria is indirect, via its downstream targets. Consequently, we explored the effect of 
UDCA treatment on selected AKT downstream targets (CREB, FOX01, mTOR and hexokinase) 
to elucidate the mechanism by which UDCA exerts its recue effect. However, none of them 
showed a significant response either to UDCA or to the positive control, IGF, regardless of the 
trail of different techniques and treatment conditions. More work is needed to verify these results 




7.5 UDCA doses 
In this project, the beneficial UDCA dose required in SH-SY5Y cells was higher than the beneficial 
dose in fibroblasts. A UDCA concentration of 100 nM significantly increased ATP levels in parkin 
fibroblasts, and an even lower concentration (10 nM) was sufficient to increase ATP levels in 
LRRK2 G2019S fibroblasts of PD patients and non-manifesting carriers (Mortiboys et al., 2013, 
Mortiboys et al., 2015). On the other hand, the rescue effect of UDCA in SH-SY5Y cells was only 
significant at doses higher than 100 µM [Figure 5.4]. The application of UDCA doses in SH-SY5Y 
cells at micro molar scales was also reported in previous studies. For example, 100 – 200 µM 
UDCA significantly increased viability and decreased ROS levels in SH-SY5Y cells stressed with 
sodium nitroprusside (Chun and Low, 2012). In addition, 100 µM TUDCA was required to increase 
viability and ATP levels and to decrease ROS levels in CCCP and MPP+ stressed SH-SY5Y cells 
(Rosa et al., 2017, Fonseca et al., 2017). The difference in UDCA doses between fibroblasts and 
SH-SY5Y cells is justifiable, given the mismatch in cell type, culturing conditions and the 
underlying mitochondrial defect. However, it raises the question of whether high UDCA doses 
would be needed in humans to induce effective protection against neuronal loss.  
The implication of this need is that the administration of exceedingly high UDCA doses will induce 
side effects and cytotoxicity in the human body. Additionally, the ingested UDCA doses and blood 
UDCA levels are not measures of UDCA concentrations in the CNS, due to the BBB. There is 
limited knowledge about the bioavailability of UDCA in the CNS. Parry and colleagues have 
previously reported that UDCA crosses the BBB in a dose-dependent manner (Parry et al., 2010). 
However, the study showed that the mean concentration in the CSF, at a dose of 15 mg/kg/day, 
was 86.69 nM. Increasing the dose to 50 mg/kg produced a mean CSF concentration of 
191.11 nM (Parry et al., 2010). On the other hand, the UDCA serum concentration ranged 
between 7 and 30 µM (Parry et al., 2010). This apparent partial permeability of the BBB implies 
that the rescue effect of UDCA in in vitro studies should be achieved at a low concentration. Only 
a limited number of studies have assessed the protective effect of UDCA in primary neuronal 
cells. In mouse cortical neurons, with small interfering RNA-mediated parkin knockdown, a UDCA 
dose of 10 pM was sufficient to restore ATP depletion (Mortiboys et al., 2013). However, in a 
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different study, where mouse cortical neurons were stressed with MPP+, 100 µM TUDCA was 
required to restore ATP to the levels of the unstressed control (Rosa et al., 2017). More work is 
needed to elucidate the effective UDCA dose in neuronal models of PD.  
7.6 Future work  
7.6.1 Alternative AKT downstream targets 
AKT has a vast number of substrates. Only a few of them were selected to be investigated in this 
project and did not show a significant response to UDCA treatment. Other AKT substrates that 
might be involved in the UDCA-mediated rescue effect are briefly reviewed below. 
Apoptotic proteins 
The pro-apoptotic protein BAD is directly phosphorylated by AKT (Franke et al., 2003). The 
phosphorylation neutralises BAD activity by facilitating its interaction with 14-3-3 proteins, 
allowing the anti-apoptotic factors to prevail (Aghazadeh and Papadopoulos, 2016). AKT has also 
been reported to phosphorylate the mouse double minute 2 homolog (MDM2) and, consequently, 
increase its activity and nuclear translocation (Downward, 2004). MDM2 is a potent inhibitor of 
the p53 protein, which is a major regulator of cell death in response to various stress conditions. 
p53 stimulates the expression of multiple pro-apoptotic proteins, such as BAX, NOXA, PUMA and 
FAS (Khoo et al., 2014). In addition, AKT phosphorylates and inhibits the pro-apoptotic protein 
BAX, by preventing its insertion into the mitochondria (Kale et al., 2018). 
GSK3β 
GSK3β has various vital cellular functions other than glucose metabolism, such as the regulation 
of cellular signalling and the regulation of cell survival and differentiation (Beurel et al., 2015). 
Activated AKT inhibits GSK3β via phosphorylation. This inactivation regulates inflammatory 
pathways, such as the NF-B pathway (Zhang et al., 2014a), which has been implicated in the 
pathogenesis of PD (Herrero et al., 2015). The inhibition of GSK3β decreases the release of pro-
inflammatory cytokines, such as IL-6 and interferons, and increases the release of anti-
inflammatory cytokines, such as IL-10 (Martin et al., 2005). Additionally, overexpression of active 
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GSK3β in mitochondria has been reported to intensify the apoptotic effects of rotenone and 
MPP+, and reduce the activity of complex I and overall ATP production (King et al., 2008). 
7.6.2 Glucocorticoid receptors 
As mentioned in the introduction section, UDCA is a steroid-based molecule. In the drug 
screening paper published by our group, half of the positive hits in the second stage of the screen 
were steroids or steroid-related compounds (Mortiboys et al., 2013). Additionally, blocking the 
GRs (either via the application of Mifepristone or via RNA-mediated knockdown) eliminated the 
rescue effect of the structurally similar compound, UCA, in parkin fibroblasts (Mortiboys et al., 
2013). The GRs act as a ligand-dependent transcription factors. When activated, GRs translocate 
into the nucleus and regulate the transcription of various genes in a highly cell- and context-
specific manner (classical glucocorticoid pathway) (Herrero et al., 2015). GRs interact with the 
pro-inflammatory transcription factor activator protein 1 (AP1) and nuclear factor NF-kB, and 
neutralise their activity, which is the main mechanism by which glucocorticoids alleviate 
inflammation (Moreira et al., 2017). Evidence shows that GRs also act via a non-genomic 
mechanism (non-classical pathway). This mechanism mediates a relatively more rapid response 
and involves various signalling pathways, such as PI3K, AKT and MAPK (Oakley and Cidlowski, 
2013). The non-classical pathway is triggered by the dissociation of accessory proteins from the 
GRs complex upon the binding of the glucocorticoid legends. Among the released proteins is the 
BAG family molecular chaperone regulator 1 (BAG-1), which is involved in the regulation of 
apoptosis and neuronal differentiation (Shen et al., 2016, Samarasinghe et al., 2012). 
7.6.3 Mitophagy pathway 
Recently, Fonseca and colleagues showed that the rescue effect of TUDCA was associated with 
significant upregulation in autophagy and mitophagy in CCCP-stressed SH-SY5Y cells (Fonseca 
et al., 2017). TUDCA treatment increased the levels of full-length PINK1 in the mitochondria 
concomitantly with increased expression and translocation of Parkin (Fonseca et al., 2017). 
Importantly, 50% knockdown of parkin via siRNA was sufficient to abolish the positive effect of 
TUDCA on ATP levels (Fonseca et al., 2017). In the drug screening paper, UDCA restored ATP 
levels in parkin mutant fibroblasts (Mortiboys et al., 2013). These findings suggest that 
upregulation in mitophagy mediates, at least in part, the cytoprotective effect of UDCA. 
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7.7 Concluding remarks 
The main aim of this project is to investigate the rescue effect of UDCA in the context of PD. 
Previous work by our group revealed that UDCA rescues mitochondrial function in parkin patients’ 
fibroblasts (Mortiboys et al., 2013) [Figure 7.1]. The work presented in this project suggests that 
this rescue effect is not associated with an increase in mitochondrial biogenesis. Consequently, 
we investigated the ability of UDCA to activate the Nrf2 pathway, which is one of the most 
important antioxidant pathways in cells. Using an ARE reporter CHO cells, we found that UDCA 
induced a small dose-dependent increase in Nrf2 activation. However, this increase was not 
translated into a reduction in oxidative stress level in copper-stressed CHO cells. Moreover, 
UDCA treatment did not rescue CHO cells when they were stressed with rotenone/CCCP. 
In neuronal-like cells (SH-SY5Y cells) stressed with CCCP, UDCA treatment significantly 
increased ATP levels and decreased cytotoxicity. This rescue effect was not associated with 
increased expression of Nrf2 target genes, but it was associated with a significant increase in 
AKT activation. Inhibition of the AKT pathway abolished the beneficial effect of UDCA on ATP. 
Notably, the cytotoxicity level remained unchanged, indicating that the rescue effect of UDCA is 
partially dependent on AKT. The effect of UDCA treatment on the phosphorylation of selected 
AKT downstream targets was investigated but no positive results were obtained. More work is 






Figure 7.1 A summary of the main research questions and the main findings in this projects 
The figure shows the main research questions (in red boxes) and the main findings (in green boxes) in this 
project. Based on the literature review and a previous work carried out by our group, upregulation in 
mitochondrial pathogenesis, AKT pathway and Nrf2 pathway are plausible mechanisms that mediate the 
cytoprotective effect of UDCA in the context of PD. The work presented in this project demonstrated that 
the rescue effect of UDCA is reproducible in cells of neuronal nature (SH-SY5Y cells), and that the rescue 
effect is partially dependant on the AKT pathway. More work is needed to identify the AKT downstream 
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